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Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which 
primarily results from the selective loss of dopaminergic neurons in the substantia 
nigra. Mutations in leucine-rich repeat kinase 2 (LRRK2) have been linked to 
autosomal familial and sporadic PD. It is now estimated that approximately 1% of 
Parkinson’s disease (PD) results from mutations in LRRK2. Previous studies have 
established that the most common mutation, which replaces G2019, located within 
the magnesium binding DFG motif in the kinase domain, with a serine residue 
enhances protein kinase activity between 2 to 4 folds. Recently our lab in 
collaboration with Matthias Mann’s lab discovered that LRRK2 phosphorylates a 
subset of Rab GTPases including Rab8A and Rab10. Moreover, it was shown that 
LRRK2 PD-associated mutations including G2019S, Y1669C and R1441C/G exhibit 
an enhanced phosphorylation of Rab10 and Rab8A in cells. Based on this data it 
was suggested that overactivation of LRRK2, which leads to an increased 
phosphorylation of indicated Rab GTPases, may lie behind the mechanism by which 
LRRK2 causes disease. To date, a number of compounds such as LRRK2-IN-1, 
GSK2578215A and MLI-2 have been described as fairly selective LRRK2 inhibitors. 
It was reported that treatment of cells and mice with these inhibitors completely 
blocks Rab10 and Rab8A phosphorylation in cells. These results indicated that 
inhibition of the LRRK2 kinase activity could be a possible treatment for PD. In a 
previous work, our laboratory found that treatment of cells or mice with structurally 
diverse LRRK2 inhibitors results in rapid dephosphorylation of LRRK2 at two 
residues: S910 and S935. Our results suggest that these sites do not comprise 
LRRK2 autophosphorylation sites but are instead regulated by a distinct signalling 
mechanism that is controlled by LRRK2.  
In the first part of my thesis I investigate the physiological function of LRRK2 S910 
and S935 residues in cell using LRRK2 [S910A+S935A] knock-in mouse model. I 
found that in vivo, LRRK2 S910A+S935A mutation evidently reduced Rab10 and 
Rab8A phosphorylation in MEFs suggesting that this mutation is important for 
LRRK2 kinase activity. Moreover, I found that LRRK2 [S910A+S935A] mutation 
leads to decreased total levels of full length LRRK2 in kidneys, indicating that LRRK2 
could be regulated differently in these tissues. In this chapter I also report the 
histopathological data for brains, kidneys and lungs that shows that the LRRK2 
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[S910A+S935A] mutation does not cause any major pathology in these tissues. This 
data indicates that the previously reported kidney and lung phenotype observed in 
LRRK2 KO and KD mice is not likely to be due to S910 and S935 dephosphorylation. 
However, behaviour phenotyping of LRRK2 [S910A+S935A] knock in mice revealed 
that they performed significantly worse in the rotarod test compared with their 
littermate wild type mice. In future, it would be interesting to perform additional 
behaviour tests with these mice to confirm these results.  
In the second chapter, the initial aim was to address whether or not MYPT1 
comprised a physiological substrate of LRRK2, and if so to investigate whether it 
was involved in the negative feedback regulation of LRRK2 on S910/S935. For this 
purpose, I used transcription activator-like effector nucleases (TALENs) as well as 
CRISPR/Cas9 gene editing techniques to attempt to knock out MYPT1 from HEK293 
cells but I was unable to obtain homozygous knockout cell lines, which might be 
result of inviability of MYPT1 deficiency. In parallel experiments, in an attempt to 
confirm the interaction of MYPT1 and LRRK2, I immunoprecipitated endogenous 
LRRK2 and MYPT1 from wild type and homozygous LRRK2 knockout mouse 
embryonic fibroblasts (MEFs). This revealed that MYPT1 did not co-
immunoprecipitate with endogenous LRRK2, casting doubt over the previously 
reported data suggesting these proteins interact. Finally, I used orbitrap-based 
phospho-site mass spectrometry to analyse changes in overexpressed and 
endogenous MYPT1 phosphorylation, and was unable to demonstrate that treatment 
of cells with LRRK2 inhibitors induced dephosphorylation of MYPT1 on residues that 
had been identified to be phosphorylated in vitro by LRRK2. In conclusion, results 
presented in this study cast doubt that MYPT1 is a direct LRRK2 substrate.  
In the third part of the thesis, my aim was to widen to identify novel LRRK2 
substrates or regulators. For this purpose I performed a comparative mass 
spectrometry analysis to analyse LRRK2 interactors that co-immunoprecipitate with 
endogenous LRRK2 immunoprecipitated from LRRK2 wild type, LRRK2 
[S910A+S935A] knock-in and LRRK2 KO MEFs. I present the table comprising 
identified potential LRRK2 interactors and attempt to validate some of the proteins 
from the list. Unfortunately, my data showed that tested proteins including PALM 
protein do not seem to bind LRRK2. In this chapter, I also performed LRRK2 
substrate specificity analysis, which suggested that LRRK2 could phosphorylate 
serines as well as threonines in vitro. Particularly, LRRK2 G2019S seems to 
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phosphorylate serine residues much more efficiently than threonine. This data is 
supported by previous studies, for instance, LRRK2 G2019S was reported to have 
an enhanced autophosphorylation at S1292. Moreover, Rab12 is another LRRK2 
substrate being validated at the moment and it was shown that it is phosphorylated 
by LRRK2 at S106. In future, it would be interesting to investigate how LRRK2 
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1.1 Signal transduction 
All living organisms are made of cells. The cell is the basic unit of life and in order to 
survive, cells must respond to changes in the surrounding environment that would 
allow them to navigate towards nutrients, to communicate with other cells and to 
divide. Often, a single cell is subjected to numerous signals at the same time, and it 
then assimilates the information it encounters into a mechanism of action called cell 
signal transduction. Usually, cell signal transduction begins with the external signal 
molecule (for instance, a growth factor, hormone or amino acid) binding to a receptor 
situated in the cell membrane. Following stimulation of the receptor, activation of 
different cellular enzymes leads to a cell’s response.  
To transmit and amplify signals, cells employ specific intracellular molecules like 
enzymes and small molecules called secondary messengers (for instance, Ca2+ or 
cAMP). Activated enzymes propagate the signal by catalysing a huge number of 
distinct enzymatic reactions such as a covalent attachment or a proteolytic cleavage. 
On the other hand, secondary messengers diffuse in large quantities, bind and 
trigger signalling proteins. As a result, enzymes and secondary messengers activate 
a chemical transmission to their downstream effectors.  
One interesting example of cell signaling transduction is the fight-or-flight response, 
which takes place when a harmful event or threat for survival is encountered. In a 
situation of stress, adrenaline is released. The binding of adrenaline to an adrenergic 
receptor, situated in the liver cell’s plasma membrane, starts a cascade of reactions 
inside the cell. Adenylyl cyclase, a membrane-bound enzyme, becomes activated by 
G-protein molecules associated with the adrenergic receptor. Activated adenylyl





cytoplasm, bind and activate protein kinase A (PKA). In the liver, PKA 
phosphorylates another enzyme, glycogen phosphorylase, which converts glycogen 
into glucose-6-P (Figure 1.1).  
 
Figure 1.1: Schematic representation of the fight-or-flight response. During stress, 
adrenaline is released from adrenal glands. The binding of adrenaline to an adrenergic 
receptor, situated in the liver cell’s plasma membrane activates adenylyl cyclase, which then 
catalyses the formation of cAMP that diffuse through the cytoplasm and trigger the activity of 
a PKA. Activated PKA phosphorylates glycogen phosphorylase that converts glycogen into 
glycogen-6P. Glucose is then secreted into the blood and used for fight-or-flight response. 
 
Through this cell signalling cascade adrenaline provokes the liver to secrete glucose 
into the blood during the fight-or-flight response. Increased concentration of glucose 
in blood supplies body with extra energy resulting into a visible increase in strength 





1.2 Protein phosphorylation 
1.2.1 The significance of protein phosphorylation in signal transduction 
Phosphorylation is performed by enzymes called protein kinases, which catalyse the 
transfer of the γ-phosphate from ATP to specific amino acid residues of the substrate 
protein. It was shown that in eukaryotes these are typically Ser, Thr and Tyr amino 
acids (Ubersax & Ferrell, 2007). Protein kinases are encoded by one of the largest 
families of genes in eukaryotes as they contribute almost to 2% of the genome 
(Rubin et al., 2000). As a matter of fact, protein kinases phosphorylate approximately 
30% of human proteins (Manning, 2005). Not surprisingly, protein phosphorylation is 
a very important type of post-translational modification observed in signal 
transduction as it affects every cellular aspect, including metabolism, growth, 
division, differentiation, motility, organelle trafficking, membrane transport, muscle 
contraction, immunity, learning and memory. Phosphorylation is a reversible process 
and it is controlled by protein phosphatases. Phosphorylation and dephosphorylation 
can alter the function of a protein in almost every possible manner (Figure 1.2).  
 
Figure.1.2: Summary of protein phosphorylation and its function. Protein 
phosphorylation is catalysed by protein kinases whereas protein dephosphorylation is 
catalysed by protein phosphatases. Phosphorylation can alter a targeted protein in different 





This is because the phosphate group is negatively charged and its addition or 
removal results in a local charge change. As a consequence, this can lead to an 
increased or decreased biological activity of the enzyme, stabilise it or target it for 
destruction. Furthermore, phosphorylation may speed up or restrict the movement of 
the enzyme between subcellular organelles, assist or inhibit protein–protein 
interactions. The simplicity, and reversibility of phosphorylation together with the 
availability of ATP, as a phosphoryl donor, justifies its selection as the most universal 
regulatory mechanism acquired by eukaryotic cells (Cohen, 2000).  
Kinase activity was first mentioned in 1954 when Gene Kennedy described a liver 
enzyme, which catalysed the phosphorylation of casein (Burnett & Kennedy, 1954). 
Soon after its discovery, Fischer and Krebs revealed that the interconversion of 
phosphorylase b to phosphorylase a was associated with a 
phosphorylation/dephosphorylation process (Fischer & Krebs, 1955). In particular, 
they demonstrated that the b form could be transformed to the a form in the 
presence of Mg2+/ATP and an enzyme they termed phosphorylase kinase (Krebs & 
Fischer, 1956). Phosphorylase kinase was consequently shown by other groups to 
catalyse the transfer of the γ-phosphoryl group of ATP to a specific serine residue on 
phosphorylase b (Fischer, Graves, Crittenden, & Krebs, 1959). Furthermore, in 1950, 
Earl Sutherland demonstrated that glycogenolysis could be triggered if liver slices 
were incubated with adrenalin (Robison & Sutherland, 1971). Then he established 
that the activity of phosphorylase a was augmented under these conditions, 
revealing that a hormone could influence the activity of a protein kinase. Recent 
research in the field of phosphorylation pushed forward the development of specific 





remarkable importance of protein kinases phosphorylation explains a huge scientific 
interest in this area. 
1.2.2 Protein kinases - the human kinome 
The discovery of the first protein kinase in the late fifties led to subsequent findings 
of other protein kinases. It turned out that kinases share a similar conserved catalytic 
region (kinase domain) of approximately 250-300 residues, which is responsible for 
the transfer of a γ-phosphate from ATP to its substrate, but considerably differentiate 
outside the kinase region. Interestingly, these distinct regions of the kinase often 
comprise other auxiliary domains that provide it with additional function including 
specific localization, protein-protein interaction or even another catalytic activity. In 
2001, the Human Genome Project allowed for the sequencing of the entire human 
genome. This permitted to identify all 518 human protein kinases (Manning, Whyte, 
Martinez, Hunter, & Sudarsanam, 2002). The identified kinases were arranged in a 
phylogenetic tree based on their evolutionary deviations of the kinase domain 
residues, creating the so called kinome (Figure 1.3). Based on sequence similarity 
the human kinome is divided into seven major groups: AGC (PKA, PKC and PKG 
family), CAMK (Ca2+/Calmodulin-dependent kinases family), CK1 (Caesin kinase 1 
family), CMGC (CDK, MAPK, GSK3 and CLK family), STE (homologues of the yeast 
Sterile kinase family), TK (Tyrosine kinases family) and TKL (Tyrosine-kinase like 
family) (Manning et al., 2002). Members of the same group are normally activated 
and regulated in a similar fashion as well as have similar substrate preference.  
In addition, there is also another group of kinases called atypical kinases, which 
does not share the sequence similarity with the rest of the kinome but folds in the 
same three-dimensional structure and possesses the same kinase activity.  





pseudokinases that have preserved the kinase fold but that have lost important 
catalytic residues (Manning et al., 2002). The role of pseudokinases reminds 
unclear, however it was hypothesized that these proteins might serve as a scaffold 
for other proteins or allosterically control another functional kinase (Boudeau, 






Figure 1.3: The Human Kinome. Phylogenetic tree of human protein kinases adopted from 






1.2.3 General characteristics of protein kinase 
For the first time, the crystal structural of a catalytic domain of cyclic adenosine 
monophosphate (cAMP)-dependent protein kinase (PKA) was solved by Knighton in 
1991 (Knighton et al., 1991). Further studies by distinct groups have revealed that 
the kinase domain is very well conserved (Hanks & Hunter, 1995). In fact, a kinase 
fold usually possesses roughly 250-300 amino acids, which form 12 subdomains 
arranged into two lobes (Figure 1.4). The role of the smaller N-terminal lobe (N-lobe) 
is to bind and coordinate ATP whereas the larger C-terminal lobe (C-lobe) is 
responsible for substrate binding and for providing the residues that are crucial for 
catalysis. The N-lobe (subdomains I-IV) is composed of five-stranded β-sheets and 
one α-helix called the C-helix while the C-lobe (subdomains VI-XII) is composed of 
six α-helices. In addition, the two lobes are interconnected by a hinge region, which 
forms a part of the active site and allow them to be flexible to acquire active or 
inactive conformations. 
In the N-lobe, the subdomain I contains a flexible glycine rich loop with a GxGxxG 
motif (where “x” stands for any amino acid) and the subdomain II comprises a 
conserved lysine in the VAIK motif, which binds to and coordinates the  α and β 
phosphates of ATP by main-chain amide interactions. This interaction is maintained 
by subdomain III. The C-lobe comprises an essential HRDxxxN motif of subdomain 
V positioned in the catalytic loop. It contains an aspartate, which acts as a base of 
phosphotransfer and of an asparagine residue that sustains the catalytic loop and 
chelates the secondary Mg 2+ ion. Another highly conserved DFG motif of subdomain 
VII includes an important aspartate residue that chelates the primary Mg 2+and 
secures correct positioning of the γ phosphate of ATP. Subdomain VIII possesses 





bridge with the conserved arginine in subdomain XI in order to promote stability of 
the C-lobe. The region between the DFG and APE motifs is called the activation loop 
(or T-loop) that contains the crucial Ser/Thr residue (Hanks & Hunter, 1995).  
Kinases are normally activated by phosphorylation within the T-loop, which is 
responsible for the rearrangement of the C-helix and the stabilization of the N- and 
C-lobes in the active conformation allowing the correct positioning of the substrate. 
For instance, the maximal activation of PKA-Cα subunit takes place upon 
phosphorylation of Thr197 in the activation loop (Cheng, Ma, Moore, Hemmings, & 
Taylor, 1998). Moreover, kinases are reported to be capable of phosphorylating 
themselves, a process called autophosphorylation (cis-phosphorylation) as well as to 
phosphorylate adjacent kinases with a dimer or a higher order multimer (Hanks & 
Hunter, 1995). Autophosphorylation is reported to be critical for protein kinase 
activity and/or stability. Sometimes, a stimulus is needed to prime a substrate so that 
kinase can phosphorylate it. For instance, GSK3 can only phosphorylate numerous 
substrates after these are phosphorylated three residues away by a priming kinase 
such as casein kinase 2 (CK2) (Hagen & Vidal-Puig, 2002). The other example is the 
ribosomal protein S6 kinase 1 (S6K1), which phosphorylates S6K1 on the 
hydrophobic motif at the conserved threonine residue Thr 389. This phosphorylation 
causes a docking site for phosphoinositide-dependent kinase-1 (PDK1), which 
subsequently phosphorylates S6K1 on the T loop at the conserved threonine residue 
Thr 229 promoting full activity of S6K (Frodin et al., 2002).  
The majority of the kinases phosphorylate their specific substrates at a specific site. 
In fact, by analysing different substrates of a particular kinase a possible consensus 
motif sequence could be deduced. The consensus sequence stands for the amino 





site. For example, a consensus sequence for phosphorylation site of CDK is 
[S/T*]PX[K/R], where S/T* stands for the phosphorylated serine or threonine, P for 
proline, K for lysine, R for arginine and X could be any amino acid (Holt et al., 2009). 
As overactivation of multiple protein kinases have been shown to be implicated in 
several human diseases, over the last decades pharmaceutical companies focused 
on the development of highly specific structurally based ATP competitive kinase 
inhibitors in a hope to cure diseases. For example, the drug Imatinib (marketed by 
Novartis as Glivec) was approved for clinical use in 2001 for the treatment of some 
types of leukaemia, blood disorders and cancers. It works by specifically inhibiting 






Figure 1.4: Schematic ribbon representation of the subdomain structure of a kinase 
domain of Abl tyrosine kinase inhibited by imatinib (adopted from Cell Biology 
Promotion). Imatinib binds the ATP binding pocket of the kinase inhibiting the kinase. The 
activation segment is not phosphorylated and hides the substrate binding site. Glu and Asp 
are no longer coordinating ATP binding. 
 
1.2.4 Phosphorylation and human disease 
As mentioned previously, protein phosphorylation is important in cell signal 
transduction and is likely to influence every possible cellular process. In spite of the 
fact that kinases experience a selective pressure to prevent genetic mutations, they 
still take place. This could lead to inactivation of a kinase, an abnormal increase in its 
activity, mislocalization or aggregations, subsequently resulting in serious human 
diseases. Table 1.1 summarized some of protein kinases identified to be mutated in 
inherited human diseases (Lahiry et al, 2010). 
Table 1.1: Kinases mutated in human diseases. 
Protein Kinase Human disease 
ABL Chronic myeloid leukemia 
ALK1 Hereditary haemorrhagic telangiectasia type 2 
AMRH2 Persistent Muellerian dust syndrome 
AMPK Wolff-Parkinson-White Syndrome 
ATM Ataxia telangiectasia 
ATR Seckel syndrome type 1 
BMPR1A Juvenile polyposis syndrome primary pulmonary hypertension 
BMPR2 Primary pulmonary hypertension 
B-Raf 
Cardiofaciocutaneous syndrome (CFC), melanoma, sporadic cancers 
BTK X-linked agammaglobulinemia 
CASK X-linked mental retardation  
CDK4 Melanoma, sporadic cancers 
CDKDL5 X-linked infantile spasm syndrome 
CHK2 Li-Fraumeni syndrome, sporadic cancers 
CHK1δ Familial advanced sleep phase syndrome 
DMPK Myotonic dystrophy 
EGFR Non-small cell lung cancers  
EIF2AK3 Wolcott-Rallison syndrome 
ERBB2 Hereditary familial diffuse gastric cancer, glioma 






Apert syndrome, Antley-Bixler syndrome, Beare-Stevenson cutis gyrate syndrome, 
Crouzon syndrome, Familial scaphocephaly syndrome, Jackson-Weiss syndrome, 
Pfeiffer syndrome 
FGFR3 
Achondroplasia, Crouzon syndrome, Muenke syndrome, Thanatophoric dysplasia 
FLT3 Acute myeloid leukemia 
FLT4 Milroy disease, Juvenile hemangioma 
GRK1 Oguchi disease 
GRK4 Hypertension 
GUCY2D Leber congenital amaurosis type 1, Cone-rod dystrophy 
INSR Insulin resistance, leprechaunism 
IRAK4 Hyporesponsiveness to bacterial infection 
JAK2 Polycythaemia 
JAK3 Severe combined immunodeficiency 
KIT Gastrointestinal stromal tumours 
LCK Leukaemia 
LIMK1 Williams-Beuren syndrome 
LRRK2 Hereditary Parkinson's disease 
LTK Systemic lupus erythematosus 
MAP2K3 Colon cancer 
MAST3 Inflammatory bowel disease 
MASTL Thrombocytopaenia 
MERTK Retinitis pigmentosa 
MET Hereditary papillary renal carcinoma 
MYLK2 Cardiomyopathy 
NTRK1 Congenital insensitivity to pain, thyroid papillary carcinoma 
PAK3 X-linked mantal retardation 
PDGFRβ Chronic myelogenous leukemia 
PHKγ2 Autosomal liver glycogenosis 
PI3K Sporadic cancers 
PINK Hereditary early-onset Parkinson's disease 
PKCγ Spinocerebellar ataxia type 14 
PRKX/Y XX male syndrome and Swyer's syndrome (XY females) 
RET Hirschsprung disease, sporadic cancers 
ROR2 Robinow disease 
RSK2 Coffin-Lowry syndrome 
STK11 Peutz-Jeghers syndrome, sporadic cancers 
TEK Venous malformations  
TTBK2 Spinocerebellar ataxia type 11 
TGFBR2 Various cancers 
WINK1/4 Pseudohypoaldosteronism type II 







1.3 Overview of Parkinson’s disease 
1.3.1 Introduction to Parkinson’s disease 
The first clear medical description of Parkinson’s disease (PD) as a neurological 
syndrome was written nearly two hundred years ago, in 1817 by a British physician 
named James Parkinson in his monograph “An essay on the Shaking Palsy” 
(Parkinson, 1817). He documented the clinical features as follows (Parkinson, 1817): 
  
Involuntary tremulous motion, with lessened muscular power, in parts not in action 
and even when supported; with a propensity to bend the trunk forward, and to pass 
from a walking to a running pace: the senses and intellects being uninjured.  
 
Fifty years later, the French neurologist Jean-Martin Charcot categorized 
bradykinesia, a slowness of movement, as a separate cardinal symptom of the 
illness (Parkinson, 2002) and subsequently named it as Parkinson’s disease in 
honour of James Parkinson. Further clinical descriptions and studies presented more 
clinical and morphological information about Parkinson’s disease however it was not 
until the early twentieth century that the substantia nigra in the midbrain was 
reported as the most significant pathological hallmark of PD (Greenfield & 
Bosanquet, 1953). In fact, PD was shown to be characterized by the selective loss of 
pigmented dopaminergic neurons in the substantia nigra, particularly affecting the 
ventral component of the pars compacta (Zecca et al., 2001). By the time of death, 
this region of the brain has lost 50-70% of its neurons compared with the same 
region in unaffected individuals (Riederer & Wuketich, 1976). Moreover, neurons that 





bodies’, first observed in 1912 by Frederick Lewy in a post-mortem PD brain (Lewy, 
1992).  
1.3.2 Epidemiology, risk factors and clinical s of Parkinson’s disease 
Parkinson’s disease is one of the most common progressive neurodegenerative 
disorders that develops over many years, leading to motor symptoms including 
tremor, rigidity, reduced motor activity and postural instability as well as non-motor 
symptoms such as cognitive impairment, mood disorders, sleep difficulties, loss of 
sense of smell, speech and swallowing problems (Dauer & Przedborski). PD is 
incurable and characterised pathologically by the progressive loss of dopaminergic 
neurons from the substantia nigra. The substantia nigra cells generate dopamine, a 
chemical messenger responsible for transmitting signals within the brain that allow 
for coordination of movement. Loss of dopamine leads to neuronal death without 
normal control, leaving patients less able to control their movement (Goldenberg, 
2008).  Parkinson’s primarily affects people aged ≥ 50, however younger people can 
get it too. It is estimated that one in every 500 has PD, which is about 127,000 
people in the UK (Parkinson’s UK data). Moreover, the majority of studies report men 
to be slightly more often affected than females (Gillies, Pienaar, Vohra, & Qamhawi, 
2014). Furthermore, some studies suggest that the incidence of PD varies according 
to the race or the ethnicity, and it is the highest among Hispanics, followed by non-
Hispanic Whites, Asians and Blacks (Gillies et al., 2014). With the world aging 
population, the management of PD is likely to prove to be a very vital and 
challenging task of medical practice and general physicians. However, in spite of  
huge efforts in research, to date there is no treatment to arrest the progression of 
PD. Available pharmaceutical and surgical methods can only alleviate some of the 





progression of the disorder. Furthermore, identification of environmental factors that 
predispose to the development of PD has proven difficult. It was suggested by 
several studies that living in a rural environment appears to increase the risk of PD 
(Berry, La Vecchia, & Nicotera, 2010). This was justified by the fact that some 
epidemiological studies have shown a correlation between exposure to pesticide use 
and wood preservatives. Interestingly, the only consistent environmental factor is a 
strong negative correlation between cigarette smoking, caffeine intake and the 
development of the disease (Checkoway et al., 2002) and the most reliable risk 
factor for developing PD is a positive family history. The mechanism by which 
smoking might protect PD is unclear. 
1.3.3 Genetics of Parkinson’s disease 
The cause of PD remains unknown and it is usually described as a sporadic disease. 
However, our understanding of the pathogenesis of the disease has been boosted in 
the last decade with the identification of several gene mutations, which might give 
some insights on the mechanism of pathogenesis in sporadic PD (Klein & 
Westenberger, 2012). Investigation of these genes and proteins that they encode for 
provide significant understanding into the mechanism of the disease. Once we 
comprehend the mechanism it will be possible to develop better treatments for PD by 
identifying and therapeutically exploiting key molecules involved in the pathogenic 








Table 1.2: Genes linked to Parkinson’s disease (LRRK2 is highlighted in red).  
LOCUS MODE TYPE GENE FUNCTION REFERENCES 





al., 1997)  
PARK 2 Autosomal-recessive Early onset PD Parkin 
Ubiquitin 
ligase 
(Lucking et al., 2000) 
PARK 3 Autosomal-dominant Late onset PD Unknown 
  
(Gasser et al., 
1998)  
PARK 5 Autosomal-dominant Late onset PD UCH-L1 
DUB 
 (Y. Liu, Fallon, 
Lashuel, Liu, & 
Lansbury, 2002) 
PARK 6 Autosomal-recessive Early onset PD PINK1 
Kinase 
(Valente et al., 
2004)  
PARK 7 Autosomal-recessive Early onset PD DJ-1 
Oxidative 
Chaperone 
(Bonifati et al.,  
2003) 




(Paisan-Ruiz et al., 
2004; Zimprich et 
al.,2004) 
PARK 9 Autosomal-recessive Early onset PD ATP13A2 
ATPase 
(Ramirez et al., 
2006) 
PARK 10 Complex Late onset PD Unknown   (Farrer et al., 2006)  
PARK 11 Complex Late onset PD GIGYF2   (Lautier et al., 2008)  
PARK 12 X-linked Late onset PD Unknown     
PARK 13 Autosomal-dominant Late onset PD HtrA2/Omi 
Serine 
protease 
(Strauss et al., 
2005)  
PARK 14 Autosomal-recessive Early onset PD PLA2G6 
Phospholipa
se A2 
 (Yoshino et al., 
2010) 
PARK 15 Autosomal-recessive Early onset PD FBXO7 
F Box protein 
 (Di Fonzo et al., 
2009) 
PARK 16 Complex Late onset PD 
Rab7L1 
and 4 other 
genes 
  (Satake et al., 2009)  
PARK 17 Complex Late onset PD GAK 
Kinase 
(Y. P. Chen et al., 
2013)  
PARK 18 Complex Late onset PD HLA 
Immune 
recognition 
 (Hamza et al., 2010) 
PARK 19 Autosomal-dominant Late onset PD VPS35 
Vesicle 
trafficking 
 (Vilarino-Guell et al., 
2011) 




 (Quadri et al., 2013) 
PARK 21 X-linked Early onset PD RAB39B 
Vesicle 
trafficking 
 (Lochte et al., 2016) 
PARK22 Autosomal-dominant Late onset PD CHCHD2 
Transcription 
factor 
 (Funayama et al., 
2015) 
PARK23 Autosomal-recessive Early onset PD VPS13C 
Vesicle 
trafficking 










1.3.4 Autosomal Dominant Parkinson’s disease 
It has been reported by several studies that mutations in the α-synuclein gene 
(SNCA) and leucine-rich repeat kinase 2 (LRRK2) are the most common mutations 
that lead to familial autosomal dominant PD. 
A lot of attention was focused on α-synuclein protein as it was found as a main 
component of Lewy body aggregates identified in post-mortem brain of sporadic and 
inherited  (Spillantini et al., 1997). In 1997, mutations in SNCA were for the first time 
shown to be linked to PD in an Italian kindred and three unrelated families of Greek 
origin with autosomal-dominant inheritance for the PD phenotype (Polymeropoulos 
et al., 1997). Mutations are responsible of autosomal dominant early-onset PD (<40 
years) (Conway, Harper, & Lansbury, 1998). To date five missense mutations 
including A53T, A30P, E46K, G51D and H50Q as well as gene duplications and 
triplications have been described in different families of Greek, Korean, Swedish, 
German and Spanish origin (Klein & Westenberger, 2012). Penetrance of mutations 
tends to be high and brain pathology is characterized by abundant α-synuclein-
positive neuronal inclusions. In spite of a lot of effort being made there is not much 
information regarding SNCA function and it remains unknown. SNCA is described as 
a presynaptic protein thought to be implicated in neuronal plasticity (Stefanis, 2012). 
In addition, SNCA is known to be natively unfolded and be able to form toxic 
protofibrils (Conway et al., 2000). Several missense mutations have been reported to 
accelerate the formation of these and lead to formation of toxic β-sheets (Wise-Scira, 
Aloglu, Dunn, Sakallioglu, & Coskuner, 2013). The occurrence of gene duplications 
or triplications leads to an early onset of clinical symptoms with a more severe 





In 2004, the human leucine-rich repeat kinase 2 (LRRK2) gene was identified as the 
most common causative gene of autosomal-dominant inherited and sporadic PD 
(Paisan-Ruiz et al., 2004; Zimprich et al., 2004). It accounts for 1-2% of all 
Parkinson’s cases (Pankratz & Foroud, 2007). The frequency in familial cases is 5-
15% while in sporadic cases it is around 1%, and it is clinically indistinguishable from 
typical, idiopathic and late-onset PD (Klein & Westenberger, 2012). Thus, the LRRK2 
protein has emerged as a promising therapeutic target for the treatment of PD. 
LRRK2 G2019S is a particularly common mutation, occurring in up to 2-7% of 
Caucasian cases of familial Parkinson’s disease and 1% in sporadic cases (J. Q. Li, 
Tan, & Yu, 2014). In total, over 50 variants have been identified in LRRK2 thus far, 
but only some of them were consistently proven to be pathogenic. Amongst them is 
the G2019S mutation that is the most common one with a frequency of 2% in the 
North American clinical populations and the British Parkinson’s Disease Brain Bank 
specimens, and it is particularly frequent in Ashkenazy Jewish, Portuguese and 
North African Arabian PD patients even in the absence of a clear family history 
(Hardy, Cai, Cookson, Gwinn-Hardy, & Singleton, 2006). In general, the clinical 
characteristics of patients with the LRRK2 gene mutations, in particular those with 
the common G2019S mutation, are very similar to those of idiopathic PD 
(Williams‐Gray et al., 2006). Nigrostriatal cell loss and gliosis are common 
observations in patients with LRRK2 mutations, and the majority also have Lewy 
bodies. The structure of LRRK2 has not been solved yet. Yet it is known that LRRK2 
possesses kinase and GTPase activities both in vitro and in vivo. The protein domain 







1.3.5. Autosomal Recessive Parkinson’s disease 
Mutations in PARKIN (PARK2), PINK1 (PARK6) and DJ1 (PARK7) are the most 
common cause of autosomal recessive forms of PD described to date. In this thesis 
section I will describe two proteins that our laboratory currently is working on: PINK 
(a kinase) and PARKIN (an E3 ligase). 
Mutations in the Parkin protein are shown to be the main cause of an early onset of 
autosomal recessive PD (between 30-40 years old). In addition, there are reports of 
Juvenile PD (less than 21 years old), which were also linked to Parkin (Hedrich et al., 
2004). Parkin is a 465 amino acid protein, which comprises of a regulatory Ubl 
domain (residues 1-76); a RING0 domain (residues 145-215); a RING1 domain 
(residues 236-293) that binds to an E2; an IBR domain (residues 327- 380); and a 
RING2 domain that mediates the enzyme’s catalytic activity (413- 450) (Zhang et al., 
2000) (Figure 1.5). Parkin contains a highly conserved catalytic cysteine C431 that 
acts as an ubiquitin acceptor that forms an intermediate thioester bond prior to 
ubiquitylation of its substrate (Wenzel, Lissounov, Brzovic, & Klevit, 2011). Studies 
revealed that the C431F mutation completely blocks Parkin’s catalytic activity 
(Trempe et al., 2013). It was reported that Parkin exhibits auto-ubiquitylation, mono 
and multi-mono ubiquitylation functions but it lacks of preference for a single 
ubiquitin type topology (Hampe, Ardila-Osorio, Fournier, Brice, & Corti, 2006; 
Kazlauskaite et al., 2014). PD missense mutations can occur in any domain 
throughout the protein and rearrangements such as deletions or duplications of 
exons also occur. The exact role of Parkin within cell is unclear. It was reported that 
it has a neuroprotection role against mitochondrial dependent apoptosis (Moore, 
2006) but it was also shown that Parkin KO possesses an increased vulnerability to 





Parkin, a cytoplasmic protein, was shown to translocate to mitochondria upon 
mitochondria stress (Zheng & Hunter, 2013).  
 
Figure 1.5: Schematic diagram of Parkin protein (a) Linear domain organization and 
structural domain boundaries. L denotes linker and T, the tether. (b) Overall ribbon 
diagram of R0RBR (left) and overall surface structure (right). Adopted from (Riley et al., 
2013). 
 
Another protein that is most commonly mutated in autosomal recessive PD is PINK. 
PINK is known as a 581 amino acid Ser/Thr kinase. It is a unique kinase as it 
comprises mitochondrial targeting sequence (MTS) and a transmembrane domain. 
Moreover, the catalytic kinase domain comprises three insertions that are not 
common in other kinases (Cardona, Sanchez-Mut, Dopazo, & Perez-Tur, 2011). 
Because of MTS, PINK gets imported to mitochondria, where it translocates first to 
the outer membrane through translocase of the outer membrane TOM and then to 
the inner membrane through TIM23 and TIM40 complexes (Lazarou, Jin, Kane, & 
Youle, 2012). Upon mitochondrial translocation PINK experiences sequential 
cleavage by different mitochondrial proteases (Greene et al., 2012). The remaining 
C-terminal fragment of PINK is then released to the cytoplasm where it gets 





of PINK. Quite recently, it was established that mitochondrial membrane potential 
controls PINK’s stability (Lin & Kang, 2008). In fact, mitochondrial depolarization 
inhibits PINK cleavage and degradation, leading to its accumulation on the outer 
mitochondrial membrane where it gets exposed to cytosol and to its potential 
substrates and interactors.  PD mutations in PINK1 are found to be distributed 
throughout the length of the protein and most of these mutations lead to loss-of-
function of PINK kinase activity. 
Figure 1.6: Schematic diagram of Pink protein. MTS- mitochondrial targeting sequence, 
TM –transmembrane helix, Ins1, Ins2, Ins3 – insertions 1,2 and 3 respectively, CTD – C-
terminal domain. 
 
It is now established that PINK1 and Parkin share a mechanistic pathway in the 
pathogenesis of PD. First of all it was discovered that upon mitochondrial 
depolarization PINK gets accumulated in the outer mitochondrial membrane where it 
phosphorylates Parkin at S65, located within its Ubl domain (Kondapalli et al., 2012) 
This phosphorylation results in Parkin conformational change, release of Ubl domain 
and Parkin activation (Kazlauskaite et al., 2014). Secondly, it was found that PINK 
also phosphorylated ubiquitin at S65 (Kazlauskaite et al., 2015). Phosphorylated 
ubiquitin is then capable of binding to non-phosphorylated Parkin making it more 
accessible to PINK-dependent phosphorylation (Kazlauskaite et al., 2015). The 
discovery of phospho-ubiquitin mediated Parkin activation (Figure 1.7) provides a 





phospho-ubiquitin as potential therapeutic compounds (Kazlauskaite & Muqit, 2015). 
However, at the moment the development of activators has proven very difficult in 
contrast to inhibitors in drug discovery.  
 
 
Figure 1.7: Schematic diagram of PINK/Parkin mechanistic interplay .Upon activation of 
PINK1 by mitochondrial depolarisation, PINK1 can phosphorylate ubiquitin to generate 
phospho-ubiquitinPhospho-Ser65. Binding of ubiquitinPhospho-Ser65 to non-phosphorylated Parkin can 
disrupt intramolecular interaction of Ubiquitin-like (Ubl) domain to Parkin C-terminus. The 
Ser65 residue on Ubl becomes more accessible for PINK1-dependent phosphorylation 













1.4.1 Discovery of LRRK2 and LRRK2 mutations associated with PD 
The LRRK2 gene is the greatest genetic contributor to Parkinson's disease 
discovered to date and it is found in 1-2% of all Parkinson’s cases. It was discovered 
in 2004, following the previous identification of a new locus for Parkinson’s disease 
called PARK8, which maps to chromosome locus 12p11.2-q13.1 and corresponds to 
approximately 116 genes (Funayama et al., 2002). Two independent research 
laboratories led by Thomas Gasser and Nic Woods identified a novel gene to 
comprise missense mutations segregating with PARK8-linked PD. In Wood’s 
laboratory, this gene was named a dardarin (derived from the Basque word “dardara” 
meaning tremor) that was identified to comprise two missense mutations segregated 
with the disease in four Basque families R1396G and a fifth British family Y1654C 
(Paisan-Ruiz et al., 2004). In Gasser’s laboratory, LRRK2 (dardarin) was reported to 
possess missense mutations in the same amino acid residues of the LRRK2 gene in 
two large pedigrees of German-Canadian origin. In the former case, the identified 
mutation results in an identical missense mutation Y1699C, with the different 
numbering due to the addition of an extra 45 amino acids corresponding to exon 6), 
while in the latter case a different mutation leads to a substitution of the same 
arginine residue with a cysteine R1441C (Zimprich et al., 2004). Moreover, the 
analysis of an additional 32 families led to the identification of R1441C mutation in an 
unrelated family as well as two more missense mutations (I2020T and I1122V) and a 
putative splice site mutation in three other families (Zimprich et al., 2004). 
Importantly, in both studies mutations were segregated with the disease and 
appeared highly penetrant (Shen, 2004). Further studies by a Japanese group 





the one reported by Zimprich (Funayama et al., 2005). It was also reported that the 
R1441H (Spanaki, Latsoudis, & Plaitakis, 2006) and N1437H (Puschmann et al., 
2012) mutations are linked to PD. However, the most common and prevalent 
mutation reported by multiple studies, including the study by Kachergus, is the 
LRRK2 G2019S mutation that accounts for PD in several families within Europe and 
North America (Kachergus et al., 2005). G2019S is the most commonly reported 
LRRK2 mutation. In fact, in some populations the frequency of the G2019S mutation 
is extremely high, accounting for up to 20% in Ashkenazi Jews and 40% in North 
African Arabs (Ozelius et al., 2006). Moreover, the penetrance of the G2019S 
mutation is 28% in people that are 59 years old, 51% in 69 years old people and 
74% in those that are 79 years (Kalinderi, Bostantjopoulou, & Fidani, 2016). 
Interestingly, the phenotype of the LRRK2 mutations in observed families were 
remarkably similar. It was noted that the mean age at onset was 65 years, with the 
majority of patients in these families displaying unilateral hand or leg tremor and an 
absence of cognitive impairment as well as an excellent response to L-Dopa 
treatment. Although numerous mutations have been reported since the discovery of 
LRRK2, the seven mutations described in the present thesis are the ones best 
established and studied. Intriguingly, PD-associated mutations affect nearly every 
catalytic and protein-protein interaction domain of LRRK2 indicating that LRRK2 
might function  as upstream central integrator of multiple signalling pathways that are 
crucial for the proper functioning of neurons (Mata, Wedemeyer, Farrer, Taylor, & 
Gallo, 2006).  A molecular understanding of how LRRK2 interacts with its neuronal 
signalling partners and how it transduces cellular signals is likely to reveal novel 






1.4.2 Domain architecture of LRRK2  
The LRRK2 gene contains 51 exons and its encoded protein is 2527 amino acids 
long (286 kDa) (Figure 1.8). LRRK2 is mainly a cytoplasmic protein with several 
functional domains. Sequence analysis indicates several domain, including armadillo 
repeat folds (35-660 residues), ankyrin repeats (702-822 residues), a leucine-rich 
repeats (LRRs) (983-1319 residues), a GTPase (1335-1845 residues), a kinase 
(1859-2138 residues) and a WD40-repeat domain (2142-2498 residues) (Mata et al., 
2006) (Figure 1.8). The presence of multiple protein interaction domains (armadillo, 
ankyrin, LRR and WD40) suggests that LRRK2, in addition to its predicted protein 
kinase and GTPase activities, might serve as a scaffold for the assembly of a 
multiprotein signalling complex (Mata et al., 2006). However, because these 
domains can bind distinct proteins, the physiological LRRK2 binding partners cannot 
be predicted a priori and require extensive experimental identification. Interestingly, 
four major phosphorylation sites including S910, S935, S955 and S973 were 
discovered to be located between ankyrin and LRR domains (Doggett, Zhao, Mork, 
Hu, & Nichols, 2012; Dzamko et al., 2010). It was shown that treatment of cells with 
distinct LRRK2 kinase inhibitors results in dephosphorylation of these sites. In 
addition, it was reported that these sites are not LRRK2 autophosphorylation sites 
and are regulated indirectly by LRRK2-dependent protein kinase or protein 
phosphatase (Doggett et al., 2012; Dzamko et al., 2010). This data suggests 
functional importance of these domains. (S910 and S935 sites will be discussed in 








Figure 1.8: Schematic representation of the LRRK2 protein with the seven proven 
pathogenic mutations (in red) above the protein organization (Corti et al., 2011). LRRK2 has 
2,527 amino acids and comprises several conserved domains: ARM (Armadillo), ANK 
(ankyrin repeat), LRR (leucine-rich repeat), GTPase, kinase and WD40 domain. 
 
LRRK2 (and related LRRK1 protein, which possess a similar domain structure) is an 
exceptional protein because it encodes two enzymatic activities, a protein kinase and 
a putative GTPase within a single polypeptide chain. Biochemical studies revealed 
that LRRK2 is capable of undergoing autophosphorylation (Greggio et al., 2008) and 
phosphorylation (Jaleel et al., 2007) as well as GTP hydrolysis  (L. Guo et al., 2007) 
both in vitro and in vivo.  
In terms of the LRRK2 kinase domain, LRRK2 belongs to the Tyrosine Kinase-Like 
(TKL) subfamily of human protein kinases, whose members show sequence 
similarity to both Ser/Thr and Tyr kinases, though these kinases only phosphorylate 
Ser/Thr residues and not Tyr. LRRK2 substrate specificity analysis employing a 
positional scanning peptide approach revealed that LRRK2 tolerates a wider range 
of amino acids in its substrate compared with other protein kinase but importantly, it 
has a strong preference for phosphorylating threonine in vitro (Nichols et al., 2009b). 
The TKL subgroup includes several MAPKKKs, including the Raf proteins and 
mixed-lineage kinases (MLKs), which primarily trigger the ERK and JNK pathways, 





monomeric GTPases Ras and Cdc42/Rac, respectively (Mata et al., 2006). 
Furthermore, activation of Raf requires Ras-induced membrane targeting and 
multiple phosphorylation events, including activation-loop phosphorylation and 
possibly dimerization ((Mata et al., 2006). Likewise, Cdc42 promotes dimerization, 
activation-loop phosphorylation and membrane targeting of MLK3 ((Mata et al., 
2006)). The similarity of LRRK2 to these kinases indicates that they may share some 
aspects of regulation. This is also supported by the fact that immunoprecipitated 
LRRK2 appears to display low specific activity suggesting that it is in an inhibited, 
less active state, and might be activated by some unknown activator. It could be that 
an important cofactor or stimulus is absent in the preparation. It could also be that 
the large LRRK2 protein depends on chaperones for proper folding and activity and it 
is possible that only a fraction of the immunoprecipitated LRRK2 is functional. 
Recently, our laboratory made a significant breakthrough in identifying a subset of 
Rab GTPases, including Rab10 and Rab8A as LRRK2 physiological substrates 
(Steger et al., 2016). It was demonstrated that LRRK2 directly regulates Rab 
isoforms by phosphorylating conserved threonine residue in the Rab Switch-II 
domain, which is important for interacting with Rab’s effectors such as Rabin-8 and 
GDI that activate them (Steger et al., 2016). This data indicated that LRRK2 
phosphorylation is likely to be inhibitory on Rab biology (details will be discussed 
later in Section 1.5.1.1). There are two PD-associated LRRK2 mutations that are 
located within the kinase domain: G2019S and I2020T, and lie at the N-terminal 
boundary of the activation segment, with position 2019 corresponding to the glycine 
residue of the conserved DFG sequence.  It was reported that in vitro and vivo, these 
mutations result in an increase of Rab10 phosphorylation and therefore enhanced 





The GTPase domain of LRRK2 is classified to a family of the small G-protein 
superfamily of Ras-like GTPases called the ROC family (Taymans, 2012). In contrast 
with most of  members of the Ras-GTPase superfamily that exist as single-domain 
proteins, the GTPase sequence of the ROC family proteins is embedded in large 
multidomain proteins. Although LRRK2 encodes both a GTPase and a kinase 
domain, several of its homologues, including MFHAS1 or plant and prokaryotic 
ROCO proteins, do not contain a kinase sequence and only encode the ROC-
GTPase catalytic domain (Taymans, 2012).  This suggests that the GTPase function 
could be primarily a function of ROCOs. On the basis of homology with its ROC 
domain, the closest homologous GTPase to LRRK2 is LRRK1 with a 48% amino 
acid similarity and 27% amino acid identity. Several studies have now confirmed the 
biochemical activity of the LRRK2 GTPase domain using radioactivity-labelled 
guanine nucleotides. Further testing of GTP binding of multiple disease GTPase 
domain mutants demonstrated that the GTPase activities of R1441C/G/H and 
Y1699C mutants are inhibited to levels comparable with the functional mutants 
K1347A or T1348N (Tsika & Moore, 2013). By contrast, the GTPase activity of 
kinase domain mutants (G2019S and I2020T) are unchanged compared with the 
wild-type. Interestingly, GTPase domain mutations did not appear to affect the 
LRRK2 kinase activity in vitro. However, in vivo, all disease-associated mutants 
located within GTPase domain, including R1441H, R1441C, R1441G, N1437H and 
Y1699C appeared to evidently enhance Rab10 phosphorylation in MEF cells, 
indicating that these mutants enhance LRRK2 kinase activity (G. Ito et al., 2016; 
Steger et al., 2016). 
As kinases are common effectors of the Ras family proteins, one hypothesis that has 





the LRRK2 GTPase. However, there is no evidence to date to support this 
hypothesis as it was also suggested that autophosphorylation of LRRK2 controls 
GTPase activity (Z. Liu, Mobley, DeLucas, Kahn, & West, 2016). In fact, a major 
LRRK2 S1292 phosphorylation sites has been identified and recently pS1292 
antibody was generated (Sheng et al., 2012). This would allow in future to monitor 
LRRK2 autophosphorylation in vivo. However, to date the exact mechanism of 
interplay between these two domains reminds unclear.  
At the moment, it seems that overactivation of LRRK2 leading to inhibition of Rab 
GTPases may lie behind the mechanism by which LRRK2 causes disease. Due to 
this, many drug companies as well as our laboratory have generated a number of 
structurally diverse and highly selective LRRK2 inhibitors, these include compounds 
such as LRRK2-IN-1 (Deng et al., 2011), GSK2578215A (Reith et al., 2012) or the 
recently developed MLI-2 compound (Fell et al., 2015). 
1.5 Cell signal transduction by LRRK2 
1.5.1 Discovery of a subset of Rab GTPases as LRRK2 physiological 
substrates 
It was not until 2016, following a great multi-national effort by groups sponsored by 
the Michael J Fox Foundation, that a subset of Rab GTPases, including Rab10 and 
Rab8A were established to be direct physiological LRRK2 substrates (Steger et al., 
2016). For this purpose, a dual phosphoproteomic screening approach was 
implemented in parallel with genetic, biochemical and pharmaceutical approaches. 
Primary mouse embryonic fibroblasts (MEFs) derived from LRRK2 [G2019S] and 
WT littermate mice were treated with two structurally different LRRK2 inhibitors 
(GSK257821A and HG-10-102-01) and DMSO as a control to observe the changes 





[A2016T], a drug resistant mutant, and WT littermate, were treated with the recently 
developed powerful inhibitor MLI-2 to observe the changed in phosphosites in 
LRRK2 WT but not [A2016T] mutant (Steger et al., 2016). A state-of-the-art workflow 
for phosphopeptide enrichment, label-free LC-MS/MS and the MaxQuant 
environment for stringent statistical data evaluation performed by Steger identified 
900 high-confidence phosphopeptides in each of replicate in both screens. By 
overlapping the results of two orthogonal screens surprisingly only two phospho-
peptides passed stringent filtering criteria: pS935 LRRK2 and T73 Rab10 (Steger et 
al., 2016). This small number of identified phosphosites suggests that LRRK2 is a 
very low activity kinase or that it is in inhibited state. 
To verify that Rab10 is a physiological LRRK2 substrate, a number of experiments 
took place. Table 1.3 shows the criteria for validating LRRK2 substrates that have 
been met for Rab10 and Rab8A proteins. These includes in vitro validation of LRRK2 
phosphorylation to prove that Rabs are direct LRRK2 substrates, in vivo 
pharmaceutical evidence that inhibition of LRRK2 kinase activity by distinct LRRK2 
kinase inhibitors results in suppression of Rabs phosphorylation at the mapped site 
as well as genetic confirmation, for instance known LRRK2 disease-associated 
mutants enhance phosphorylation of the Rabs compared with the wild type but this 
phosphorylation is significantly suppressed in LRRK2 KO cells. Together these 
results strongly indicate that Rab10 and Rab8A are indeed direct LRRK2 










Table 1.3: The criteria for validating LRRK2 substrate 
 
Rab10 and Rab8a are members of Rab GTPases that comprise of 70 family 
members in humans, and they are critical players in all forms of intracellular 
vesicular trafficking events. They cycle between the cytosol, in which they are GDP 
bound and inactive, and specific membrane compartments, where they are activated 
by GDP/GTP exchange. Equivalent site of Rab10 T73 and Rab8A T72 was shown to 
be highly conserved in approximately 50 human Rab-family, indicating that this site 
could have an important functional role. Typical Rab GTPase exhibits a similar core 
structure comprising a conserved P loop, switch I and switch II domains. T73 Rab10 

















Figure 1.9: LRRK2 phosphorylates Rab10 at T73 located within switch II domain. 
 
Switch II was established to change the conformation upon nucleotide binding and 
regulate the interaction of Rabs with multiple regulatory proteins such as guanosine 
nucleotide dissociation inhibitors (GDIs) and guanine exchange factors (GEFs). 
Typically, prenylated Rab GTPases are localized in the cytosol in their GDP-bound 
(inactive) conformations bound to a cytosolic protein GDIs (Hutagalung & Novick, 
2011). Cytosolic Rab-GDI complexes represent a pool of recycling proteins that can 
deliver Rabs to specific membrane compartments. Rab delivery to cellular 
membrane compartments requires release of GDIs and the membrane-associated 
Rab protein are activated by exchanging its bound GDP for GTP (GEFs facilitates 
exchange of GDP to GTP) (Hutagalung & Novick, 2011). It was reported that the 
affinity of GDIs and GEFs for Rabs are evidently diminished in response to increased 





overactive LRRK2, which results in increased Rab phosphorylation, leads to Rab 
dissociation from GDIs in the cytosol with concomitant membrane insertion. As a 
result, the relative pool of membrane bound and cytosolic Rab is altered, disturbing 
intracellular trafficking. Moreover, PD-associated LRRK2 mutations would shift the 
membrane-cytosol balance of Rabs toward the membrane compartment, thereby 
causing accumulation of inactive Rabs in the membranes (Steger et al., 2016) 
(Figure 1.10). 
 
Figure 1.10: Evidence points to LRRK2 inhibiting Rab isoforms by preventing 











1.5.2 Evidence supporting link between Rab GTPases and PD 
Several mutations in a subset of Rab GTPases including Rab39B and Rab7L1 were 
reported to be linked to PD. 
Mutations in Rab39B were shown to be associated with the X-linked early onset PD 
(Lochte et al., 2016). To date, there are four X-linked Rab genes and three of them, 
including Rab39B, are specific to the brain (Lesage et al., 2015). Most identified 
mutations in Rab39B lead to a complete loss of function, for instance, a ∼45-kb 
deletion resulting in the complete loss of RAB39B in an Australian kindred and a 
missense mutation in a large Wisconsin kindred (Lesage et al., 2015). This indicates 
that Rab39b loss of function may lie behind mechanism of PD. 
Another Rab protein widely reported to be mutated in PD is Rab7L1 (Satake et al., 
2009). Rab7L1 (also known as Rab29), is one of 5 genes that is mutated in 
Parkinson’s patients that have the PARK16 mutation. It was reported by some that 
mutation in Rab7L1, the rs1572931 single-nucleotide polymorphism (SNP) of the 
putative promoter of the member RAS oncogene family-like 1 (RAB7L1) gene, is 
associated with reduced risk for Parkinson's disease (PD) in the Ashkenazi Jewish 
population but not in Chinese population (X. Y. Guo et al., 2014). Whereas other lab 
demonstrate that RAB7L1 (p.K157R) and SLC41A1 (p.A350V) variants are causing 
PD (Tucci et al., 2010). Overall studies suggest that mutation in Rab7L1 cause a 
complex late onset PD. Moreover, it was shown that RAB7L1 interacts with LRRK2 
(Beilina et al., 2014) and together they regulate axonal morphology and lysosome 
integrity in diverse cellular contexts (Kuwahara et al., 2016). Depletion of Rab7L1 
reportedly induced loss of dopaminergic neurons, similar to that observed with 
LRRK2-G2019S expression (MacLeod et al., 2013).These findings suggest that 





Moreover, overexpression of Rab8a, Rab1 and Rab3a protein attenuated α-
synuclein-induced cytotoxicity in cellular and animal models of PD (G. Ito et al., 
2016). 
As mentioned previously LRRK2 phosphorylates Rab10 and Rab8A at T73 and T72 
respectively. Interestingly, it was also reported that PINK regulates phosphorylation 
of Rab8A at S111 and that this phosphorylation at S111 significantly impairs Rab8A 
activation by its cognate guanine nucleotide exchange factor (GEF) (Lai et al., 2015). 
This data suggests that PINK1 and LRRK2 converge on regulating Rab GTPase 
biology. This findings are of great interest as they suggest a link between the PINK 
and LRRK2 pathways in controlling PD biology (Figure 1.11).  
 









1.5.3 Identification of S910 and S935 as major LRRK2 phosphorylation sites 
In a previous study, our laboratory identified a useful biomarker for LRRK2 activity. 
We revealed that treatment of cells or mice with every structurally distinct LRRK2 
kinase inhibitor, tested in our lab, causes dephosphorylation of LRRK2 at two 
residues: Ser910 and Ser935 (Dzamko et al., 2010). Moreover, the data indicated 
that these sites do not comprise LRRK2 autophosphorylation sites but are instead 
regulated by a distinct signalling mechanism that is controlled by LRRK2. One of the 
reported evince is that in macrophages, S910 and S935 were shown to be 
phosphorylated by the IkappaB kinase family and that pharmacological inhibition of 
LRRK2 kinase activity did not cause dephosphorylation of these sites, suggesting 
that these sites are not LRRK2 autophosphorylation sites (Dzamko et al., 2012). 
Furthermore, it was reported that LRRK2 binds to 14-3-3 isoforms via the 
phosphorylation of S910 and S935 (Dzamko et al., 2010; Nichols et al., 2010). 14-3-
3s comprise an abundant family of proteins that primarily targets phosphorylated S 
and T residues (MacKintosh, 2004). They acts as dimers allowing phosphorylated 
peptides to dock directly into each side of the inner groove of the 14-3-3 dimer 
(MacKintosh, 2004). The ability of 14-3-3s to simultaneously bind phosphosites has 
an important functional impact. For example, they can induce a dramatic 
conformational change in the target protein or cause its dissociation resulting in a 
change of protein subcellular localization. It was shown that dephosphorylation of 
S910 and S935 residues results in disruption of 14-3-3s binding and LRRK2 
accumulation within inclusion bodies in vitro (Dzamko et al., 2010). In addition, 
dephosphorylation of S910 and S935 are used in our laboratory as biomarkers to 





1.6 Genetic and pharmacological studies of LRRK2 using a mouse model 
1.6.1 Phenotype of LRRK2 knock-out and knock-in genetic mice models 
LRRK2 knock-out (LRRK2 KO) mouse model 
To study the normal function of LRRK2 in vivo, LRRK2 KO mice were generated and 
examined throughout their life span by different laboratories. It was reported that 
LRRK2 KO mice appear normal and display no obvious phenotype (Tong et al., 
2012). Moreover, deletion of LRRK2 did not appear to influence the number of 
dopaminergic neurons and the levels of striatal dopamine in mice (Tong et al., 2012). 
Besides, in LRRK2 KO mice there was no evidence of abnormal accumulation and 
aggregation of α-synuclein and ubiquitin, which is normally observed in PD patients, 
in aged LRRK2 KO brains (Tong et al., 2012). Unexpectedly, it was reported that 
LRRK2 KO mice develop age-dependent abnormalities in the kidneys. It was shown 
that by approximately 20 months of age, LRRK2 KO kidneys appeared significantly 
smaller in size (30% less in weight), much darker in color and displayed a rough and 
granular surface (Tong et al., 2012). Biochemical analysis of aged LRRK2 KO 
kidneys showed an evident increase in the levels of α-synuclein, ubiquitinated 
proteins and abnormal accumulation of lipofuscin granules (Tong et al., 2012). It was 
then hypothesized that the autophagy-lysosomal pathway, which has been 
implicated in neurodegenerative disorders such as PD, was impaired in LRRK2 KO 
kidneys. Furthermore, additional research showed that deletion of LRRK2 causes 
alterations in proximal tubule secondary lysosomes and lung type II pneumocyte 
lamellar bodies (Herzig et al., 2011), suggesting LRRK2’s role in homeostasis of 
lamellar bodies in lung type II pneumocytes. It was reported that there is no 
compensatory upregulation of LRRK1 in the absence of LRRK2 (Reyniers et al., 





linked to PD (Schulte et al., 2014), indicating that the observed phenotype is linked 
to the removal of the LRRK2 protein. Studies of LRRK2-deficient rats confirmed 
kidney and some lung morphological and histological alterations observed in LRRK2 
KO mice suggesting that LRRK2’s involvement with kidney and lung homeostasis is 
not only observed in mice and may be conserved across various species (Baptista et 
al., 2013). These observations are of potential concern for a drug that would be used 
for the chronic treatment of PD, as they suggest that LRRK2 inhibition can lead to a 
severe phenotype in the peripheral organs. 
LRRK2 kinase dead (LRRK2 KD) mouse model 
In order to determine how kinase function contributes to the roles of LRRK2 in vivo, 
mutant mice were generated by distinct laboratories carrying kinase-inactivating 
point mutations, including D1994S. It was reported that no brain phenotype was 
observed in LRRK2 KD as well as LRRK2 KO mice (Herzig et al., 2011). However, 
the LRRK2 KD mice were reported to develop a dark kidney phenotype at an age of 
26 months similar to that observed in LRRK2 KO mice (Herzig et al., 2011). These 
studies strongly indicated that LRRK2 kinase activity might be responsible for kidney 
phenotype. However, there was no evidence to suggest that the lung phenotype 
observed in LRRK2 KO mice was due to the inactivation of the LRRK2 kinase 
activity, and thus indicating that other functions of LRRK2 such as scaffold or 
GTPase activity could be implicated in this phenomenon (Herzig et al., 2011). 
Interestingly, it was reported that the loss of the LRRK2 kinase function in the 
kidneys results in a significant reduction in full-length LRRK2 protein levels, and this 
might be responsible for triggered changes in the kidneys (Herzig et al., 2011). As it 
was previously described, LRRK2 inhibition results in dephosphorylation of LRRK2 





activity. Interestingly, it was observed that in the LRRK2 [D2017A] KD knock-in S910 
and S935 are still phosphorylated despite loss of LRRK2 activity (Genta Ito, 
Fujimoto, Kamikawaji, Kuwahara, & Iwatsubo, 2014). This could be explained by a 
compensation mechanism, which took place in LRRK2 [D2017A] KD mice and in 
which the upstream kinase that phosphorylates these sites becomes uncoupled from 
LRRK2.  
LRRK2 gain of function mutation: [G2019S] and [R1441G] mouse model 
G2019S is the most commonly reported LRRK2 mutation, which accounts for the 
vast majority of LRRK2-associated PD cases. As it was previously described, it is 
located within the subdomain VII DFG of the kinase domain and was shown to 
increase LRRK2 kinase activity two to three folds both in vitro and in vivo. It was 
shown that G2019S mutant mice do not display a dark kidney phenotype as 
observed in LRRK2 KO and KD mice (Herzig et al., 2011). It was also observed that 
no lung phenotype was associated with the G2019S mutant as well as KD. 
Interestingly, the G2019S mutation that enhances kinase activity did not show any 
destabilization effects on the protein in the kidney of mutant mice. It also was noted 
that the G2019S mutation did not result in an enhanced phosphorylation at the S910 
and S935 sites suggesting that stimulated LRRK2 kinase activity does not increase 
phosphorylation of these residues further. (Herzig et al., 2011). Furthermore, it 
appears that this mutation does not cause any major brain phenotype (Herzig et al., 
2011). However, a recent report suggests altered development of the synapse 
structure and function in striatum in mice caused by the G2019S mutation 
(Matikainen-Ankney et al., 2016). Therefore, these observations provide a novel 





may predispose striatal circuitry to both motor and nonmotor dysfunction later on in 
life (Matikainen-Ankney et al., 2016).  
R1441G is another well-characterized LRRK2 PD-associated mutation (Y. Li et al., 
2009). It is known to be located within the GTPase domain and it was not shown in 
vitro to alter the LRRK2 kinase activity. However, after the discovery of the Rab10 
protein as a physiological LRRK2 substrate, it was possible to assess the impact of 
LRRK2 R1441G mutation in vivo (G. Ito et al., 2016). Remarkably, in this mouse 
model LRRK2 phosphorylates Rab8A and Rab10 more than 4 fold compared with 
the wild type. These observations strongly suggest that overactivation of LRRK2 
kinase activity is implicated in the disease. A R1441G transgenic mouse displayed 
the most evident PD-associated phenotype (Y. Li et al., 2009). It was reported that it 
had an age-dependent and progressive motor-activity deficits, beginning with 
reduced mobility that was reminiscent of hypokinesia in PD (Y. Li et al., 2009). 
Moreover, levodopa and a direct-acting dopamine agonist, apomorphine, both 
reversed these deficits. Furthermore, a pathological analysis of the brain revealed no 
general abnormalities in brain structure but substantia nigra pars compacta (SNpc) 
abnormalities such a decrease of the average cell body size, a marked diminution in 
the number of tyrosine hydroxylase–positive dendrites as well as impaired dopamine 
release. These findings suggest that R1441G transgenic mice are to date the best 
PD models that successfully recapitulate the motor behaviour, neurochemical and 
histopathological features of controlled human disease (Y. Li et al., 2009). In fact, 
these mice could serve as a powerful tool for in vivo mechanistic studies and 
therapeutic development. Interestingly enough, it is reported that both in vitro and in 
vivo, R1441G mutation results in dephosphorylation of S910 and S935 sites (Muda 





sites results in loss of 14-3-3 binding in vitro and mislocalization, it was hypothesized 
that phosphorylation of S910 and S935 sites could be associated with PD. This is the 
reason why our laboratory aimed to understand the biological significance of these 
sites. 
1.6.2 Phenotype of pharmacological inhibition of the LRRK2 kinase activity 
Inhibition of the LRRK2 kinase activity is under investigation as a possible treatment 
for PD. However, the safety implications of targeting the LRRK2 activity are not fully 
understood. It was reported that treatment of non-human monkeys (NHPs) with 
distinct LRRK2 kinase inhibitors resulted in the abnormal accumulation of lamellar 
bodies in type II pneumocytes (Fuji et al., 2015) . Furthermore, it was suggested that 
lung toxicity may be the primary clinical safety liability of LRRK2 kinase inhibitors in 
patients (Fuji et al., 2015). Due to the fact that the same lung toxicity was observed 
in LRRK2 KO mice but not in LRRK2 KD mice, it could be that employed inhibitors 
altered another aspect of the LRRK2 function or the observed phenotype could be 
due to an off-target effect. In future, it would be important to test the effect of 
different, more specific inhibitors such as ML-2 in NHPs to completely rule out the 
possibility of off-target effect. It is interesting to note that no lung phenotype in mice 
or rats treated with the same inhibitors was observed, which highlights the 
importance of species selection when evaluating clinical safety of LRRK2 kinase 
inhibitors. In fact, rodents might not be adequate model to recapitulate the effect of 
LRRK2 kinase inhibitors.  Interestingly, pharmacological inhibition of LRRK2 kinase 
activity in NHPs resulted in a trend towards a decrease in the total LRRK2 in kidneys 
and PBMCs. This is consistent with LRRK2 KD results and suggests that the LRRK2 
kinase activity could be implicated in the kidney phenotype. As it is known that 





important to assess whether dephosphorylation of these sites is implicated in the 






























2.1 Materials  
2.1.1 Commercial reagents  
Adenosine 5’-triphosphate sodium salt (ATP), anti-HA-agarose, anti-FLAG-agarose, 
ammonium persulphate (APS), ampicillin, benzamidine, bovine serum albumin 
(BSA), bromophenol blue (BPB), dimethyl pimelimidate (DMP), dimethyl sulphoxide 
(DMSO), ethidium bromide, hydrogen peroxide, iodoacetamide, puromycin, N-
ethylmaleimide (NEM), sodium dodecyl sulphate (SDS), sodium tetraborate, 
thymidine, N, N, N‟, N‟-Tetramethylethylenediamine (TEMED), Triton-X-100 and 
Tween-20 were from Sigma-Aldrich (Poole, UK). Protein A-agarose, Protein G-
sepharose, Glutathione-sepharose, Enhanced chemiluminescence (ECL) kit and 
Hyperfilm MP were from Merck. Dulbecco‟s modified eagle medium (DMEM), Opti-
MEM reduced serum media, Foetal bovine serum (FBS), tissue culture grade 
Dulbecco‟s phosphate buffered serum (PBS), Trypsin/EDTA solution, L-glutamine, 
non-essential amino acids, vitamins, sodium pyruvate and antibiotic/antimycotic were 
from GIBCO (Paisley, UK). [γ32P]-labelled ATP was purchased from Perkin Elmer. 
Acetic acid, acetone, ammonium bicarbonate, ethanol, glycerol, glycine, 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (Hepes), isopropanol, magnesium 
chloride, manganese chloride, methanol, 2-mercaptoethanol, orthophosphoric acid, 
potassium chloride, sodium chloride, sodium ethylenediaminetetraacetic acid 
(EDTA), sodium ethylene glycol tetraacetic acid (EGTA), sodium fluoride, sodium β-
glycerophosphate, sodium orthovanadate, sucrose and 
Tris(hydroxymethyl)methylamine (Tris) were from BDH (Butterworth, UK) or Sigma-
Aldrich (Poole, UK). Microcystin-LR was from Enzo Life Sciences (NY, USA). 6, 24 
and 96 well tissue culture plates, cell culture dishes, cryovials and Spin-X columns 





Plus pre-stained protein markers were from Bio-Rad (Herts, UK). Cell scrapers were 
from Costar (Cambridge, USA). 40% (w/v) 29:1 Acrylamide: Bis-Acrylamide solution 
was from Flowgen Bioscience. Pre-cast NuPAGE Novex SDS polyacrylamide 4-12% 
Bis-Tris gels, NuPAGE MES and MOPS running buffer (20X), 10X NuPAGE sample 
reducing agent, 4X NuPAGE LDS sample buffer, Colloidal blue staining kit, Alexa 
Fluor donkey secondary antibodies were from Invitrogen (Paisley, UK). Instant-Blue 
stain was from Expedeon, UK. Photographic developer (LX24) and liquid fixer 
(FX40) were from Kodak (Liverpool, UK). X-ray films were from Konica Corporation 
(Japan). Agarose, phenylmethanesulphonylfluoride (PMSF), Geneticin (G418) and 
Isopropyl-β-D-thiogalactopyranoside (IPTG) were from Melford Laboratories 
(Chelsworth, UK). Restriction enzymes, DNA ligase and DNA ladder were from New 
England Biolabs (Hertfordshire, UK). Coomassie protein assay reagent (Bradford 
reagent) was from Pierce (Chester, UK). Hygromycin, blasticidin and 
polyethylenimine (PEI) were from Polysciences (Warrington, PA). Skimmed milk 
(Marvel) was from Premier Beverages (Stafford, UK). Taq DNA polymerase in 
storage buffer A, sequencing grade trypsin and nucleotide mix (dNTP) were from 
Promega (UK). Sequencing grade Asp-N was from Roche. P81 paper and 3 mm 
chromatography paper were from Whatman InterInternational Ltd (Maidstone, UK). 
Plasmid Maxi kits were from Qiagen Ltd (Crawley, UK). Acetonitrile (HPLC grade), 
trichloroacetic acid (TCA) and trifluoroacetic acid (TFA) were from Rathburn 
Chemicals (Walkerburn, UK). Protran BA nitrocellulose membrane was purchased 
from Schleicher and Schuell (Anderman and Co. Ltd., Surrey, UK). HRP-conjugated 
secondary antibodies and Super Signal West Dura extended duration substrate were 
from Thermo-scientific (Essex, UK). Mouse Rota-Rod was purchased from Ugo 





2.1.2 In-house reagents  
Oligonucleotide primers were custom synthesised by the University of Dundee 
oligonucleotide synthesis service. Bacterial culture medium Luria Bertani broth (LB) 
and LB agar plates were provided by the College of Life Sciences media kitchen 
service.  
2.1.3 Antibodies  
2.1.3.1 In-house antibodies  
In-house sheep polyclonal antibodies (Table 2.1) were generated by the Division of 
Signal Transduction Therapy (DSTT, University of Dundee). For this purpose, 
antisera were raised in sheep by Diagnostics Scotland (Carluke - Lanarkshire, UK). 
Then, all in-house antibodies were affinity purified on CH-Sepharose covalently 
coupled to the corresponding antigen. 
In-house phospho-specific antibodies were produced by Division of Signal 
Transduction Therapy (DSTT, University of Dundee). For this purpose, the phospho-
peptide immunogen was conjugated to BSA and also separately to keyhole limpet 
haemocyanin (KLH). Then, these BSA and KLH conjugates were injected into sheep 
along with Freund’s Adjuvant. Treated sheep was left to recover for three weeks and 
then were injected again with a booster and the first bleed was collected a week 
later. This was repeated to produce a total of 3-5 bleeds. Each bleed was allowed to 
clot overnight at 4°C, centrifuged at 1500xg for 60 min at 4°C and filtered through 
glass wool prior to storage at -20°C. To purify the antibodies, serum was heated for 
20 min at 56°C and filtered through a 0.4 micron filter. The anti-serum was diluted 
with an equal volume of 50 mM Tris-HCL pH 7.5 containing 2% Triton-X 100 and 
passed through a column of phospho-peptide immunogen couple to Sepharose. 





against PBS. Solubility of respective non-phospho peptide was determined and 
dissolved in a buffer of appropriate pH range. In my experiments antibodies were 
used at a concentration of 1 μg/ml in 5% skimmed milk in TBST (0.1% Tween20). 
Phospho-specific antibodies were used at a concentration of 1 μg/ml in 5% BSA in 
TBST supplemented with non-phospho peptide (10 μg/ml) to increase specificity. 
Table 2.1:  List of in-house antibodies 
Antibody Antigen Species Bleed 
anti-LRRK2 Human LRRK2 (100 - 500) Monoclonal Rabbit 
10-12 
1 
anti-pS935 LRRK2 NLQRHSNS*LGPIFDH 




anti-pS910 LRRK2 VKKKSNS*ISVGEFY 






Human MYPT1 (714-1005) Polyclonal 
S662B 
1 
anti-pThr500 MYPT1 GTRLAYVTPT*IPRRLASTSSS 




anti-RPS15 Human RPS15 Polyclonal 
S775D 
1-3 
anti-pT136 RPS15 HGRPGIGAT*HSSRFIPLK 






2.3.1.2. Commercial/gifted antibodies  
Table 2.2 presents antibodies obtained from the indicated commercial sources and 













Table 2.2: List of commercial antibodies used in this thesis 
Antibody Company Catalogue Number Host 
HA-HRP Roche 12013819001 - 
FLAG-HRP Sigma A8592 
 
- 
14-3-3 Santa Cruz Sc-629 Rabbit 
GAPDH Cell Signalling 2118 Rabbit 
Rab10 Cell Signalling 8127 Rabbit 
Rab8A Cell Signalling D22D8 Rabbit 
MYPT1 Celli Signalling 2634 Rabbit 
PALM Sigma-Aldrich 356-370 Rabbit 
MAP4K4 Cell Signalling 5146 Rabbit 
GFP Chromotek 3H9 Rat 
 
2.1.4 Plasmids  
Dr. M. Wightman, Dr.  M. Peggie, and Mr. T. McCartney performed the cloning, 
subcloning and mutagenesis of the constructs reported in my thesis. Table 2.3 
summarises all the mammalian constructs used in this work while Table 2.4 lists the 
constructs used to purify recombinant proteins from E.coli BL21 DE3 cells (2.2.4). 
Table 2.3: Mammalian expression constructs 
Expressed Proteins Plasmid  Clone ID 
FLAG-LRRK2 [1-1326](WT) pcDNA5-FRT/TO-FLAG LRRK2 N-Term(1-
1326) 
DU13369 
FLAG-LRRK2 [1326-end](WT) pcDNA5-FRT/TO-FLAG LRRK2C- 
-Term(1326-end) 
DU13588 
FLAG-LRRK2 [full length](WT) pcDNA5-FRT/TO-FLAG LRRK2 DU13952 
GST-LRRK2[1326-end](G2019S) pEBG LRRK2 1326-end G2019S DU44733 
FLAG-MYPT1 [A498T+T500A] pcDNA5D frtTO FLAG MYPT1 A498T DU48541 
FLAG-RPS15(WT) pcDNA5D frtTO FLAG MYPT1 A498T 
T500A 
DU48540 
FLAG-RPS15 T136A pCMV5D FLAG RPS15 DU25491 
FLAG-EMPTY pCMV5D FLAG RPS15 T136A DU48728 
FLAG-KCC3A T1039E pcDNA5 FRT/TO DU41457 





FLAG-SGK3 pcDNA frtTO FLAG SGK3 DU42867 
FLAG MYPT1 WT pcDNA frtTO FLAG MYPT1 WT DU30035 
GFP-EMPTY pcDNA frtTO GFP DU52527 
GFP-LRRK2 WT pcDNA frtTO GFP LRRK2 full WT DU13363 
GFP-LRRK2 [S910A+S935A] pcDNA frtTO GFP LRRK2 S910A+S935A DU30902 
GFP-MYPT1 WT pcDNA5D frtTO GFP MYPT1 rescue DU52526 






pcDNA5D FRT/TO GFP MYPT1 guide 
protected + T500A 
DU50641 
HA-EMPTY pcDNA5 FRT/TO HA empty DU50659 
HA-14-3-3 pCMV-HA 14-3-3 zeta DU6742 
HA-PALM pcDNA5D frtTO HA PALM DU48752 
HA-GNAI2 pCMV5-HA2 GNAI2 DU16892 
HA-MRIP pCMV5-HA M-RIP DU11147 
HA-NRAS pCMV5D HA NRAS DU48137 
HA-SNAP23 pCMV5D HA SNAP23 DU25495 
HA-THBS1 pCMV5D HA THBS1 DU25544 
 
Table 2.4: Bacterial expression constructs 
Expressed Proteins Plasmid Clone 
ID 
GST-MYPT1 pGEX-6-MYPT1 (human) protein 










GST-RPS15 pGEX RPS15 WT DU48445 
GST-RPS15 T136A pGEX RPS15 T136A DU48444 
GST-PALM pGEX PALM DU25823 
GST-PALM2 pGEX PALM2 DU48735  
GST-PALM3 pGEX6P1 PALM3 DU48825 
GST-PALMD pGEX6P3 PALMD DU48940 





GST-SNAP23 pGEX6P1 SNAP23 DU48915 
GST-CTNNA1 pGEX6P1 CTNNA1 DU25458 
GST-M-RIP pGEX6P-1 M-Rip DU46333 
GST-MME(1-29) pGEX6P1 MME DU25496 
GST-MME(52-end) pGEX6P1 MME Y52-end DU25562 
GST-CAPZB pGEX6P-1-CAPZB DU3292 
GST-GNAI2 pGEX6P1 GNAI2 DU46316 
 
In addition to described plasmids I used TALE monomer template plasmids 
(Addgene): pNI_v2, pNG_v2, pNN_v2, pHD_v2; TALE transcriptional activator 
(TALE-TF) plasmids (Addgene): pTALE-TF_v2 (NI), pTALE-TF_v2 (NG), pTALE-
TF_v2 (NN), pTALE-TF_v2 (HD); TALE nuclease (TALEN) backbone plasmids 
(Addgene): pTALEN_v2 (NI), pTALEN_v2 (NG), pTALEN_v2 (NN), pTALEN_v2 
(HD) were obtained as a single kit from the Zhang Lab plasmid collection at 
Addgene. 
2.1.5 Inhibitors  
Table 2.5 summarises the various small molecule inhibitors used in this thesis. All 
LRRK2 kinase inhibitors were synthesized in house by Dr Natalia Shpiro (DSTT, 









Table 2.5: Kinase and phosphatase inhibitors  
Compound Target Structure MW (g/mol) Publication 
GSK2578215A LRRK2 
 





570.69 Deng X. (2011) 









 Matthew J. Fell 









Cohen, & Codd, 
1990) 
 
2.1.6 Buffers  
Table 2.6 summarises buffers used in this work. Lysis buffers comprise a cocktail of 
different phosphatase inhibitors. For instance, sodium fluoride, sodium 
pyrophosphate, sodium β-glycerophosphate inhibit serine/threonine protein 
phosphatases whereas sodium orthovanadate (Na3VO4) inhibits protein tyrosine 
phosphatases. Sodium orthovanadate was prepared by several rounds of boiling, 
cooling to room temperature on ice and then adjusted to pH 10. This was repeated 
until the pH was stable at pH 10 and the solution remained colourless. This ensures 
that the majority of sodium orthovanadate is in the monomeric state enabling 
inhibition of tyrosine phosphatases. EDTA and EGTA are chelating agents. EDTA 
chelates divalent cations including Mg2+ and thus inhibits metal dependent enzymes 





towards Ca2+. Benzamidine and PMSF are added to inhibit serine proteases and 
metallo, aspartyl, cysteinyl, and seryl proteinases.  
Table 2.6: Buffers and compositions 
Buffer Composition 
1% Triton Lysis Buffer 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM 
EDTA, 1% (v/v) Triton X-100, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 5 mM 
sodium pyrophosphate, 0.27 M sucrose, 
0.1% β-mercaptoethanol, 1 mM benzamidine 
and 0.1 mM phenylmethanesulphonylfluoride 
(PMSF) and one mini Complete™ protease 
inhibitor cocktail tablet per 10ml of lysis 
buffer. 
1% Triton Phosphatase lysis Buffer 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM 
EDTA, 1% (v/v) Triton X-100, 0.27 M 
sucrose, 0.1% β-mercaptoethanol, 1 mM 
benzamidine and 0.1mM phenylmethane-
sulphonylfluoride (PMSF) and one mini 
Complete™ protease inhibitor cocktail tablet 
per 10ml of lysis buffer. 
Phosphate buffered saline (PBS) 137mM NaCl, 2.7mM KCl, 8.1mM di-sodium 
hydrogen phosphate, 1.5mM potassium 
dihydrogen phosphate pH 7.4. 
GST bacterial lysis buffer 50 mM Tris/HCl pH 7.5, 270 mM sucrose, 
150 mM NaCl, 0.1 mM EGTA, 1 mM 
benzamidine 0.2 mM PMSF and 0.1% β-
mercaptoethanol. 
GST bacterial elution buffer 50 mM Tris/HCl pH 7.5, 270 mM sucrose, 
150 mM NaCl, 0.1 mM EGTA, 50 mM 
glutathione, 1 mM benzamidine 0.2 mM 
PMSF and 0.1% β-mercaptoethanol. Adjust 
pH to 7.5.  
8 M Urea Lysis Buffer Add 8 M urea to the 1% Triton lysis buffer 
described previously. 
Buffer A 50mM Tris-HCl pH 7.5, 0.1mM EGTA, and 
0.1% β-mercaptoethanol. 
TBST 50 mM Tris-HCl pH 7.5, 0.15 M NaCl and 
0.1% (v/v) Tween-20 
5X SDS-PAGE Sample Buffer 5% SDS, 5% (v/v) β-mercaptoethanol, 
250mM Tris-HCl pH 6.8, 32.5% (v/v) glycerol, 
Bromophenol Blue for blue colour intensity. 
SDS-PAGE Running Buffer 25mM Tris-HCl pH 8.3, 192mM Glycine, 
0.1% (w/v) SDS. 
4x Laemmli’s Sample Buffer 250 mM Tris-HCl pH 6.8, 8% (w/v) SDS, 40% 
(v/v) glycerol, 0.02% (w/v) Bromophenol 
Blue. Add MnCl2 at a final concentration of 10 
mM to all samples. 
Phos-tag lysis buffer  50 mM Tris-HCl pH 7.5 , 1%(v/v) Triton X-
100, 1 mM EGTA, 1 mM sodium 
orthovanadate, 50 mM NaF,0.1%(v/v) β-
mercaptoethanol,10 mM β-glycerophosphate, 
5 mM sodium pyrophosphate, 1μg/ml 
mycrocystin-LR, 0.27 M sucrose and one 





tablet per 10ml of lysis buffer. 
Phos-tag washing buffers Wash 1-2: transfer buffer containing 10 mM 
EDTA and 0.05% SDS. Wash 3: transfer 
buffer containing 10 mM EDTA (no SDS). 
Western Blotting Transfer Buffer 48mM Tris-HCl, 39mM Glycine, 20% (v/v) 
Methanol.  
 
ECL Solution 1 0.1M Tris-HCl pH 8.5, 2.5 mM Luminol, 
0.4mM p-Coumaric acid. 
ECL Solution 2 0.1M Tris-HCl pH 8.5, 5.6mM Hydrogen 
peroxide. 
TAE buffer 40mM Tris-acetate pH 8, 1mM EDTA. 
Kinase assay reaction buffer 50mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 10 
mM MgCl2, 2 mM DTT and 0.1 mM [γ-32P] 
ATP (approx. 500 cpm/pmol). 
 
2.1.6 Cell lines  
I generated LRRK2 WT, LRRK2 [S910A+S935A] knock-in and LRRK2 KO mouse 
embryonic fibroblasts (MEFs) by prolonged passaging of MEF cells derived from 
LRRK2 WT, LRRK2 [S910A+S935A] knock-in or LRRK2 KO mouse.  
HEK293 [MAP4K4 (1-9) KO] cells were kindly provided by Professor Kun-Liang 
Guan’s laboratory from University of San Diego. 
2.1.7 Animals 
LRRK2 [S910A+S935A] mice were purchased from Taconic-Artemis GmbH, 
Germany. Animals were maintained under specific pathogen-free conditions and 
routine animal tail and ear notching was carried out by staff in the College of Life 
Sciences Transgenic Unit (University of Dundee). All procedures were carried out in 
accordance with the regulations set by the University of Dundee and the United 
Kingdom Home Office.  
2.1.8 Instruments  
X-Cell SureLock Mini-cell electrophoresis systems and X-Cell II Blot modules were 
from Invitrogen (Paisley, UK). AE6450 Atto Vertical Dual Mini Slab Kits were from 





processors and gel dryer apparatus were from BioRad (Herts, UK). X-omat 
autoradiography cassettes with intensifying screens were from Kodak. Automatic film 
processor was from Konica Corporation. The Procise 494C Sequenator was from 
Applied Biosystems (Foster City, USA). HPLC system components were obtained 
from Dionex (Camberley, UK). The Vydac 218TP54 C18 reverse phase HPLC 
column was from Separations group. The LTQ-orbitrap mass spectrometer and 
Nanodrop was from Thermo Scientific. The PCR thermocycler (PTC-200) was from 
MJ Research. The 96-well Versamax plate reader was from Molecular Devices 
(Wokingham, UK) Thermomixer IP shakers were purchased from Eppendorf 
(Cambridge, UK). Centrifuge tubes, rotors and centrifuges were from Beckmann. 
Biofuge pico microcentrifuge was from Haraeus Instruments (Osterode, Germany). 
pH meters and electrodes were from Horiba (Kyoto, Japan). Scintillation counter (Tri-
Carb 2800 TR) was from Perkin-Elmer. Vibrax-VR platform shaker was from IKA. 
Balances were from Ohaus. Sonicators were from Sonics and Materials. Speed-vacs 
were from CHRIST. Gel Electrophoresis System (Horison 11-14) was from Life 
Technologies. Tissue culture class II safety cabinets were from Medical Air 
Technology (Oldham, UK). CO2 incubators were from Mackay and Lynn (Dundee, 










2.2 Methods  
2.2.1 MOLECULAR BIOLOGY METHODS 
2.2.1.1 Transformation and plasmid purification from E.coli  
Calcium competent E.coli DH5α cells were kindly provided by Dr Mark Peggie using 
a previously described method (Inoue et al, 1990). For each transformation, 
approximately 5-20 ng DNA was added to 35 µl of competent cells and incubated on 
ice for 5 min. Cells were then subjected to heat shock at 42°C for 90 s in a water 
bath to induce the uptake of DNA and briefly placed back on ice. Bacteria were then 
spread onto LB agar plates containing 100 µg/ml ampicillin and incubated at 37°C 
overnight. DNA for mammalian cell transfection was amplified in E.coli DH5α strain. 
2.2.1.2 Purification of plasmid DNA from E.coli 
Transformed DH5α E.coli were cultured in 150 ml LB containing 200 mg/L ampicillin 
at 37°C overnight and cells were pelleted by centrifugation at 6000 g for 15 min. 
Plasmid DNA was purified using a Qiagen plasmid Maxi kit according to the 
manufacturer’s instructions. This yields an approximate of 0.5-1 mg plasmid DNA. 
2.2.1.3 Measurement of DNA concentration  
DNA concentration was measured using NanoDrop according to manufacturer’s 
instructions. DNA absorb at 260nM. Absorbance was also measured at 280nM 
because calculation of 260/280 ratio permits the calculation of purity. Ratios of 
greater than 1.8 are considered as pure. Lower ratios suggest the presence of 








2.2.1.4 Restriction enzyme digests of plasmid DNA 
Restriction digests were carried out using 1 µg DNA in the presence of 2 µl 10X 
stock of the appropriate digestion buffer and 1U of corresponding restriction enzyme 
in a final volume of 20 µl. Reactions were incubated at 37°C for 3 hrs and analyzed 
via agarose gel electrophoresis.  
2.2.1.5 DNA mutagenesis 
All mutagenesis reactions were performed using the QuikChange site directed 
mutagenesis method (Stratagene) with KOD polymerase (Novagen) as per 
manufacturing instructions. DNA constructs were verified by DNA sequencing. 
2.2.1.6 Genome editing-TALENs: (Knocking out MYPT1 from HEK293 cells 
using TALENs). 
 
Transcription activator-like nucleases (TALENs) were synthesized and assembled by 
Golden Gate digestion-ligation, using a standard protocol (Sanjana et al., 2012) with 
the help of Dr Piotr Szyniarowski. MYPT1 TALENs were designed to target MYPT1 
1st exon as shown in a Table 2.7. Spacer strand sequence between two TALENs 
was chosen so that it comprises PVUII restriction site. 





















NN NI NI NN 
NI NG NN NN 
HD NN NN NI 
HD NN HD NN 
NI NI NN 
HD NG HD NN 
NN NI NN HD 
HD  NN NI NG 







Lipofectamine (Invitrogen) was used to transiently transfect HEK293 cells with 4 µg 





single cell cloned manually as well as by FACS machine (Dr Rosie Clarke). Single 
cell clones were then selected and tested by PCR, and PVUII restriction enzyme 
digestion. The DNA of clones cleaved by TALENs was then extracted; PCR products 
were inserted into TOPO vector and sequenced. Then, these clones were re-single 
cell cloned again and tested by PCR or Western blotting. 
2.2.1.7 Genome editing-CRISPR/Cas9: (Knocking out MYPT1 from HEK293 




Table 2.8: CRISPR/Cas9 construction details (All constructs generated by Thomas 
McCartney, DSTT, University of Dundee) 
Materials Function  Sequence 
Guide RNA/Cas9 D10A complex 1) Each guide RNA contains a 20 
nucleotide guide sequence, 
which directs Cas9 D10A 
nickase to a 20 nucleotide DNA 
target via Watson-Crick base 
pairing. 
2) Cas9 creates a double-nick 
induced DSB that can be 
repaired by either NHEJ or HDR 
Targeting MYPT1 exon3:  
 
Antisense RNA guide:  
GTCCTCCTCCGCAATATCTAA  
cloned into the Cas9 D10A vector pX335 
 
Sense RNA guide: 
GCAAAATGAAGTTAATCGGCA 
cloned into pBABED puro U6 
Guide protected MYPT1 
sequences 
 
Previous studies strongly indicated 
that MYPT1 KO is lethal. Guide 
protected MYPT1 sequences allow 
to rescue this phenotype. 
Sequence 1 :  
pcDNA5D frtTO GFP MYPT1 rescue 
(guide protected) 
Sequence 2:  
pcDNA5D FRT/TO GFP MYPT1 guide 
protected + T500A 
Sequence3:  




Generation of stable cell lines 
Cell lines with the stable inducible overexpression of GFP-MYPT1 wild-type or 
indicated mutants were generated using Flp-In T-Rex System (Invitrogen) following 
manufacturer's instructions. This system allows a tetracycline-inducible expression of 





vector encoding the gene of interest. Critically, over-expressed MYPT1 proteins were 
designed by Thomas McCartney to be resistant to antisense and sense 
CRISPR/CAS9 guides created to target endogenous MYPT1 by introducing silent 
mutations at the targeted region.   
Targeting endogenous MYPT1 protein by CRISPR/Cas9 
HEK293 cells stably over-expressing GFP MYPT1 WT or mutant protein where 
harvest in recovery media ((DMEM supplemented with 10% (v/v) foetal bovine serum 
(FBS), 2 mM L-glutamine, antibiotic/antimycotic, 1X non-essential amino acids, 1mM 
sodium pyruvate, hygromycin and blasticidin) and transfected with 1 µg of each anti-
sense and sense guide RNAs using PEI transfection reagent (see PEI transfection 
section). 24 hours later media was replaced with selection media comprising 2µg/ml 
Puromycin. Cells that have been successfully transfected with the puromycin 
plasmid are likely to have taken up the remaining constructs also. 24 hours later, 
selection media was replaced again with media containing 2.0 μg/ml Puromycin to 
continue selection. Then, cells were placed into recovery media and transfected 
again with guide RNA/Cas9 complex to maximize the chances of transfection. 24 
hours after transfection cells were selected again with puromycin containing media. 
Next day cells were prepared for FAC sorting and sorted into 96 well plates, each 
contain a single cell. Cells were left to recover in recovering media for couple of 
weeks and then were screen by western blotting. It is important to note that at all 
stages, recovery and selecting media was supplemented with hygromycin and 
blasticidin to ensure the expressing of rescue MYPT1. Experience has proven that in 







2.2.1.8 Agarose gel electrophoresis  
1.7 g of agarose was boiled in 170 ml of 1X TAE buffer. 10 μl of 10 mg/ml ethidium 
bromide were added after the boiled agarose solution cooled down to approximately 
50-60°C and then poured into the gel casting tray. The gel was allowed to solidify 
and electrophoresis was carried out at 100 V for 45 min. 
2.2.1.9 DNA sequencing  
The sequencing was carried out by DNA sequencing service (School of Life 
Sciences, University of Dundee) using DYEnamic ET terminator chemistry kit 
(Amersham Biosciences) on Applied Biosystems sequencers. 
2.2.2 MAMMALIAN CELL CULTURE 
2.2.2.1 Cell culture 
HEK293, HEK293T, HEK293 FLP/IN TREX and MEF cells were grown in 
Dulbecco‟s modified eagle medium (DMEM) supplemented with 10% (v/v) foetal 
bovine serum (FBS), 2mM L-glutamine, antibiotic/antimycotic, 1X non-essential 
amino acids and 1mM sodium pyruvate. Procedures were done under aseptic 
conditions meeting biological safety category 2 regulations. Cells were grown at 
37°C in a 5% CO2 water-saturated incubator. For the passaging, adherent cells were 
washed once with PBS and then incubated with Trypsin/EDTA for 3-5 min at room 
temperature or at 37°C. Fresh media was added and detached cells were 
resuspended in cell culture medium and split at a 1:2 – 1:20 ratios for continued 
culture. 
2.2.2.2 Freezing/thawing of cell lines 
Confluent cells grown in T-75 flasks were trypsinized and collected in culture media 





resuspended in 3 ml of freezing media (50% DMEM/ 40%FBS/ 10% DMSO). 
Aliquots of cells (1 ml) in cryovials were stored in a Nalgene Mr Frosty Freezing 
Container at -80°C for 2 days, and transferred to liquid nitrogen. To thaw the cells, 
each vial was placed in 37°C water bath for 3 min and cells were added to a T-25 
flask containing 10 ml of culture media. Cells were allowed to attach and given a 
media change a day later to remove trace amounts of DMSO. 
2.2.2.3 Transfection of cells using polyethylenimine (PEI) 
Cells were transiently transfected using the polyethylenimine (PEI) method 
(Durocher et al., 2002). 1 mg/mL PEI stock was prepared in 20 mM Hepes (pH 7). 
For transfection of cells grown on 10 cm dishes, 5 µg of DNA was mixed with 20 µL 
1mg/mL PEI and 1 mL serum-free DMEM and left for 15 min at room temperature 
before being added to cells. Cells were harvested 36 hrs post transfection. 
2.2.2.4 Treatment of cells with inhibitors and other agents  
Cells were treated with 1 µM of indicated LRRK2 inhibitor or DMSO control for 1hr 
(or other time point if otherwise indicated) before whole cell lysis.  
2.2.2.5 Generation of stable cell lines  
To ensure low-level uniform expression of recombinant proteins, manufacturer's 
instructions (Invitrogen) were followed to generate stable cell lines that express GFP-
tagged forms of proteins (cDNA subcloned into pcDNA5-FRT-TO plasmid) in a 
tetracycline inducible manner. Flp-In T-REx-293 host cells containing integrated FRT 
recombination site sequences and Tet repressor, were co-transfected with 9 µg of 
pOG44 plasmid (which constitutively expresses the Flp recombinase), and 1 µg of 
pcDNA5/FRT/TO vector containing a hygromycin resistance gene for selection of the 





Cells were selected for hygromycin and blasticidin resistance three days after 
transfection by adding new medium containing hygromycin (100 µg/ml) and 
blasticidin (7.5 µg/ml). After 3 weeks of selection, colonies were trypsinized and 
expanded. Expression of the recombinant protein was induced with 0.1 µg/ml of 
tetracycline for 24 hours. 
2.2.2.6 Cell/tissue lysis 
Cells were lysed using mammalian cell lysis buffer as listed in 2.1.6. Lysates were 
clarified by centrifugation at 15,000 g for 10 min at 4 °C and the supernatant was 
collected. 
2.2.3 PROTEIN BIOCHEMISTRY 
2.2.3.1 Purification of GST recombinant proteins from HEK293 cells 
50-60% confluent HEK293 cells were transfected with corresponding GST-tagged 
LRRK2 constructs by PEI method described previously and harvested following 36-
48 hr. Clarified cell lysates were incubated for 1 hour on a rotating platform with 
glutathione-Sepharose 4B (20 μl beads/5 mg of cell lysate) previously equilibrated in 
PBS. Afterwards, the beads were washed three times with Lysis Buffer containing 
0.5 M NaCl and two times with Buffer A. GST-tagged proteins were eluted from the 
resin with an equal volume of Buffer A supplemented with 150 mM NaCl, 0.27M 
sucrose and 40mM glutathione (pH 7.5-8) for 10min at room temperature on a 
rotating platform. The elution was repeated and all the elusions were pooled 
together, filtered through a 0.22 μm Spin-X column aliquoted, snap-frozen in liquid 
nitrogen and stored at -80°C. Concentration of purified recombinant proteins was 
estimated by Bradford assay and their purity was estimated by SDS-PAGE.  
2.2.3.2 Estimation of protein concentration 





using the Bradford method in a 96 well plate format (Bradford, 1976). 0.2 ml of 
Bradford reagent (Pierce) was added to 10µl of diluted sample (cell lysates were 
usually diluted 10-fold in water). 10ul of water was used as a blank. For a standard 
curve 10μl of serial dilutions of BSA were used (1, 0.5, 0.25, 0.125 and 0.00063 
mg/ml). Absorbance at 595 nm was measured using a 96 well plate reader. All 
samples were measured in triplicate and a standard curve was generated for each 
analysis. Bradford method is a colorimetric protein assay, based on an absorbance 
shift from 465 nm (red) to 595 nm (blue) upon binding to proteins. The Coomassie 
dye binds to arginines, aromatic amino acids, and histidines. For purified proteins, 
Coomassie staining of polyacrylamide gel verified sample purity additionally. 
2.2.3.3 Covalent coupling of antibodies 
Antibodies were covalently coupled to protein G-Sepharose with a dimethyl 
pimelimidate (DMP) cross-linking procedure. DMP has two functional imine groups, 
which interact with free amine groups at pH range 7.0-10.0 to form amidine bonds. 
Antibody-coupled beads (1 µg antibody per 1 µl beads) were prepared by incubating 
antibody with Protein – G Sepharose beads at 4°C for 1hr. The beads were washed 
5 times with 10 volumes of 0.1 M sodium borate pH 9 and then resuspended in 10 
volumes of 0.1 M sodium borate pH 9 containing freshly added dimethyl 
pimelimidate (a fresh batch used every time) to a concentration of 20 mM and 
incubated for 30 min at room temperature with gentle mixing. The beads were 
pelleted and then reincubated with dimethyl pimelimidate. The beads were washed 4 
times with 10 volumes of 50 mM glycine pH 2.5 to remove all the antibodies that 
were not covalently coupled to the beads. The beads were then washed twice with 
0.2 M Tris-HCl pH 8 and incubated in this buffer for a further 2 h at room temp with 





amine group of Tris. The antibody-coupled beads were stored in PBS containing 
0.02% (w/v) sodium azide at 4ºC for up to one month. 
2.2.3.4. Immunoprecipitation 
1 mg of cell lysate was incubated with 5 μg of antibody coupled to 5 μl of protein G-
Sepharose for 2 hrs at 4°C on a rotating wheel. For overexpressed protein 
immunoprecipitation, depending on the tag of the protein, 5 μl of FLAG-agarose or 
HA-agarose or GST-sepharose beads was incubated with 200 μg of cell lysate for 2-
4 hrs at 4°C on a rotating wheel. The mixture was centrifuged for 1 min at 8,000 g 
and the supernatant was removed. The immunoprecipitates were washed twice with 
0.5 ml of Lysis Buffer containing 0.15 M NaCl and twice with 0.5 ml of Buffer A. Then 
either they were used for further assays. Alternatively, immunoprecipitates are 
resuspended in 2xSDS sample buffer (or 2 x NuPAGE LDS sample buffer for mass 
spectrometry) lacking reducing agent for 10 mins prior to filtering through Spin-X 
columns to remove antibody-bound bead, then reducing agent was added to the 
eluted samples and they were heated at 90 oC for 5 mins. 
2.2.3.5 Resolution of protein samples via SDS-PAGE 
SDS polyacrylamide gel electrophoresis (SDS/PAGE) helps to resolve proteins 
according to their apparent molecular weight. SDS and LDS are anionic detergents, 
which coat proteins to give them a net negative charge that is proportional to their 
molecular weight. This enables the migration of proteins through an acrylamide gel 
at a rate that is proportional to their size. Samples are also incubated with reducing 
agents, DTT or βME, to break disulphide linkages and unravel the protein further, to 
ensure it is linear. Cell extract protein in an LDS buffer (20 µg) was subjected to 
SDS/PAGE. A stacking gel (pH 6.8) (125 mM Tris HCl pH 6.8, 0.1% SDS, 4% 





proteins into a narrow band so that they all enter the resolving gel (pH 8.6) 
(contained 375 mM Tris-HCl (pH 8.6), 0.1% SDS and 8-10% acrylamide, TEMED 
and APS) at the same time, enabling proteins of similar molecular weight to migrate 
in tight bands. Resolving gels were composed of different percentages of 
acrylamide, which helped to best resolve proteins of a particular molecular weight. 
The gels were run in Tris-glycine SDS running buffer at a constant 120 V until the 
dye front had reached the bottom of the gel. The electric field applied to the gel 
promotes the migration of the negatively charged proteins away from the cathode, at 
the top of the gel, to the anode. Commercial pre-cast gels (4-12% Bis-Tris, NuPAGE) 
were used if ubiquitin chains were to be investigated or if proteins were to be 
subjected to mass spectrometry. Commercial gels were run in MOPS buffer 
(NuPAGE) if samples were prepared for Mass Spectrometry at a constant 120 V.  
2.2.3.6 Resolution of protein samples via Phos-tag gel and immunoblot 
analysis 
 
Gels for Phos-tag SDS-PAGE consisted of a stacking gel (4%(w/v) acrylamide, 125 
mM Tris-HCl pH 6.8, 0.1%(w/v) SDS, 0.2% (v/v) TEMED, 0.08%(w/v) ammonium 
persulfate (APS)) and a separating gel (12% (w/v) acrylamide, 375 mM Tris-HCl pH 
8.8, 0.1% (w/v) SDS, 75 μM Phos-tag acrylamide, 100 μM MnCl2, 0.1%(v/v) 
TEMED, 0.05% (w/v) APS). Gel mixture was degassed for 10 minutes before adding 
TEMED and APS.  
Cell/tissue were lysed in the absence of EDTA. Lysates were then mixed with 4× 
SDS-PAGE sample buffer (250 mM Tris-HCl pH 6.8, 8% (w/v) SDS, 40% (v/v) 
glycerol, 0.02% (w/v) bromophenol blue and 4% (v/v) β- mercaptoethanol), 
supplemented with 10 mM MnCl2, heated at 95 ºC for 5 minutes and centrifuged at 





Bis-Tris 4-12% gels and electrophoresed at 70 V for the stacking part and at 150 V 
for the separating part with the running buffer (25 mM Tris, 192 mM glycine, 
0.1%(w/v) SDS). Gels were then stained with Colloidal Blue Staining Kit (Life 
Technologies) according to the manufacturer’s instructions. For immunoblot analysis, 
gels were washed for 10 minutes in the transfer buffer (48 mM Tris, 39 mM glycine, 
20%(v/v) methanol) containing 10 mM EDTA and 0.05%(w/v) SDS three times, 
followed by one wash in the transfer buffer containing 0.05% SDS for 10 min. 
Proteins were electrophoretically transferred to nitrocellulose membranes 
(Amersham Protran 0.45 μm NC; GE Healthcare) at 100 V for 180 minutes on ice in 
the transfer buffer without SDS/EDTA. Transferred membranes were blocked with 
5% (w/v) non-fat dry milk (NFDM) dissolved in TBS-T (20 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.1%(v/v) Tween-20) at room temperature for 30 minutes. Membranes 
were then incubated with primary antibodies diluted in 5% Non-fat Dry Milk & Skim 
Milk Powder in TBS-T overnight at 4 ºC. After washing membranes in TBS-T, 
membranes were incubated with HRP-labelled secondary antibodies diluted in 5% 
Non-fat Dry Milk & Skim Milk Powder in TBS-T at room temperature for 1 hour. After 
washing membranes in TBS-T, protein bands were detected by exposing films 
(Medical Film (Konica Minolta) for normal immunoblot and Amersham Hyperfilm ECL 
(GE Healthcare) for Phos-tag immunoblot) to the membranes using an ECL solution 
(Amersham ECL Western Blotting Detection Reagents (GE Healthcare) for normal 
immunoblot and SuperSignal West Dura Extended Duration (Thermo Fisher 
Scientific) for Phos-tag immunoblot). 
2.2.3.7 Coomassie staining of polyacrylamide gel 
Polyacrylamide gels were stained in Instant Blue or Colloidal Coomassie staining 





2.2.3.8 Desiccation of polyacrylamide gels and autoradiography 
Before drying, gels were incubated in 5% glycerol for 10 min and sandwiched 
between two sheets of pre-wet cellophane. The gels were then dried in a GelAir 
Dryer for approximately 1 hour. Dried gels were then exposed to Hyperfilm MP for 24 
hours in an X-Oma autoradiography cassette at -80oC. Films were then developed 
using Konica auto-developer. 
2.2.3.9 Transfer of proteins onto nitrocellulose membranes 
Gels were sandwiched between nylon! sponges, Whatman 3 mm filter papers and 
nitrocellulose membrane all soaked in transfer buffer. The transfer cell was 
submerged in transfer buffer and transfer carried out at 750 mA for 1 hour. 
2.2.3.10 Immunoblotting 
After transfer, membranes were stained with Ponceau S and destained in distilled 
water in order to visualize the transferred proteins. Non-specific binding of antibodies 
was prevented by incubating the membranes with 5% (w/v) skimmed milk in TBST 
for 2 hour at room temperature. Membranes were then incubated with primary 
antibodies diluted according manufacture instructions in either 5% (w/v) skimmed 
milk or BSA in TBST at 4 oC for 16 hours. Membranes were next washed three times 
for 10 min with TBST. Horseradish peroxidase (HRP)-conjugated secondary 
antibodies diluted at 1:2500  in 5% (w/v) skimmed milk in TBST were incubated with 
the membranes for 1 hour at room temperature and the membranes were washed 
three more times with TBST. Membranes were then incubated with the enhanced 
chemiluminescence (ECL) substrate and exposed to X-ray films for various length of 
time. Films were developed using a Konica automatic developer. Were indicated, 
signals were visualized using the OdysseyTM Infrared Imaging System instead of 





either IRD800 or Alexa680 dyes and the signal captured and quantified with an 
Odyssey Infrared Imaging System. 
2.2.4 IN-VITRO ASSAYS 
2.2.4.1 Kinase assay 
Kinase assays employing a protein substrate 
Indicated amounts of kinases were incubated with 1 µg of purified protein substrate 
in the presence of 0.1 mM [γ32-ATP] and 10 mM Magnesium acetate in Buffer A at 
30oC for times indicated in the figure legends. Reactions were terminated with SDS 
sample buffer.  
Kinase assays employing a peptide substrate 
In vitro LRRK2 wild-type and mutants' activities were measured using Cerenkov 
counting of incorporation of radioactive 32P from [γ32P]-labelled ATP into a 
corresponding substrate peptide used (Nictide or LRRKtide). A typical 50 µl kinase 
reaction consisted of 10 mM magnesium acetate, 0.1mM [γ32P] ATP (450-500 
cpm/pmol), 0.1% β-mercaptoethanol, 100 or 300 µM of peptide substrate. Control 
reactions contained either no kinase or IPs with IgG control antibody. Reactions 
were incubated at 30°C for 30 min and were eventually terminated by pipetting 40 μl 
onto a 2 square cm of P81 paper (which binds substrates that contain a net basic 
charge at acidic pH) which was dropped to a beaker containing 50 mM 
orthophosphoric acid. Papers were washed four times in 50 mM orthophosphoric 
acid to remove any unbound radioactivity. Papers were then washed in acetone for 3 
min and air dried. Papers were folded and transferred to 1.5ml tubes and Cerenkov 
counting was done on a liquid scintillation counter. Kinase activity was expressed as 
specific activity (units of activity per mg of protein or lysate used for IP of the protein). 





1µmol of phosphate per 1 µmol of substrate peptide per minute. 
2.2.5 MASS SPECTROMETRY ANALYSIS 
2.2.5.1 Processing protein bands for analysis by mass spectrometry 
Proteins were reduced with 10 mM DTT at 92°C for 5min and alkylated with 50 mM 
Iodoacetamide before resolving by SDS-PAGE and stained using Colloidal 
Coomassie staining solution. Samples for mass spectrometry were prepared in a 
laminar flow hood. Protein bands were excised from the gel using a sterile scalpel 
and placed in a 1.5 ml Eppendorf tube. Gel pieces were washed sequentially with 
0.5 ml of water, 50% acetonitrile/water, 0.1 M NH4HCO3 and 50% acetonitrile/50 mM 
NH4HCO3. All washes were performed for 10 min on a Vibrax shaking platform. 
Once colorless, gel pieces were shrunk with 0.3 ml acetonitrile for 15 min. 
Acetonitrile was aspirated and trace amounts removed by drying sample in a Speed-
Vac. Gel pieces were then incubated for 16 h with 5 mg/ml trypsin in 25 mM 
triethylammonium bicarbonate (TEA) at 30°C on a shaker. An equal volume of 
acetonitrile (same as trypsin) was added to each sample and further incubated on a 
shaking platform for 15 min. The supernatants were transferred to clean tubes and 
dried by Speed-Vac. Another extraction was performed by adding 100 ml 50 % 
acetonitrile/2.5 % formic acid for 15 min. This supernatant was combined with the 
first extract and dried by Speed Vac. 
2.2.5.2 Processing protein bands for analysis by mass spectrometry 
All mass spectrometric (MS) analysis was performed by Dr. David Campbell, Robert 
Gourlay and Joby Varghese (College of Life Science, University of Dundee). 
Analysis of the tryptic peptides by LC-MS were performed on a Thermo LTQ-
Orbitrap system. The MS data was analysed through the Mascot search engine 





Tryptic phosphopeptides were identified by LC-MS on an ABI 4000 Q-TRAP system 
using precursor ion scanning in negative mode to search for release of the (PO3)- 
ion (-79 Da) allowing for +/-1 Da (Williamson et al, 2006), followed by MS/MS 
analysis in positive mode. The resulting data files were searched against the 
appropriate sequence, using Mascot run on an in-house server, with a peptide mass 
tolerance of 1.2 Da, a fragment mass tolerance of 0.8 Da, and with variable 
modifications allowing for phosphorylation of serine/threonine or tyrosine and for 
methionine oxidation or dioxidation. Mass Finger Printing results from Mascot were 
viewed using a Scaffold server.  
2.2.5.3 In vitro 32P-labelling of proteins and phospho-sites mapping using 
HPLC and Edman degradation 
 
5 µg of bacterially purified LRRK2 substrate was incubated with HEK293 purified-
LRRK2 kinase for 30 min at 30°C in master mix comprising Buffer A, 10 mM 
magnesium acetate and 0.1 mM [γ-32P]ATP (11,000-25,000 cpm/pmol) in a total 
reaction volume of 40 µl. The reaction was then terminated by addition of 4xLDS 
sample buffer, boiled with 10 mM DTT for 10 mins and resolved on a NuPAGE gel 
(Invitrogen), which was then stained with Colloidal Coomassie blue. Coomassie-
stained bands migrating with the expected molecular mass of corresponding LRRK2 
substarate were excised from the gel and digested with trypsin or Asp-N (as 
described previously). Following digestion with specific protease depending on the 
protein sequence (Trypsin or Asp-N), > 95% of the 32P radioactivity incorporated in 
the gel bands was recovered and samples were then subjected to HPLC on a Vydac 
C18 column equilibrated in 0.1% (w/v) trifluoroacetic acid (TFA), with a linear 
acetonitrile gradient at a flow rate of 0.2 ml/minute. Fractions of 0.1 ml were collected 





searched using Mascot (www.matrixscience.com) run on an in-house system 
allowing for Phospho (S/T), Phospho (Y), Oxidation (M) and Dioxidation (M) as 
variable modifications. Individual MS/MS spectra were inspected using Xcalibur 2.2 
software. The site of phosphorylation of all the 32P labelled peptides was determined 
by solid-phase Edman degradation on an Applied Biosystems 494C sequencer of 
the peptide coupled to Sequelon-AA membrane (Applied Biosystems) as described 
previously(Campbell and Morrice, 2002). HPLC, LC-MS and Edman degradation 
was performed by Mr. Robert Gourlay. 
2.2.5.4 In vivo Phospho-site mapping of LRRK2 substrate 
In over-expressed cell system 
Flp-In T-Rex HEK 293 cells stably expressing GFP tagged LRRK2 [G2019S] were 
co-transfected with the respective HA or FLAG tagged  LRRK2 substrates, 
induced with 0.1µg/ml of Doxycycline and then treated with DMSO control or 1µM 
LRRK2 specific LRRK2 kinase inhibitors for 1 hour (LRRK2-IN1 and GSK2578215A). 
Approximately 15 mg of lysate was subjected to immunoprecipitation with anti-FLAG-
agarose for 2 hours at 4 oC and then eluted in LDS sample buffer. Samples were 
passed through Spin-X column to remove the bead and boiled with 10 mM DTT to 
denature proteins. The immunoprecipitated were then resolved on a NuPAGE gel 
(Invitrogen), which was then stained with Colloidal Coomassie blue. Coomassie-
stained bands migrating with the expected molecular mass of corresponding LRRK2 
substarate were excised from the gel and digested with trypsin (as described 
previously) and samples underwent phosphosite analysis with LTQ-Orbitrap Velos. 
Individual MS/MS spectra containing the phospho-sites of interest were inspected 
using Xcalibur 2.2 software to determine any obvious changes in phospho-mapped 





In endogenous cell system 
MEF LRRK2 wild type or drug resistant LRRK2 [A2016T] mutant cells were treated 
with 10 nM of MLI-2 inhibitor for 1 hour. Approximately 30 mgs of lysate was 
subjected to immunoprecipitation with anti-MYPT1 antibody covalently coupled to G-
sepharose beads (as described previously) for 2 hours at 4 oC and then eluted in 
LDS sample buffer. Samples were passed through Spin-X column to remove the 
bead and boiled with 10mM DTT to denature proteins. The immunoprecipitated were 
then resolved on a NuPAGE gel (Invitrogen), which was then stained with Colloidal 
Coomassie blue. Coomassie-stained bands migrating with the expected molecular 
mass of corresponding LRRK2 substarate were excised from the gel and digested 
with trypsin (as described previously) and samples underwent phosphosite analysis 
with LTQ-Orbitrap Velos. Individual MS/MS spectra containing the phospho-sites of 
interest were inspected using Xcalibur 2.2 software to determine any obvious 
changes in phospho-mapped sites in response to LRRK2 inhibition. 
2.2.6 MOUSE MODEL 
2.2.6.1 Generation of LRRK2 knock-in mouse model of the corresponding 
S910A+S935A mutations 
 
The constitutive LRRK2 [S910A+S935A] knock-in mouse line was produced by 
implementing a targeting strategy based on NCBI transcript NM_025730.3, to 
introduce two point mutations S910A and S935A into exon 21 of the LRRK2 gene by 
homologous recombination in mouse embryonic stem cells (Taconic-Artemis GmbH, 
Germany).  
To start with, the S910A and S935A mutations have been introduced into exon 21 by 
site-directed mutagenesis with the QuickChangeII site-directed mutagenesis kit 





selection marker PuroR has been flanked by FRT sites and inserted into intron 21. 5’ 
& 3’ homology arms (approx. 4.1 & 6 kb respectively) flanking exon 21 were 
generated using Phusion High-Fidelity DNA Polymerase (New England BioLabs) on 
a C57BL/6J genomic DNA template. The 5’ & 3’ homology arms comprising mutated 
exon 21 were subcloned into a parental targeting vector to achieve the positioning of 
the loxP & FRT sites and PGKneo cassette. For this purpose the targeting vector 
was generated using BAC clones from the C57BL/6J RPCIB-731 BAC library which 
then were transfected into the Taconic-Artemis C57BL/6N Tac ES cell line. 
Homologous recombinant clones were selected using positive (PuroR) and negative 
(Thymidine kinase - Tk) selection. The constitutive knock-in allele comprising desired 
mutations was obtained after Flp-mediated removal of the selection marker. The 
targeting construct was linearized and electroporated into ES cells according to 
standard methods. Successful gene targeting of ES cells at the 5’ and 3’end was 
confirmed by sequencing of a ~6 kb PCR product. Properly targeted ES cell clones 
were then subjected to the diploid injection into BALB/c blastocysts and implanted 
into foster mothers according to standard procedures. Male chimaeras resulting from 
the S910A+S935A targeted ES cells were bred with C57BL/6J female mice 
expressing cre recombinase from the ROSA26 locus to facilitate removal of the loxP 
flanked PGKneo cassette in vivo, and germline transmission was identified by the 
presence of black, strain C57BL/6, offspring (G1) and PCR. 
2.2.6.2 Genotyping of mice via PCR 
Genotyping of mice was performed by PCR using genomic DNA isolated from ear 
biopsies. For LRRK2-S910A+S935A knock-in mouse, primers 5’- 
GTGCTTGAAGTTTGATCATAATGC-3’  and  5’- 





knock-in alleles (WT- 326bp, KI- 401bp; heteroduplex formation). The PCR program 
consisted of 5 min at 95 ºC, then 35 cycles of 30 s at 95 ºC, 30 s at 60 ºC and 30 s at 
72 ºC, and then 5 min at 72 ºC. DNA sequencing was used to confirm the knock-in 
mutation and performed by DNA Sequencing & Services (MRC-PPU; 
http://www.dnaseq.co.uk/) using Applied Biosystems Big-Dye version 3.1 chemistry 
on Applied Biosystems model 3730 automated capillary DNA sequencer. Genotyping 
was performed by Elaine Forsyth and Gail Gilmour.  
2.2.6.3 Mouse motor phenotyping: rotarod test 
Accelerating rotarod test 
On each testing day, a mouse was placed on each of 5 lanes of a rotarod (Model 
47600, Ugo Basile, Italy), with the beam (diameter = 3 cm) rotating at a constant 
speed of 6 r.p.m. Each mouse occupied the same lane during each testing day, but 
lane occupancy was counterbalanced between subjects such that each lane was 
used by approximately the same number of wild type and homozygous mice across 
the series of runs carried out within each day. Once all lanes were occupied, the 
beam accelerated at a constant rate from 6 to 50 r.p.m. over a 300-s period. Latency 
to first lose grip on the beam was recorded. ‘Loss of grip’ included both falling from 
the beam and clinging to the rotating beam to avoid falling. If a mouse lost grip 
because of turning around on the beam, it was immediately placed back on the 
rotarod facing in the correct direction; these incidents were not counted in the 
analysis of latency to lose grip. Testing continued for a total of 24 days in 3 sets with 
2 weeks breaks after 8 repeats. All trials were recorded and latencies were analysed. 
Fixed-speed rotarod test 
Fixed-speed rotarod testing was carried out in a single day. Mice were placed on the 





recorded from the moment the mouse was released. Mice were tested at 
approximately 1-h intervals using progressively increasing rotational speeds—10, 20, 
30 and 40 r.p.m. Mice occupied the same lanes as during accelerating rotarod 
training. All trials were recorded and latencies were analysed. 
2.2.6.4 Lysis of mouse tissues  
Mouse tissues were rapidly excised, frozen in liquid nitrogen and stored at -80°C 
until use. Tissues were weighed and homogenised in a 10-fold excess of ice-cold 
lysis buffer (usually TRIS-CHAPS buffer unless otherwise stated). Lysates were 
clarified by centrifugation at 3,000 g for 15 min at 4°C and supernatants then further 
centrifuged at 18,000 g for 20 min at 4°C. Lysates that were aliquoted, snap frozen 
and stored at -80°C. 
2.2.6.5 Generation of LRRK2 [S910A+S935A] mouse embryonic fibroblasts 
(MEFs) 
 
Littermate matched wild-type and homozygous LRRK2 [S910A+S935A] mouse 
embryonic fibroblasts (MEFs) were isolated from mouse embryos at day E12.5 
resulting from crosses between heterozygous LRRK2 [S910A+S935A] / WT mice 
using a previously described protocol [11909979]. Cells were genotyped as 
described previously. Homozygous LRRK2 [S910A+S935A] knock-in as well as the 
wild type cells generated from the same littermate were spontaneously immortalised 
by prolonged passaging in parallel for at least 20 passages before being used for 
Phos-tag experiments. Genotype of these cells was also confirmed by immunoblot 
analysis with phospho 910 and 935 antibodies.  
2.2.6.6 Statistics 
Statistical significance was assessed by one or two-way analysis of variance 





were performed at three times with similar results obtained on each occasion. Error 
bars indicate the standard deviation (SD) or standard error of the mean (SEM), as 
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As discussed in the introduction to this point (Section 1.4), previous studies in our 
laboratory identified an important biomarker for LRRK2 activity. It was reported that 
treatment of cells or mice with structurally different LRRK2 kinase inhibitors leads to 
dephosphorylation of LRRK2 at two residues: S910 and S935 (Dzamko et al., 2010) 
(Figure 3.1). Moreover, the results strongly indicated that S910 and S935 residues 
are not LRRK2 autophosphorylation sites (Dzamko et al., 2010; Dzamko et al., 
2012).  
 
Figure 3.1: Schematic representation of LRRK2 protein highlighting S910 and S935 
location. 
 
In our laboratory it was hypothesised that these sites are regulated by a distinct 
signaling mechanism that is controlled by LRRK2. According to this model, LRRK2 
functions as an upstream constituent of a signal transduction pathway that either 
directly or indirectly stimulates the activity of a protein kinase or inhibits the activity of 
protein phosphatase that acts on S910 and S935 (Dzamko et al., 2010). In addition, 
very recent unpublished work by Francesca Tonelli has shown that inhibition of cells 
with an LRRK2 inhibitor induces dephosphorylation of S935 as well as of S1292 (a 
known LRRK2 autophosphorylation sites described in Section 1.4.2) and that 





phosphatase inhibitor Calyculin A in the continuous presence of LRRK2 kinase 
inhibitor. This indicates that LRRK2 can be phosphorylated by an LRRK2 
independent kinase.  
However, other studies proved that phosphorylation of LRRK2 at these sites could 
also be uncoupled from LRRK2 kinase activity (Genta Ito et al., 2014). First of all, it 
was shown that catalytically inactive LRRK2 [D2017A] knock-in mice still have S910 
and S935 phosphorylated in cells and that these sites are not dephosphorylated in 
response to LRRK2 inhibitors, suggesting that phosphorylation of these sites does 
not require LRRK2 kinase activity (Genta Ito et al., 2014). Secondly, it was also 
described that the G2019S mutation does not enhance Ser935 phosphorylation, 
indicating that increased LRRK2 kinase activity does not result in amplified Ser935 
phosphorylation (Genta Ito et al., 2014). This result also suggests that monitoring 
S935 phosphorylation might not be a very useful reporter for intrinsic LRRK2 kinase 
activity. An alternative model has been put forward suggesting that inhibition of 
LRRK2 kinase activity with specific LRRK2 kinase inhibitors leads to a 
conformational change of LRRK2 protein kinase resulting in inhibition of access of a 
protein kinase or an enhanced access of a protein phosphatase to these sites 
(Genta Ito et al., 2014). Scientifically for this model to be correct every LRRK2 
inhibitor that has been developed thus far would need to have the ability of altering 
the conformation of LRRK2 and thereby prevent its dephosphorylation at S910 and 
S935. To sum up, according to the model 1, dephosphorylation of S910 and S935 is 
dependent on indirect LRRK2 kinase activity (Figure 3.2 A) while model 2 suggests 
that dephosphorylation of LRRK2 is a result of LRRK2 conformational change 






Figure 3.2: Schematic representation of LRRK2 S910 and S935 regulation within the 
cell under normal and inhibitor-treated conditions. (A) According to the model 1, under 
normal conditions LRRK2 either activates a protein kinase or blocks the activity of a protein 
phosphatase that acts on S910 and S935. Upon inhibition of LRRK2 kinase activity occurs 
dephosphorylation of S910 and S935 through inactivation of a protein kinase activity or 
recovery of a protein phosphatase activity. (B) According to the model 2, under normal 
condition LRRK2 S910 and S935 residues are constitutively phosphorylated by a protein 
kinase. Inhibition of LRRK2 kinase activity results in a conformational change, which 
exposes S910 and S935 sites in such a way that provides an enhanced access of a protein 
phosphatase to these sites and blocks entree of a protein kinase. As a consequence, these 
sites are dephosphorylated due to LRRK2 Inhibition. 
 
In this chapter, the work presented addresses whether phosphorylation of S910 and 
S935 has a biological role in vivo. As dephosphorylation of these sites will mimic the 
effect of long-term LRRK2 inhibitor treatment and could be linked to safety risks 







3.2.1 Generation of mouse embryonic fibroblasts  
Taconic Artemis generated heterozygous LRRK2 [S910A+S935A] knock-in mice by 
introducing S910A and S935A mutations into the exon 21 (2.2.6.1 Materials and 
Methods section). I then bred heterozygous mice to obtain homozygous LRRK2 
[S910A+S935A] knock-in mice with the aim to investigate the importance of S910 
and S935 phosphorylation in vivo. Homozygous LRRK2 knock-in mice are viable and 
don’t display any obvious overall phenotype compared with the wild type (Figure 
3.3). The summary of the targeting strategy for generation of LRRK2 
[S910A+S935A] mice, PCR and sequencing data confirming successful mutation of 
these sites to alanine are shown in the Figure 3.3. 
 
Figure 3.3: Targeting strategy for generation of LRRK2 [S910A+S935A] knock-in mice 








Mouse embryonic fibroblast (MEF) cells derived from littermate LRRK2 WT, LRRK2 
[S910A+S935A] knock-in and LRRK2 KO mice were spontaneously immortalised by 
prolonged passaging. Cell lysates derived from LRRK2 WT, LRRK2 [S910A+S935A] 
and LRRK2 KO MEFs were lysed and subjected to immunoblot analysis using total 
and phospho LRRK2 antibodies (Figure 3.4). 
 
Figure 3.4: Generation of LRRK2 [S910A+S935A] knock-in MEFs. LRRK2 
[S910A+S935A], WT and KO MEFs were generated by prolonged passaging. Cell lysates 
derived from these cells were subjected to immunoblot analysis with indicated monoclonal 
total and phospho LRRK2 antibodies; GAPDH was used as a loading control. 
 
As expected, no S910 and S935 phosphorylation was detected in LRRK2 knock-in 
MEFs in contrast to the LRRK2 WT. Moreover, the total levels of endogenous 
LRRK2 in LRRK2 WT MEFs are similar to the total levels of endogenous LRRK2 in 
LRRK2 [S910A+S935A] MEFs. These results insinuate that S910A+S935A mutation 







3.2.2 Assessment of endogenous LRRK2 WT and LRRK2 [S910A+S935A] 
kinase activity in vitro 
The importance of S910 and S935 is discussed in the Introduction (Section 1.5.2 and 
3.1). 
Several members of the Rab family, including Rab8a and Rab10 GTPases were 
recently discovered in our lab to be direct physiological LRRK2 substrates (Steger et 
al., 2016). In order to examine whether S910A+S935A mutation has an impact on 
endogenous LRRK2 kinase activity, LRRK2 was immunoprecipitated from MEF 
LRRK2 WT, MEF LRRK2 [S910A+S935A] knock-in or MEF LRRK2 KO cells. These 
immunoprecipitates were then incubated with bacterially purified Rab8A protein in 
the presence or absence of LRRK2 specific kinase inhibitor and Mg2+-[y-32 ATP] for 
30 mins at 30ºC at 1000 rpm. Reactions were stopped with 4xLDS sample buffer and 
subjected to autoradiography and immunoblot analysis with indicated LRRK2 
antibodies (Figure 3.5). My results show that endogenous LRRK2 protein kinase 
activity is similar to LRRK2 [S910A+S935A] activity in vitro, suggesting that 
S910A+S935A mutation has no effect on LRRK2 kinase activity on its physiological 
substrate in vitro.  My data also shows that in vitro, inhibition of endogenously 
immunoprecipitated LRRK2 kinase activity with specific LRRK2 kinase inhibitor does 







Figure 3.5: Assessment of immunoprecipitated endogenous LRRK2 kinase activity 
from LRRK2 [S910A+S935A] and LRRK2 WT MEFs. Endogenous LRRK2 proteins were 
immunoprecipitated with monoclonal total LRRK2 antibody from LRRK2 WT, LRRK2 
[S910A+S935A] and LRRK2 KO MEFs. Purified LRRK2 proteins were then incubated with 
bacterially purified Rab8A and Mg 2+-[γ- 32ATP] for 30 minutes at 30 °C at 1000 rpm in 
presence or absence of LRRK2 kinase inhibitor (1 M GSK257821A). Immunoprecipitates 
were then subjected to electrophoresis on a polyacrylamide gel, autoradiography and 
immunoblot analysis with indicated antibodies.  
3.2.3 Assessment of endogenous LRRK2 WT and LRRK2 [S910A+S935A] 
kinase activity in vivo 
To assess whether LRRK2 [S910A+S935A] mutation has an impact on endogenous 
LRRK2 kinase activity, I used a new technique that has been recently optimised in 





endogenous Rab8A and Rab10 in LRRK2 WT and LRRK2 [S910A+S935A] MEFs.  
“Phos-tag” or 1,3-bis[bis(pyridin-2-ylmethyl) amino]propan-2-olato dizinc(II) complex, 
was first described to bind to phosphate ions with much higher affinity (Kd ~ 25 nM 
for phenyl) phosphate than other ions (Kinoshita, Takahashi, Takeda, Shiro, & Koike, 
2004). Further studies established that Phos-tag also interacts with high affinity with 
proteins comprising phosphorylated Ser, Thr or Tyr residues (Kinoshita, Yamada, 
Takeda, Kinoshita-Kikuta, & Koike, 2005). Based on this finding, a “Phos-tag 
Acrylamide”, a modified version of Phos-tag,  (N-(5-(2-
acryloylaminoethylcarbamoyl)pyridin-2-ylmetyl)-N,N′,N′-tris(pyridin-2-yl methyl)-1,3-
diaminopropan-2-ol) was developed that when polymerised into SDS-polyacrylamide 
gels retarded electrophoretic mobility of phosphorylated proteins, leading to a 
substantial mobility shifts (Kinoshita, Kinoshita-Kikuta, Takiyama, & Koike, 2006). 
This approach has been shown to be particularly useful for analysing 
phosphorylation of relatively small proteins that are phosphorylated at a single 
residue such as Rab8A and Rab10. 
To assess LRRK2 mediated phosphorylation of endogenous Rab10 (or Rab8A) in 
MEFs, firstly, LRRK2 WT and LRRK2 [S910A+S935A] knock-in MEFs were treated 
with DMSO or LRRK2 kinase inhibitor GSK2578215A at 1µM concentration for 1 
hour. Then treated mouse fibroblasts were lysed in the 1% Triton EDTA free lysis 
buffer, pre-cleared lysates were then resolved on Phos-tag SDS gel (see Materials 
and Methods) and subjected into the immunoblot analysis using Rab10 antibody 






Figure 3.6: Use of the Phos-tag approach to assess the impact of LRRK2 
S910A/S935A mutations on its substrate Rab10. Littermate WT and LRRK2 
[S910A+S935A] knock-in MEFs were treated with or without 1 μM GSK2578215A for 1 hour. 
Cell lysates were prepared and Rab10 phosphorylation was analysed by a Phos-tag assay 
(top panel). Control immunoblots were done on normal gels with the indicated antibodies. 
Bands corresponding to phosphorylated and non-phosphorylated Rab10 were marked with 
open (○) and filled (●) circles, respectively. Similar results were obtained in at least two 
separate experiments. 
 
According to my results, Rab10 phosphorylation in LRRK2 [S910A+S935A] MEFs is 
remarkably reduced compared to its littermate wild type cells. Importantly, total 
LRRK2 levels are not affected by LRRK2 [S910A+S935A] mutation.  This data 
indicates that in vivo, phosphorylation of LRRK2 at S910 and S935 residues is 
important for LRRK2 activity as mutation of these sites to alanine dramatically 





My preliminary results also revealed that phosphorylation of Rab8A in LRRK2 
[S910A+S935A] knock-in MEFs is also evidently reduced compared with the LRRK2 
WT MEFs whereas total LRRK2 levels remained unchanged (Figure 3.7). 
 
Figure 3.7: Use of the Phos-tag approach to assess the impact of LRRK2 
S910A/S935A mutations on its substrate Rab8A. Littermate WT and LRRK2 
[S910A+S935A] knock-in as well as LRRK2 KO MEFs were treated with or without 1 μM 
GSK2578215A for 1 hour. Cell lysates were prepared and Rab8A phosphorylation was 
analysed by a Phos-tag assay (top panel). Control immunoblots were done on normal gels 
with the indicated antibodies.  
 
It was previously reported that in HEK293 cells  stably over-expressing GFP-LRRK2 
WT or GFP-LRRK2 [S910A+S935A] knock-in proteins, S910A+S935A mutation 
doesn’t have an impact on LRRK2 kinase activity in vitro (Nichols et al., 2010), these 
results are consistent with my in vitro kinase data. However, it was also shown that 
phosphorylation of LRRK2 S910 and S935 residues is important for LRRK2 
localization as mutation of these sites to alanine or dephosphorylation of these sites 





within the cytoplasm (Nichols et al., 2010). As according to my phos-tag experiments 
in MEFs, Rab10 and Rab8A phosphorylation by LRRK2 is significantly reduced in 
LRRK2 [S910A+S935A] knock-in cells compared to the wild type MEF cells 
indicating that dephosphorylation of these sites diminishes LRRK2 activity in vivo, 
one explanation could be that in MEF cells, LRRK2 [S910A+S935A] mutation causes 
aggregations within the cytoplasm making less LRRK2 available for its substrate 
phosphorylation. 
3.2.4 Assessment of total endogenous LRRK2 expression levels in 4 months 
old LRRK2 [S910A+S935A] and LRRK2 WT mice tissues 
As it was described in the Introduction (Section 1.5), kidneys derived from LRRK2 
KD D1994A displayed reduced levels of full length LRRK2 (Herzig et al., 2011). 
Interestingly, it was also shown that inhibition of LRRK2 kinase activity results in 
reduced LRRK2 levels in kidneys (Fuji et al., 2015). This data suggests that LRRK2 
kinase activity could be implicated in its stability. However, in LRRK2 gain-function 
mouse models such as G2019S or R1441G there is no evidence to support this 
theory as LRRK2 levels are comparable with the wild type mice (Y. Li et al., 2009; 
Matikainen-Ankney et al., 2016). I argued whether phosphorylation of S910 and 
S935 can alter LRRK2 expression levels. 
To address whether LRRK2 [S910A+S935A] mutation has an effect on protein 
stability in brains, lungs or kidneys, three brains, lungs and kidneys were extracted  
from 4 months old six littermates comprising three LRRK2 WT and three LRRK2 
[S910A+S935A] mice. Half of these tissues were lysed in 1% Triton and the other 
half in 1% Rapigest. 1% Triton buffer was used as it solubilizes all soluble proteins 
whereas 1% Rapigest buffer solubilizes all protein, including membrane proteins. 





LRRK2 even if it localizes at the membrane or forms a non-soluble aggregates. 
Lysates derived from these samples were then subjected to immunoblot analysis 
with phospho LRRK2 935 and total (N- and C-terminal) LRRK2 antibodies (Figure 




Figure 3.8: Schematic representation of the LRRK2 protein domain structure, 
indicating the approximate epitope site for two monoclonal antibodies tested: N-terminal 
LRRK2 antibody (UDD3) and C-terminal LRRK2 antibody (N241A/34). 
 
According to my results, total levels of full length LRRK2 protein in LRRK2 WT brains 
are the same as in LRRK2 [S910A+S935A] knock-in brains (n>0.05; two-way 
ANOVA), suggesting that in brain tissues [S910A+S935A] mutation has no influence 
on LRRK2 stability and expression (Figure 3.9). However, in kidneys, there is a 
significant decrease in total LRRK2 levels in LRRK2 [S910A+S935A] knock in mice 
(n<0.05; two-way ANOVA), suggesting that phosphorylation of these sites but not 
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Figure 3.9: Assessment of total LRRK2 expression levels in LRRK2 WT and LRRK2 
[S910A+S935A] knock-in brain (A) Brains derived from 3 LRRK2 WT mice and 3 LRRK2 
[S910A+S935A] mice were lysed in 1% Triton or 1% Rapigest, prepared lysates were then 
subjected to immunoblot analysis with indicated phospho and total antibodies. (B) Total 
LRRK2/GAPDH and p935LRRK2/GAPDH ratio was quantified using LI-COR, no differences 
in total LRRK2 expression levels were detected between LRRK2 WT and LRRK2 
[S910A+S935A] brain samples (n>0.05; two-way ANOVA). 
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Figure 3.10: Assessment of total LRRK2 expression levels in LRRK2 WT and LRRK2 
[S910A+S935A] knock-in kidneys (A) Kidneys derived from 3 LRRK2 WT mice and 3 
LRRK2 [S910A+S935A] mice were lysed in 1% Triton or 1% Rapigest, prepared lysates 
were then subjected to immunoblot analysis with indicated phospho and total antibodies. (B) 
Total LRRK2/GAPDH and p935LRRK2/GAPDH ratio was quantified using LI-COR. Total 
LRRK2/GAPDH and p935LRRK2/GAPDH ratio was quantified using LI-COR, total LRRK2 
expression levels of LRRK2 [S910A+S935A] protein were significantly reduced compared to 
the wild type in kidney samples (n<0.05; two-way ANOVA). 
 
In lungs, the total levels of LRRK2 are very variable but no significant change in total 
LRRK2 levels were seen between the genotypes (n>0.05; two-way ANOVA) (Figure 
3.11). In fact, the variability of LRRK2 expression in lungs from one individual to 
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Figure 3.11: Assessment of total LRRK2 expression levels in LRRK2 WT and LRRK2 
[S910A+S935A] lungs (A) Lungs derived from 3 LRRK2 WT mice and 3 LRRK2 
[S910A+S935A] mice were lysed in 1% Triton or 1% Rapigest, prepared lysates were then 
subjected to immunoblot analysis with indicated phospho and total antibodies. (B) Total 
LRRK2/GAPDH and p935LRRK2/GAPDH ratio was quantified using LI-COR. No differences 
in total LRRK2 expression levels were detected between LRRK2 WT and LRRK2 
[S910A+S935A] brain samples (n>0.05; two-way ANOVA). 
 
 
My results are consistent between N- and C-terminal antibodies as well as 1% Triton 
and Rapigest lysis buffer treatment. Moreover, my data is supported by previously 
reported pharmacological and genetic studies, which show that only in kidneys, 
inhibition of LRRK2 kinase activity results in decrease in total LRRK2 levels. It 
seems that phosphorylation of S910 and S935 is important for LRRK2 stability. 
Overall, these results indicate that in kidneys there is a distinct mechanism by which 
LRRK2 is regulated.  
3.2.5 Histopathological evaluation of  LRRK2 WT and LRRK2 [S910A+S935A] 
mouse kidneys. 
As previously described in the Introduction (Section 1.6.2) the evidence is clear that 
LRRK2 KO mice and rats display an abnormal kidney and lung phenotype (Baptista 
et al., 2013; Herzig et al., 2011). Moreover, it has been shown that catalytically 





These results point to the fact that inhibition of LRRK2 kinase activity could be 
associated with kidney and/or lung pathology. However, suppression of LRRK2 
kinase activity has been proposed as an effective therapeutic strategy for slowing the 
progression of PD and reported morphological changes in kidneys and lungs upon 
LRRK2 deletion might be serious side effects that could prevent pharmaceutical 
companies from developing LRRK2 inhibitors (Baptista et al., 2013). Therefore, it is 
important to assess the safety risk of inhibition LRRK2 kinase activity.  
I have reasoned that LRRK2 [S910A+S935A] knock-in mice will mimic the long term 
effect of LRRK2 inhibitor treatment because inhibition of LRRK2 kinase activity 
results in a rapid dephosphorylation of these sites as it was previously described in 
our lab (Dzamko et al., 2010). Consequently, I investigated whether the loss of S910 
and S935 phosphorylation causes kidney pathology. For this purpose, I set up a 
collaboration with Dr Franchesco Marchesi from Veterinary School of the University 
of Glasgow. 
A total of 24 littermate animals was tested (12 wild-type and 12 homozygous knock-
in animals) at a single time point at about 18 months of age. Initial analysis revealed 
that LRRK2 knock-in kidneys displayed no obvious phenotype compared to the wild 
type (Figure 3.12). The color, size and weight of 18 months old LRRK2 
[S910A+S935A] knock-in kidneys were similar to LRRK2 WT. These results contrast 
with the reported LRRK2 KO or LRRK2 KD mouse kidney phenotype characterized 
by abnormal dark kidney staining, rough surfaces and decreased kidney size (Herzig 







Figure 3.12: Overview of LRRK2 [S910A+S935A] phenotype. Kidneys have been 
collected from LRRK2 WT and LRRK2 [S910A+S935A) knock-in mice. No obvious kidney 
phenotype was observed. No difference in pigmentation, size or weight was detected. 
 
To investigate whether there are any microscopic differences between the genotypes 
I have collected kidneys from mice at the end of perfusion fixation with 4% 
Paraformaldehyde and transferred to 10% neutral buffered formalin (NBF) (Mice 
were perfused with the help of Elaine Forsyth and Tom McWilliams). I then sent 
these tissues for the histopathological evaluation to the School of veterinary 
medicine at the University of Glasgow. Main histological findings performed by Dr 
Franchesco Marchesi from the University of Glasgow are summarized in Table 3.1. 
Blind histopathological analysis of kidneys revealed a spectrum of changes in the 
kidneys without a clearly distinctive trend across groups and genders. In this analysis 
Dr Marchesi looked at the cellular protein markers used to describe LRRK2 KO and 
kinase dead kidneys. His data shows that lymphoplasmacytic inflammatory infiltrates 
adjacent to the pelvis and with variable interstitial or perivascular distribution are 
noted in both groups and genders with overall similar severity. Tubular vacuolation, 
ranging from minimal to marked, was noted only in males from both groups. 
Additional tubular degenerative changes, including variable extents of dilation, 





material, and tubular basophilia, are also observed with overall higher frequency and 
severity in males. Only one wild type female mouse in shows a distinct phenotype 
characterised by diffused glomerular changes presented by segmental to extensive 
accumulation of coarse amorphous pale eosinophilic material causing partial to 
complete obliteration of the glomerular capillarity loops. The accumulated material is 
Congo red and Masson’s trichrome negative, strongly PAS positive and with a mixed 
staining pattern. The significance of the prominent glomerular changes noted in this 
female is unclear given the fact that this mouse is a wild type. Overall, histological 
evaluation of the kidneys in these cohorts has not identified a clear difference in the 
spectrum and severity of microscopic changes across the different groups (Figure 
3.13). 
 
Figure 3.13: A representative image showing that there is no kidney pathology in 
LRRK2 [S910A+S935A] mice. Kidneys have been collected from LRRK2 WT and LRRK2 
[S910A+S935A mice at the end of perfusion fixation with 4% paraformaldehyde and 
transferred to 10% neutral buffered formalin (NBF). Tissues have been trimmed and 
processed to paraffin blocks, microtome sectioned at 4 µm, stained with Haematoxylin and 
Eosin (HE), and examined by Dr Franchesco Marchesi (Glasgow University). Normal 







Table 3.1: Histological evaluation of mouse kidneys 
Females Group 1 LRRK2 WT mice Group 2 LRRK2 [Ser910Ala+Ser935Ala] mice 
Lymphoplasmacytic 
infiltrates 
++ + + +  -/+ ++ + ++ 
Glomerular mesangial 
thickening 
-  -/+ +  -/+ -  -/+  -/+  -/+ 
Increased glomerular 
cellulariry 
- - + - -  -/+ -  -/+ 
Glomerular eosinophilic 
deposits 
- - -  +++  - - - - 
Tubular dilation  -/+ - - - - - - - 
Tubular vacuolation - - - - - - - - 
Tubular 
degeneration/atrophy 
- - - + - - - - 
Tubular eosinophilic casts - - - +  -/+ + + + 
Tubular basophilia  -/+  -/+  -/+  -/+ -  -/+   -/+ - 
Mineralization, collecting 
ducts 
 -/+ - - - - - - - 
Pigment-laden macrophages - - -  -/+ - - -  -/+ 
Osseous metaplasia - - - - - - -  -/+ 
Males Group 1 LRRK2 WT mice Group 2 LRRK2 [Ser910Ala+Ser935Ala] mice  
Lymphoplasmacytic 
infiltrates 
+  ++  +  -/+  ++  ++ - + 
Glomerular mesangial 
thickening 
 -/+  -/+  -/+  -/+  -/+ -  -/+  -/+ 
Increased glomerular 
cellulariry 
 -/+ -  -/+ - - -  -/+  -/+ 
Glomerular eosinophilic 
deposits 
- - - -  -/+ - - - 
Tubular dilation  -/+ -  -/+ + ++ + -  -/+ 
Tubular vacuolation  -/+ + ++ +++  -/+ + ++ + 
Tubular 
degeneration/atrophy 
- -  -/+ + ++ ++ -  -/+ 
Tubular eosinophilic casts - - - - + - - - 
Tubular basophilia  -/+ + +  -/+ ++ ++  + + 
Mineralization, collecting 
ducts 
 -/+ - - -  -/+ - - - 
This experiment was carried out by our collaborator Dr Franchesco Marchesi (Glasgow University). 
Microscopic changes in the kidneys collected from LRRK2 WT and LRRK2 [Ser910Ala+Ser935Ala] have been assessed 
according to the following basic semiquantitative grading system: 
- = change no present; -/+ =minimal; + =mild; ++ =moderate; +++ =marked 
 
To sum up, microscopic changes within the examined sections of kidneys in these 
cohorts of mice are not consistent with those reported in LRRK2 knock-out and 
kinase dead mutant mice (Herzig et al., 2011; Tong et al., 2012). Histological 





spectrum and severity of microscopic changes across the different groups. This data 
strongly indicates that dephosphorylation of S910 and S935 mice has no major effect 
on kidney phenotype. 
 
3.2.6 Histopathological evaluation of  LRRK2 WT and LRRK2 [S910A+S935A] 
mouse lungs.  
 
To date, another concern regarding use of LRRK2 inhibitors as potential drugs to 
cure Parkinson’s disease are risks associated with the abnormal accumulation of 
lamellar bodies in type II pneumocytes in non-human primates reported by Reina N. 
Fuji (Fuji et al., 2015). The abnormalities in lung tissues caused by LRRK2 kinase 
inhibitors were reported to be morphologically identical to that detected in LRRK2 
knock-out mice but absent in LRRK2 kinase dead mice (Fuji et al., 2015; Herzig et 
al., 2011). However, treatment of mice with different LRRK2 kinase inhibitors even at 
high doses resulted in no changes in kidneys or lungs suggesting that mice almost 
need a complete inhibition of LRRK2 for this effect (Fuji et al., 2015).  
To address whether dephosphorylation of S910 and S935 could result in lung 
pathology in mice I have collected lungs from mice at the end of perfusion fixation 
with 4% Paraformaldehyde and transferred to 10% neutral buffered formalin (NBF) 
(mice were perfused with the help of Elaine Forsyth and Tom McWilliams) and then 
sent the tissues to our collaborator Dr Marchesi for histopathological analysis. 










Table 3.2: Histological evaluation of mouse lungs 
Females Group 1 LRRK2 WT mice Group 2 LRRK2 [Ser910Ala+Ser935Ala] mice 
Peribronchial lymphoid 
infiltrates 
+ + + ++  -/+ + - ++ 
Perivascular lymphoid 
infiltrates 
+ + + +++  -/+ +++ + +++ 
Alveolar macrophage 
accumulation 
- - - +  -/+  + -  + 
Interstitial/alveolar 
inflammatory infiltrates 
- - - - - - - + 
Alveolar haemorrhage - - - - - + - - 
Males Group 1 LRRK2 WT mice Group 2 LRRK2 [Ser910Ala+Ser935Ala] mice 
Peribronchial lymphoid 
infiltrates 
- + - + + - - - 
Perivascular lymphoid 
infiltrates 
- ++ + - +++ ++ - + 
Alveolar macrophage 
accumulation 
- - - - - - - - 
Interstitial/alveolar 
inflammatory infiltrates 
 -/+ - - - - - - - 
Type II pneumocyte 
hyperplasia 
-       - - -  -/+ 
Alveolar haemorrhage - - - - - - - - 
This experiment was carried out by our collaborator Dr Franchesco Marchesi (Glasgow University). 
Microscopic changes in the kidneys collected from LRRK2 WT and LRRK2 [Ser910Ala+Ser935Ala] have been assessed 
according to the following basic semiquantitative grading system: 
- = change no present; -/+ =minimal; + =mild; ++ =moderate; +++ =marked 
 
These findings show that in the lungs perivascular and/or peribronchial infiltrates are 
observed with overall comparable incidence and severity in females and males from 
both groups. These infiltrates are composed of large numbers of small to medium 
sized lymphocytes, in some instances with a proportion of large and apparently 
immature lymphoid elements, with variable numbers of plasma cells and fewer 
microphages. Minimal to mild alveolar macrophage accumulation is observed in one 





[S910A+S935A]. In conclusion, histological changes within the examined section of 
lungs in these cohorts of mice are not consistent with those previously published in 
LRRK2 knock-out and kinase dead mutant mice. There was no clear difference in 
the spectrum and severity of microscopic changes across the different groups 
(Figure 3.14).  
 
Figure 3.14: Histological evaluation of mouse lungs. Lungs have been collected from 
LRRK2 WT and LRRK2 [S910A+S935A] mice at the end of perfusion fixation with 4% 
paraformaldehyde and transferred to 10% neutral buffered formalin (NBF). Tissues have 
been trimmed and processed to paraffin blocks, microtome sectioned at 4 µm, stained with 
Haematoxylin and Eosin (HE), and examined by Dr Franchesco Marchesi (Glasgow 
University). Alveoli and alveolar septa appear within normal limits. 
 
This observations represent common background findings in rodents noted with 
increased incidence and severity in aged animals, suggesting that inhibition of S910 





3.2.6.7 Behavioural phenotyping of LRRK2 [S910A+S935A] knock-in mouse 
model 
 
As S910A+S935A mutation mimics the long-term inhibition of LRRK2 kinase I set up 
an aging experiment using LRRK2 WT and LRRK2 [S910A+S935A] knock-in mice to 
study how S910A+S935A mutation affects a well-being of a mouse. For my 
experiment I used 24 littermate animals (12 wild types and 12 homozygous LRRK2 
[S910A+S935A] mice). These mice were gender-matched, littermate pairs of 
heterozygous breedings. I sorted these mice into cages based on their gender and 
cage capacity (4 to 6 mice per cage) and let them age for 18 months.  During this 
time I was watching these mice and with the help of our animal unit staff noted 
weekly the individual mouse weight for 55 weeks starting from 4 months of age. 
LRRK2 [S910A+S935A] mice appeared to be healthily and did not display any 
obvious behavior phenotype compared to their wild type littermates. However, my 
results showed that S910A+S935A mutation somehow influences the body weight 
gain of mice (Figure 3.15). In fact, this mutation has a greater effect in females 
(p<0.01; two-tailed t-test). Interestingly, among 6 wild type females and their 6 
LRRK2 [S910A+S935A] females’ littermates, there was a very fat outliner LRRK2 
[S910A+S935A] mouse, which reached weight of 70 grams. A picture of this mouse 
is shown in Figure 3.15. The weight of this mouse was not taken into consideration 
for my data analysis and this mouse did not participate in any behavioral tests due to 
its over-weight conditions. Although in males there was not significant difference in 
body weight between LRRK2 WT and their LRRK2 [S910A+S935A] littermates, it 
was a clear trend that LRRK2 [S910A+S935A] males are more likely to be heavier 
than the wild types. Overall, LRRK2 [S910A+S935A] mice are heavier than their wild 






Figure 3.15: Assessment of body weight in relation to its gender and genotype. LRRK2 
WT and their LRRK2 [S910A+S935A] littermates’ mice were weighted weekly for 55 weeks. 
These body weight curves represent the body weight difference between these mice in 
relation to their gender and genotype. LRRK2 [S910A+S935A] females are heavier than 
LRRK2 WT littermates (p<0.01; two-tailed t-test0. There is a trend for LRRK2 
[S910A+S935A] males to be heavier than their wild type littermates but this trend is not 
significant (p>0.05; two-tailed t-test). Overall, LRRK2 [S910A+S935A] mice are heavier than 
their wild type littermates (p<0.05 two-tailed t-test).This picture shows the over-weighted 
LRRK2 [S910A+S935A] mouse in comparison to its wild type littermate. No other LRRK2 
knock-in females displayed such a dramatic body weight gain, therefore the weight of this 
mouse was not used in this data set. 
 
It has been previously showed by Heather Melrose’s laboratory that LRRK2 KO mice 
displayed an abnormal exploratory behavior in the open-field test characterized by 
increased anxiety in these animals (Hinkle et al., 2012). Moreover, motor and 
coordination test - rotarod, revealed that LRRK2 KO mice performed significantly 





road (Hinkle et al., 2012). Together these results strongly indicated that LRRK2 KO 
mice possess an abnormal behavior phenotype characterized by the inability of 
termination of ongoing behavior (Hinkle et al., 2012). 
In order to establish whether LRRK2 [S910A+S935A] knock-in mice display a motor 
function phenotype I also performed a motor coordination and balance rotarod test 
available in our laboratory. The rotarod test is the most commonly used test of motor 
function. It consists of a rotating road of 3 cm diameter, on which the mouse is 
placed and has to maintain its balance, and a trip switch on the floor below, which is 
set to record the latency until the mouse falls from the rotating rod (Brooks & 
Dunnett, 2009) (Figure 3.16). Mice are normally tested on separate trials at a series 
of fixed speeds (fixed speeds rotarod test), or speed increases can be incorporated 
into a single trial by using an accelerating version of the test (accelerating rotarod 
test) (Brooks & Dunnett, 2009). 
 
Figure 3.16: The overview of Rotarod.  
For my experiment I used 24 animals (12 wild types and 11 homozygous LRRK2 
[S910A+S935A] knock-in mice) at a single time point at about 18 months of age. 
These mice were gender-matched, littermate pairs of heterozygous breedings. For a 
positive control, I employed an additional extra 8 male-littermates, which comprised 





Hospital and Medical school supervised my experiment and helped me with the data 
analysis.  
I stared my trial with accelerating speed rotarod test where the rod accelerates 
smoothly from 0 to 40 rpm over a 5-minute period. Each trial was repeated 8 times at 
3 different time points with the interval of two weeks to ensure reproducibility of this 
data (Figure 3.17). My results reveled that LRRK2 [S910A+S935A] mice performed 
significantly worse on the rotarod test than their wild-type littermates (p<0.05, 
ANOVA) (Figure 3.17.A). This might indicate that phosphorylation of S910 and S935 
is implicated in motor coordination of these animals. In my hands, LRRK2 KO mice 
showed a very inconsistent performance in this test, which overall was not 
significantly different from their wild type littermates (p>0.05, ANOVA) (Figure 
3.17.B). 
Overall, my Rotarod results show that LRRK2 [S910A+S935] knock-in mice perform 
worse on the test compared with their wild type littermates, suggesting that this 


















***effect of trial p<0.0001
*effect of genotype p<0.05




































Figure 3.17: Behavioural phenotyping of LRRK2 [S910A+S935A], WT and KO mice. (A) 
Rotarod accelerating speed: Latency to fall in the rotarod test curves of LRRK2 WT versus 
LRRK2 [S910A+S935A] mice (n=12 per genotype), accelerating speed from 0rpm-40 rpm. 
Two-way ANOVA for the effect of genotype on latency to fall: p<0.05. (B) Rotarod 
accelerating speed: Latency to fall in the rotarod test curves of LRRK2 WT versus LRRK2 
KO mice (n=4 per genotype), accelerating speed from 0rpm-40 rpm. Two-way ANOVA for 
the effect of genotype on latency to fall: p>0.05. 
 
In addition, I performed rotarod fixed speeds test at 10 rpm, 20 rpm, 30 rpm and 40 
rpm rotation speed to demonstrate that transgenic phenotype is dependent on task 
difficulty (Figure 3.18). Each trial was repeated 8 times at 3 different time points with 
the interval of two weeks to ensure reproducibility of the data. My results again 
showed that LRRK2 [S910A+S935A] mutation might affect motor function in mice as 
with the increased speed of the rotating rod LRRK2 mutants perform significantly 
worse than their wild type littermates in this test (Figure 3.18.A). Consistent with the 
previous studies there is a trend for LRRK2 KO mice to perform slightly better in the 
fixed speeds rotarod test than their wild type littermates (Figure 3.18.B).  
 







***effect of trial p<0.0001
ns effect of genotype p=0.9






















































Figure 3.18: Behavioural phenotyping of LRRK2 [Ser910Ala+Ser935Ala], WT and KO 
mice. (A) Rotarod fixed speed: Latency to fall in the rotarod test of LRRK2 WT versus 
LRRK2 [S910A+S935A] mice (n=12 per genotype) at fixed speed 10 rpm, 20 rpm, 30 rpm 
and 40 rpm. Two-way ANOVA for the effect of genotype on latency to fall: p<0.05 at 20 rpm, 
30 rpm and 40 rpm; p>0.05 at 10 rpm. (B) Rotarod fixed speed: Latency to fall in the rotarod 
test of LRRK2 WT versus LRRK2 KO mice (n=4 per genotype) at fixed speed 10 rpm, 20 
























































rpm, 30 rpm and 40 rpm. Two-way ANOVA for the effect of genotype on latency to fall: 
p>0.05 at 10 rpm, 20 rpm, 30 rpm and 40 rpm. 
 
 
3.2.7 Histopathological evaluation of  LRRK2 WT and LRRK2 [S910A+S935A] 
mouse brain.  
 
In order to investigate whether LRRK2 [S910A+S935A] mutation has an effect on 
brain pathology I collected 16 brains from gender-matched littermates 8 wild type 
and 8 homozygous LRRK2 [S910A+S935A] knock-in mice at the end of 4% 
paraformaldehyde perfusion (mice were perfused with the help of Elaine Forsyth and 
Tom McWilliams) and sent these samples for further analysis to our collaborators Nic 
Dzamko and Glenda Halliday in Australia’s Neuroscience Research Institute. Ye 
Zhao and Yuhong Fu performed all experiments associated with histopathological 
evaluation of LRRK2 WT and LRRK2 [S910A+S935A] knock-in brains, which I report 
in my thesis. 
According to the obtained data regarding estimation of the number of subcortical and 
hippocampal cells, there are no significant differences in the proportions of total 
cells, mature neurons, glia, glia/neuron ratios and proliferating cells in the subcortical 
structures (basal glia, thalamus, hypothalamus and brainstem) between LRRK2 
[S910A+S935A] and WT mice (Table 3.3). In the hippocampus of the LRRK2 
[S910A+S935A] mice, there was a non-significant trend for a decrease in the 
percentage of total cells, mature neurons and glia, but glia/neuron ratios and 









Table 3.3: Mean and standard error for the estimated percentages relative to WT of 
subcortical and hippocampal cells in the different genotypes covarying for gender 
(data received from Australia’s Neuroscience Research Institute) 


























































To sum up, aged LRRK2 [S910A+S935A] mice did not displayed decreased cell 
numbers or impaired proliferation in the Subcortex. However, in the hippocampus 
there was a trend for decreased total cells, mature neurons and glia. This could 
indicate that S910A+S935A might have an effect on neuro/gliogenesis in the aging 
hippocampus.   
Quantitative assessment of the numbers of TH-positive neurons in the substantia 
nigra compacta (SNC) did not reveal any significant dopamine neuronal loss in 





Table 3.4: Calculated numbers of TH-positive dopamine neurons in SNC (data received 
from Australia’s Neuroscience Research Institute) 
TH-positive dopamine neurons in SNCD Mean SEM 
Female-WT 1698 ±78 
Male-WT 1752.5 ±78 
Female-[Ser910Ala+Ser935Ala] 1636 ±78 
Male-    [Ser910Ala+Ser935Ala] 1628.5 ±78 
 
Further analysis revealed that aged LRRK2 [S910A+S935A] mice did not display any 
differences in TH neuron morphology (Figure 3.19.A). Furthermore, all TH-positive 
SNC neurons colocalised with dopamine active transporter (DAT) and vesicular 
monoamine transporter 2 (VMAT2). Moreover, there was no significant differences in 
the staining intensity of dopamine transporters in the LRRK2 [S910A+S935A] mice 
compared with WT mice (Figure 3.19.B and 3.19.C). There was a trend for an 
increase in the proportion of T-positive SNC neurons containing α-synuclein. This 
change was associated with an increase in microglia in the SN of the LRRK2 
[S910A+S935A] mice (Figure 3 19. E). 
In conclusion, aged LRRK2 mice did not exhibit loss of TH neurons in the SN, there 
were no differences in TH morphology or the expression of dopamine transporters 
DAT and VMAT2. This data strongly indicates that LRRK2 [S910A+S935A] mice are 
unlikely to develop a Parkinson’s disease’s phenotype under basal conditions. This 
result is consistent with the previously reported findings describing LRRK2 [R1441C] 
(Tong et al., 2009) and LRRK2 [R1441G] (Liu HF et al., 2014) knock-in mice, which 








LRRK2 WT           LRRK2 [S910A+S935A] 
Figure 3.19: Dopamine system and pathological changes in the SN. (A) The numbers of 
TH-positive dopamine neurons (red) were not significantly changed between WT and KI 
groups. (B) The labelling intensity of VMAT2 (red) was not significantly different in the KI 
group. (C) The intensity of dopamine transporters labelled for DAT (green) were unchanged. 
(D) There was a trend of more -synuclein colocalization (green) in TH positive dopamine 
neurons (red) in the SNC of LRRK2 [Ser910Ala+Ser935Ala] mice. (E) Microglia (red) in the 






Asterisks denote statistical differences between the indicated groups; * p< 0.05. (Data 
received from Australia’s Neuroscience Research Institute). 
 
Further assessment of the integrity of the synapses in the dorsolateral striatum 
showed that the intensity analysis of synaptophysin and α-synuclein 
immunoreactivity in the dorsolateral striatum did not differ between LRRK2 
[S910A+S935A] and WT mice, indicating no significant changes in these synaptic 
proteins. However, the intensity of TH-immunopositive dopamine terminals was 
significantly lower in the LRRK2 [S910A+S935A] compared to WT mice (Figure 
3.20.A).This change was shown to be associated with an increase in VMAT2-
labelling intensity in the LRRK2 [S910A+S935A] mice compared with the wild type. 
No morphological abnormalities were identified in the TH or VMAT2 immunoreactive 
structures at high magnification in LRRK2 [S910A+S935A] mice compared with WT 
mice (Figure 3.20.B). These changes might suggest reduced dopamine synthesis in 
intact dopamine neurons with increased synaptic vesicles transporter to maximize 













LRRK2 WT           LRRK2 [S910A+S935A] 
Figure 3.20: Changes of dopamine synthesis in axon terminals in the dorsolateral 
striatum. (A) The intensity of TH-positive dopamine axon terminals (red) was significantly 
decreased in KI mice compared with WT mice. High magnification images show similar TH-
positive staining patterns (red). (B) The labelling intensity of VMAT2 (red) was significantly 
elevated in the KI group. Asterisks denote statistical differences between the indicated 







Decrease in VMAT2 has been reported in clinical PD due to the loss of synapses, 
and increasing VMAT2 has been proposed as a therapeutic strategy (M. K. Chen et 
al., 2008). To test whether the change in VMAT2 is an age-dependent finding I 
extracted brains from 4 and 18 months old littermate mice comprising LRRK2 
[S910A+S935A] and LRRK2 WT animals. Brains were then lysed in 1% Triton and 
subjected total cell lysates to the immunoblot analysis using VMAT2, LRRK2 total 
















Figure 3.21: Assessment of total VMAT2 and LRRK2 levels in young and aged LRRK2 
WT and LRRK2 [S910A+S935A] mice. (A) Six brains were extracted from 4 months old 
littermates: three LRRK2 WT and three LRRK2 [S910A+S935A] mice. Four brains were 
extracted from 18 months old littermates: two LRRK2 WT and two LRRK2 
[Ser910Ala+Ser935Ala] mice. All brains were lysed in 1% Triton lysis buffer and total brain 
lysates were then subjected to immunoblot analysis with indicated antibodies. (B) Four 
brains were extracted from 4 months old littermates: two LRRK2 WT and two LRRK2 
[Ser910Ala+Ser935Ala] mice. Four brains were extracted from 18 months old littermates: 
two LRRK2 WT and two LRRK2 [Ser910Ala+Ser935Ala] mice. All brains were lysed in 1% 
Triton lysis buffer and total brain lysates were then subjected to immunoblot analysis with 
indicated antibodies. 
 
According to my findings, there is no difference in VMAT2 levels between LRRK2 
WT and LRRK2 [S910A+S935A] mice brain. It could be that the differences 
observed in histopathological studies are minor and local, and could only be 
observed in a dorsolateral striatum part of the brain. It would be then interesting to 
dissect the brain and specifically analyse this specific part. It seems that in18 months 
old mice there is a higher LRRK2 expression than in 4 months old mice. 4 brains 
derived from 4 independent mice were analysed for each genotype. This indicates 





increased expression could have an impact on LRRK2 kinase activity and be linked 
to late onset PD. 
3.3 Summary 
My data suggests that the [S910A+S935A] mutation has no influence in endogenous 
immunoprecipitated LRRK2 kinase activity in vitro, which is consistent with the 
previously reported over-expressed data. Interestingly, it seems that in vivo, LRRK2 
[S910A+S935A] mutation markedly reduces Rab10 and Rab8A phosphorylation by 
LRRK2. It was previously reported that mutation of LRRK2 S910 and S935 to 
alanine or dephosphorylation of LRRK2 at these sites upon LRRK2 inhibition leads 
to loss of 14-3-3 binding. It was described that under normal conditions LRRK2 is 
diffused throughout the cytoplasm but loss of 14-3-3 binding results in its 
mislocalization and aggregation (Nichols et al., 2010). Therefore, it could be that 
when a large part of LRRK2 is sequestered into cytoplasmic aggregates, the LRRK2 
activity is reduced resulting in diminished Rab10 phosphorylation. Based on this 
findings, it seems that serines 910 and 935 are important for LRRK2 localization and 
kinase activity and also for its kinase activity. It would be interesting to study 
endogenous LRRK2 localization within cell, however, to date there is no good IHC 
antibody to address this question and needs to be developed. During my PhD, I have 
tested all available IHC antibodies but did not find one that was specifically 
recognizing LRRK2 protein in wild type but not LRRK2 KO MEFs.  
Furthermore, I showed that the [S910A+S935A] mutation results in decreased 
LRRK2 expression in kidneys. This is consistent with the previously reported genetic 
and pharmaceutical data. It could be that LRRK2 protein levels are determined by 





substrates Rab10 and Rab8A.  
As described before, at the moment there are some safety concerns associated with 
LRRK2 inhibition as a treatment for PD. As dephosphorylation of serines 910 and 
935 resemble the effect of long-term LRRK2 inhibitor treatment and could be linked 
to safety risks associated with LRRK2 inhibition, in collaboration with Dr Francisco 
Marchesi, from University of Glasgow School of Veterinary Medicine a 
histopathological analysis of LRRK2 [S910A+S935A] kidneys and lungs was 
performed. According to the results reported here, there is no evidence that 
[S910A+S935A] leads to lungs or kidneys abnormalities, indicating that LRRK2 
kinase activity but not the phosphorylation state of S910 and S935 is implicated in 
kidney phenotype. The findings also suggest that S910 and S935 phosphorylation is 
not involved in lung phenotype, suggesting that some other LRRK2 function could be 
linked to it. Based on this data, there are no risks associated with S910 and S935 
dephosphorylation in connection to kidneys and lung phenotype. However, safety 
implications linked to LRRK2 kinase inhibition remain to be addressed.  
In addition, I examined whether LRRK2 S910 and S935 phosphorylation has an 
impact on mice well-being. My data shows that mutant mice are viable and 
reproduce well. However, I have noticed that S910A+S935A knock in mice seem to 
be fatter than the wild type littermates. It is an interesting finding consistent with the 
reported data that shows LRRK2 KO rats are weightier than their wild type 
littermates (Baptista et al., 2013), indicating that S910 and S935 could play a role in 
metabolic process abnormality. 
I also tested motor coordination of S910A+S935A knock-in mice and its wild type 





than the wild type, suggesting that this mutation affects their motor coordination. To 
study this further, I set up a collaboration with Dr Nic Dzamco at Neuroscience 
Research Australia to perform a histopathological evaluation of LRRK2 WT and 
LRRK2 [S910A+S935A] brain. The data reported here shows that LRRK2 knock-in 
mice did not display decreased cell numbers or impaired proliferation in Subcortex 
but showed a trend for decrease in total cells in hippocampus, indicating that knock-
in mice might have an effect on neuro/gliogenesis. Moreover, no significant 
dopamine neuronal loss was observed in knock-in mice. No loss of TH neurons in 
the SN, no differences in TH morphology, suggesting that knock-in mice are unlikely 
to develop PD under basal conditions. This result is consistent with the previously 
reported LRRK2 R1441C and R144G knock-in mice that comprise dephosphorylated 
910 and 935 sites. Interestingly, it was noted that VMAT2 intensity in knock-in mice 
was increased in comparison with the wild type. These changes might suggest 
reduced dopamine synthesis in intact dopamine neurons with elevated synaptic 
vesicle transporter to maximize the potential for dopamine uptake. Immunoblot 
analysis of 4 and 18 months old total brain lysates revealed that there is no 
difference in VMAT2 expression between LRRK2 WT and LRRK2 knock-in mice, 
indicating that this change is minor and might be present at the localized brain 
region. My preliminary data suggests that total LRRK2 levels in the aged mice are 
higher compared with the young mice, indicating that LRRK2 protein levels might be 
increasing with age and this could be linked to the mechanism, which might lie 
behind LRRK2 pathology in PD. However, these results need to be studies further as 








Chapter 4:   
Investigating MYPT1 as a 















As described in the introduction, the presence of multiple protein interaction domains 
suggest that LRRK2, in addition to its kinase and GTPase activities can function as 
scaffold for the assembly of multiprotein signaling complexes. To elucidate the 
molecular interaction network of endogenous LRRK2, the Gloeckner’s lab in 
collaboration with Marto’s lab performed quantitative immunoprecipitation combined 
with knockdown (QUICK) experiments (Meixner et al., 2011). This approach 
assesses interactions between proteins at their endogenous levels and their normal 
cellular environment by combining stable cell isotope labelling with amino acids in 
cell culture (SILAC), RNA interference, co-immunoprecipitation and quantitative 
mass spectrometry. This study linked LRRK2 function to the actin-based 
cytoskeleton and the list of numerous interactors was published (Meixner et al., 
2011). Little validation was undertaken in this study to determine which interactions 
were genius. Myosin phosphatase target subunit 1 (MYPT1) was identified as a 
possible LRRK2 interactor in this screen. At the same time, in our laboratory, Paul 
Davies also observed that MYPT1 from HEK293 cell extract interacted with 
recombinant GFP tagged LRRK2 immobilized on a sepharose resin (unpublished 
data). Furthermore, an in vitro kinase assay performed by Dr Paul Davies revealed 
that recombinant MYPT1 was efficiently phosphorylated by LRRK2. In addition, in 
2016, Matthias Mann’s lab in collaboration with our laboratory performed a 
comparative phosphoproteomic analysis of wild type MEF and MEF LRRK2 
[A2016T] drug resistant mutant cells treated with MLI-2, a novel potent and specific 
LRRK2 inhibitor generated by Merk (Fell et al., 2015; Steger et al., 2016). One of the 






Figure 4.1: Comparative phosphoproteomic analysis of LRRK2 WT vs LRRK2 
[A2016T] MEF cells (two sample t-test, FDR=2%) Data generated by Martin Steger from 
Matthias Mann’s lab.   
 
Their data suggested that phosphorylation of MYPT1 at T498 and T500 was 
inhibited in the wild type MEFs treated with ML-I2 inhibitor but not in LRRK2 
[A2016T] (Figure 4.1). MYPT1 peptide phosphorylated at T498 and T500 was one of 
the top hit in this screen. As MYPT T498 site is not conserved in humans, it was 
hypothesized that LRRK2 could phosphorylated MYPT1 at T500 in cells. Building on 
this evidence, we speculated that MYPT might comprise a physiological substrate of 
LRRK2.  
MYPT1 (also termed PPP1R12A, M130/133, M110, MBS) is a targeting subunit of 





(called RVXF) at the N terminal (Figure 4.4.C), which allows MYPT1 to direct PP1 
specifically to its substrate.  Therefore, it was further hypothesized that 
phosphorylation of MYPT1 could result in inhibition of myosin phosphatase via 
disruption of MYPT1:PP1 ß complex leading to S910 and S935 phosphorylation. As 
a result, inhibition of LRRK2 would result in activation of myosin phosphatase and 
subsequent dephosphorylation of S910 and S935 (Figure 4.2). 
Myosin phosphatase consists of myosin phosphatase targeting subunit MYPT1, 
catalytic subunit PP1ß that belongs to the PP1 family of Ser/Thr phosphatases and 
M20 subunit of unknown function. Myosin phosphatase holoenzyme was first purified 
from chicken gizzard by my PhD supervisor Dario Alessi in 1992 as a complex of 
catalytic subunit (PP1ß), myosin targeting subunit (M130/MYPT1) and a small 
subunit of unknown function (M20) (Alessi, MacDougall, Sola, Ikebe, & Cohen, 1992; 
Scotto-Lavino, Garcia-Diaz, Du, & Frohman, 2010; Terrak, Kerff, Langsetmo, Tao, & 
Dominguez, 2004). The human MYPT family comprises MYPT1, MYPT2, MBS85, 
MYPT3 and TIMAP (M. Ito, Nakano, Erdodi, & Hartshorne, 2004). 
It was described that all family members comprise similar domain structure and 
importantly, N-terminal ankyrin repeats, which are one of the most common protein-
protein interaction domains (Mosavi, Cammett, Desrosiers, & Peng, 2004). MYPT1 is 
strictly regulated by phosphorylation and interactions with regulatory proteins. 
Various kinases were already reported to phosphorylate and inhibit MYPT1 including 
ROCK (Kimura et al., 1996), ILK (Muranyi et al., 2002), DMPK (Muranyi et al., 2001), 
ZIPK (MacDonald, Eto, Borman, Brautigan, & Haystead, 2001), PAK (Takizawa, 
Koga, & Ikebe, 2002) and Raf-1 (Broustas et al., 2002). Interestingly, most of these 
kinases are regulated by small GTPases: ROCK by RhoA, DMPK by Rac, PAK by 





chain 2 (MRLC2). MYPT1 plays a key role in regulation of MRLC2 phosphorylation 
and therefore cell contractile and motile events (Wardle et al., 2006). Also, it was 
reported to be important in mitotic progression (Matsumura et al., 2011), cytokinesis 
(Kachaner et al., 2012) and cell detachment (Zagorska et al., 2010). 
In this chapter, the aim of my project is to address whether MYPT1 is a physiological 
substrate of LRRK2 and to investigate whether phosphorylation of MYPT1 by LRRK2 
is involved in the regulation of S910 and S935 phosphorylation of LRRK2. The 








Figure 4.2: Proposed model of LRRK2 regulation. The aim is to investigate whether 
MYPT1 is a physiological substrate of LRRK2 and if so whether it was implicated in 
regulating the negative feedback loop on S910 and S935 phosphorylation. 
 
4.2 Results 
4.2.1 MYPT1 is phosphorylated by LRRK2 in vitro at T500, T524, T529, T671, 
T761 and T891 
To confirm that MYPT1 is indeed phosphorylated by LRRK2 in vitro, I 
phosphorylated bacterially-purified MYPT1 protein in presence of Mg 2+-[γ- 32ATP], 
HEK293 purified GST-tagged LRRK2 [G2019S] in parallel with three different kinase 





30 mins at 30ºC at 1000 rpm. (Figure 4.3.A). My results indicate that LRRK2 
[G2019S], but not catalytically inactive LRRK2 KD, phosphorylates MYPT1 in a time-
dependent manner. Gel pieces comprising MYPT1 protein were extracted and 
MYPT1 phosphorylation was measured by a scintillation counter (4.3.B). This data 


















Figure 4.3: MYPT1 phosphorylation by LRRK2 in vitro. (A) GST tagged LRRK2 
[G2019S] or GST-tagged kinase-inactive LRRK2 ([D2017A], [I2020G], [I2020F]) proteins 
were HEK293-purified. Purified LRRK2 proteins were incubated with recombinant GST-
tagged MYPT1 and Mg 2+-[γ- 32P] for the indicated times and subjected to electrophoresis on 
a polyacrylamide gel and autoradiography. (B) Gel pieces comprising MYPT1 protein were 
extracted and MYPT1 phosphorylation was measured by a scintillation counter. 
In order to map MYPT1 phosphorylation sites, GST-tagged bacterially purified [32P] 
MYPT1 WT protein was phosphorylated by HEK293 purified GST-tagged LRRK2 
[G2019S] kinase for 120 mins at 30ºC at 1000 rpm and digested with the 
endoproteinase Asp-N. Digests were then analysed by chromatography on a C18 
column. Six major 32-P labelled phospho-peptides were observed in MYPT1 WT 
comprising sample (Figure 4.4.A). Solid-phase Edman sequencing and mass 
spectrometry identified phosphorylation sites as T500, T524, T529, T671, T761 and 
T892. Summary of these sites is shown in the Figure 4.4.B. These sites are located 
within ankyrin repeats at the C-terminal of MYPT1 protein (Figure 4.4.C). T500 and 
T671 are the most conserved phosphorylation sites among different species (Figure 
4.4.D).  
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Figure 4.4: LRRK2 phosphorylates MYPT1 at T500, T524, T529, T671, T761 and T892. 
(A) Recombinant MYPT1 WT was incubated with LRRK2 [G2019S] in the presence of Mg2+ -
[γ-32P] ATP for 120 min at 30ºC at 1000 rpm. Phosphorylated MYPT1 was digested with 
Asp-N and peptides were separated by reversed-phase high performance liquid 
chromatography on a C18 column. The peaks containing the 32P-labeled phospho-peptides 
are labelled with the identified phosphorylated residue. (B) Summary of the mass 
spectrometry and solid-phase Edman sequencing data obtained after analysis of the peak 
fractions. The deduced amino acid sequence of each peptide is shown and the 
phosphorylated residue is indicated (in red). (C) Domain structure of MYPT1 with the 
position of residues phosphorylated by LRRK2 (T500, T524, T529, T671, T761 and T892) 
and previously reported ROCK phosphorylation sites. (D) Sequence alignments of the 
indicated species of MYPT1 proteins surrounding indicated LRRK2 phosphorylation site. 
 
Phospho-peptides Phospho site 
T.DSISRYETSSTSAG.D+P Thr 892 
E.DEYKQKYSRTY.D+P Thr 761 
R.ERRRSYLTPVR.D+P Thr 671 
R.DSSSLRTSSSYTRRKWE.D+P Thr 524 /Thr 529 





In summary, my data shows that MYPT1 is efficiently phosphorylated by LRRK2 in 
vitro at least at T500, T524, T529, T671, T761 and T892. This is consistent with the 
previously reported data showing that LRRK2 preferentially phosphorylates 
threonines over serines (Nichols et al., 2009b). Interestingly, threonines 500 (Guo A 
et al., 2011), 529 (Zhou J et al., 2009), 671 (Sharma K et al 2014) and 892 (Mulhern 
D et al., 2011) were observed to be phosphorylated in cells in global proteomic 
studies and were reported to be novel MYPT1 phosphorylation sites 
(http://www.phosphosite.org/ database), the kinases that phosphorylate these sites 
are unknown. Therefore, I set out to test whether LRRK2 could potentially 
phosphorylate these novel sites. 
4.2.2 Mutation of T500, T524, T529, T671, T761 and T891 to alanine only 
reduces but does not abolish MYPT1 phosphorylation by LRRK2 in vitro. 
                                                                      
My results showed that MYPT1 is phosphorylated by LRRK2 [G2019S] in vitro at 
T500, T524, T529, T671, T761 and T892. However, mutation of all of these residues 
to alanine although significantly reduces MYPT1 phosphorylation by LRRK2 
[G2019S] it does not completely block it (Figure 4.5). This result is expected as 
HPLC trace revealed numerous minor sites, but the abundance of these sites was 
too low to identify them, these sites are marked as “?” in the Figure 4.4. However, 
after several attempts to map these sites (data not shown), I could not find any other 
major phosphosites but detected several small phosphosites, which were difficult to 
sequence. I cannot rule out the possibility that mutation of six MYPT1 threonines 
could lead to conformational change of the protein and create additional artificial 
phosphosites in vitro.  





     
Figure 4.5: Mutation of T500+T524+T529+T671+T761+T892 to alanine reduces LRRK2 
phosphorylation in vitro. HEK293-purified LRRK2 [G2019S] was incubated with bacterially 
purified recombinant MYPT1 WT or mutant [T500A+T524A+T529A+T671A+T761A+T892A] 
proteins in presence of Mg 2+-[γ- 32ATP] and LRRK2 GSK257821A specific kinase inhibitor 
as a negative control for 30 mins at 30ºC at 1000 rpm. Samples were then subjected to 
electrophoresis on a polyacrylamide gel and autoradiography. 
 
Building on the fact that I was unable to sequence multiple minor MYPT1 
phosphorylation sites, I decided to focus on the six major sites already mapped, and 
test whether inhibition of LRRK2 kinase activity in cells results in dephosphorylation 
of these threonines.                                                                                               
4.2.3 In over-expressed system there are no significant changes in MYPT1 
phosphorylation because of LRRK2 kinase inhibitor treatment. 
 
To determine whether inhibition of LRRK2 kinase activity leads to decreased 
phosphorylation of identified MYPT1 phosphosites  (T500, T524, T529, T671, T761 
or T892) in cells, HEK293 TREx cells stably overexpressing GFP-tagged LRRK2 
[G2019S] were transiently transfected with Flag-tagged MYPT1 and treated with 
DMSO control or 1μM GSK2578215A or LRRK2-IN1 LRRK2 kinase inhibitors. Flag-
tagged MYPT1 was immunoprecipitated and resolved on a SDS gel (Figure 4.6.A). 





digestion and analyzed by mass spectrometry [Orbitrap-Classic] to determine any 
obvious changes in MYPT1 phospho-mapped sites. (Figure 4.6.B). To test whether 
these inhibitors work, cell lysates were subjected to immunoblot analysis with 



























Figure 4.6: Assessment of MYPT1 phosphorylation in HEK293 cells o/e LRRK2 
G2019S (A) Transiently over-expressed Flag-tagged MYPT1 was immunoprecipitated from 
HEK293 T-REx cells stably overexpressing GFP- tagged G2019S LRRK2 treated with 
DMSO or 1μM indicated LRRK2 inhibitors, and resolved on a SDS gel. (B) XIC for Thr671 
was generated based on the intensities in a control sample as well as in LRRK2 inhibitor 
treated samples. No statistical analysis was made. (C) Cell lysates were subjected to 
immunoblotting analysis with total and phospho LRRK2 antibodies to show that LRRK2 
kinase inhibitors worked 
 
 
Orbitrap analysis gave no evidence that peptides comprising T500, T529, T761 or 
T892 are phosphorylated in cells. However, peptide R.RRSYLTPVR.D comprising 
Thr671 was seen to be phosphorylated in a control as well as in LRRK2 inhibitor 
treated samples. Extracted ion chromatograms (XICs) for these phospho-peptides 
were made by Dr David Campbell and phosphorylation levels at these sites were 
compared for the different conditions. This result does not suggest that treatment 
with LRRK2 inhibitor lead to a significant suppression of phosphorylation of T671 in 
this experiment. 
To determine whether this result is consistent, this experiment was repeated in 
triplicates but this time with an increased LRRK2 kinase inhibitor concentration. 
HEK293 TREx cells stably overexpressing GFP-tagged LRRK2 [G2019S] were 
transiently transfected with Flag-tagged MYPT1 and treated with DMSO control or 3 





immunoprecipitated and resolved on a SDS gel (Figure 4.7.A). The protein bands 
corresponding to MYPT1 were subjected to in-gel Tryptic digestion and analyzed by 
mass spectrometry [Orbitrap-Classic] to determine any obvious changes in MYPT1 
phospho-mapped sites. (Figure 4.7.B). To test whether these inhibitors work, cell 













Figure 4.7: Assessment of MYPT1 phosphorylation in HEK23 cells o/e LRRK2 G2019S 
(A)Transiently over-expressed Flag-tagged MYPT1 was immunoprecipitated from HEK293 
T-REx cells stably overexpressing GFP- tagged G2019S LRRK2 treated with DMSO or 3μM 
GSK2578215A LRRK2 inhibitors, and resolved on a SDS gel. (B) XIC for T671 and T500 
was generated based on the intensities in a control sample as well as in LRRK2 inhibitor 
treated samples. Two sample t-test, showed no significant reduction in phosphorylation of 
T671 and T500 in the inhibitor treated samples (p>0.05) (C) Cell lysates were subjected to 
immunoblotting analysis with total and phospho LRRK2 antibodies to show that LRRK2 
kinase inhibitors worked. 
 
In this experiment, orbitrap analysis gave no evidence that peptides comprising 
T529, T761 or T892 are phosphorylated in cells. However, peptide comprising T500 
and T671 were seen to be phosphorylated in a control as well as in LRRK2 inhibitor 
treated samples. Extracted ion chromatograms (XICs) for these phospho-peptides 





compared for the different conditions. According to these results, there is a trend for 
a decrease in phosphorylation at T500 and T671 in response to LRRK2 inhibition.  
To test, whether this effect could be enhanced with the increased concentration of 
LRRK2 kinase inhibitor. This experiment was repeated with 8µM of LRRK2 kinase 
GSK258825A inhibitor. HEK293 TREx cells stably overexpressing GFP-tagged 
LRRK2 [G2019S] were transiently transfected with Flag-tagged MYPT1 and treated 
with DMSO control or 8μM GSK2578215A LRRK2 kinase inhibitors. Flag-tagged 
MYPT1 was immunoprecipitated and resolved on a SDS gel (Figure 4.8.A). The 
protein bands corresponding to MYPT1 were subjected to in-gel Tryptic digestion 
and analyzed by mass spectrometry [Orbitrap-Classic] to determine any obvious 
changes in MYPT1 phospho-mapped sites. (Figure 4.8.B). To test whether these 
inhibitors work, cell lysates were subjected to immunoblot analysis with phospho and 














Figure 4.8: Assessment of MYPT1 phosphorylation in HEK23 cells o/e LRRK2 G2019S 
(A) Transiently over-expressed Flag-tagged MYPT1 was immunoprecipitated from HEK293 
T-REx cells stably overexpressing GFP- tagged G2019S LRRK2 treated with DMSO or 8μM 
indicated LRRK2 inhibitors, and resolved on a SDS gel. (B) XIC for Thr671 and Thr500 was 
generated based on the intensities in a control sample as well as in LRRK2 inhibitor treated 
samples. Two sample t-test, showed no significant reduction in phosphorylation of Thr671 
and Thr500 in the inhibitor treated samples (p>0.05). (C) Cell lysates were subjected to 
immunoblotting analysis with total and phospho LRRK2 antibodies to show that LRRK2 
kinase inhibitors worked.  
 
In this experiment, orbitrap analysis again gave no evidence that peptides 
comprising T529, T761 or T892 are phosphorylated in cells. However, peptide 
comprising T500 and T671 were observed to be phosphorylated in a control as well 
as in LRRK2 inhibitor treated samples. Extracted ion chromatograms (XICs) for 





levels at these sites were compared for the different conditions. According to my 
results, there is a trend for a decrease in phosphorylation at T671 in response to 
LRRK2 inhibition but not at T500. 
Although this analysis is only semi-quantitative it doesn’t suggest that there is a 
significant suppression of phosphorylation at T500 and T671 in these experiments. 
In addition, I did not observe a decrease in phosphorylation at these sites in 
response to increased LRRK2 inhibition. I cannot also rule out an off-target effect 
resulting from an increased LRRK2 kinase inhibitor concentration affecting my 
results. Moreover, it could be that usage of over-expressed cells is not ideal as over-
expressed MYPT1 may not be folded properly inside the cell and as a result LRRK2 
cannot access its phosphorylation sites. To rule out this possibility I performed a 
similar experiment using endogenous proteins. 
4.2.4 In MEFs, inhibition of endogenous LRRK2 with ML-I inhibitor, results in a 
trend of T500 and T671 phosphorylation reduction. 
 
My results in over-expressed cells revealed that there are no significant changes in 
MYPT1 phosphorylation at the mapped residues due to LRRK2 kinase inhibition. 
This suggests that LRRK2 might not be directly regulating the phosphorylation of 
MYPT1. However, one limitation of the experiments I have undertaken is that I have 
focused on studying the phosphorylation of overexpressed MYPT1 that might not be 
ideal as MYPT1 exists as a complex with the protein phosphatase 1 (PP1) and the 
overexpressed protein might be mislocalized or not in a physiological conformation 
that is able to dock with LRRK2. This might explain why I have not been able to 
establish that it is dephosphorylated after I treat cells with LRRK2 inhibitors.  
To investigate how MYPT1 phosphorylation at the mapped sites is affected by 





and drug resistant MEF LRRK2 [A2016T] treated with DMSO or recently developed 
highly specific MLI-2 LRRK2 kinase inhibitor was resolved on a SDS gel. Gel bands 
corresponding to MYPT1 protein were extracted, subjected to Tryptic digestion and 
analyzed by mass spectrometry [Orbitrap-Classic] to determine any obvious changes 
in MYPT1 phospho-mapped sites (Figure 4.9A). To test whether these inhibitors 
work, cell lysates were subjected to immunoblot analysis with phospho and total 


















Figure 4.9: Assessment of MYPT1 phosphorylation in MEF cells (A) Endogenous 
MYPT1 was immunoprecipitated from MEF LRRK2 WT and MEF LRRK2 [A2016T] drug 
resistant cells treated with DMSO or indicated LRRK2 inhibitor, and resolved on a SDS gel. 
(B) XIC for T500, T671 and T892 was generated based on the intensities in a control sample 
as well as in LRRK2 inhibitor (MLI-2) treated samples (t-test, T500 downregulated in MEF 
WT cell, p<0.05; T671 downregulated in MEF WT cell, p<0.05; T892 is unregulated in MEF 
WT cells (p<0.001). (C) Cell lysates were subjected to immunoblotting analysis with total and 






First of all, my results show that MYPT1 seem to be co-immunoprecipitated with PP1 
and MLC20 proteins, suggesting that this time it is in its natural conformation. 
Interestingly, MLC20 was observed to co-immunoprecipitate with MYPT1 in LRRK2 
[A2016T] drug resistant MEFs indicating that LRRK2 inhibition could have an effect 
on myosin phosphatase. Importantly, it can be seen that in MEF LRRK2 WT cells 
there is a dephosphorylation of S935, which is not present in a drug resistant LRRK2 
[A2016T] MEF cells, indicating that the inhibition of endogenous LRRK2 in cells was 
successful. Finally, I have detected T500, T671 and T892 to be phosphorylated in 
cells in all samples. However, orbitrap analysis gave no evidence for other sites to 
be phosphorylated in cells.  Moreover, extracted ion chromatograms (XICs) for 
Thr500 revealed that there is a significant decrease (around 20%) in T500 
phosphorylation in MEF LRRK2 WT cells treated with LRRK2 inhibitor but not in a 
drug resistant MEF LRRK2 [A2016T] cells  (t-test. p<0.05). There was also a slight 
but significant decrease in T671 phosphorylation (t-test. p<0.05) in MEF LRRK2 WT 
cells. Interestingly, T892 phosphorylation went up in response to LRRK2 inhibition 
suggesting that this site might be artificial or somehow regulated in a different 
manner within the cell (Figure 4.9.B).  
Overall, my results show that T500 and T761 phosphorylation is reduced in response 
to LRRK2 inhibition in MEF LRRK2 WT but not in drug resistant cells. This suggests 
that LRRK2 could phosphorylate MYPT1 at T500 and T671 in cells. However, due to 
a minor reduction in phosphorylation at these sites, I cannot rule out that LRRK2 is 
not the only kinase, which phosphorylates these sites in cells so that phosphorylation 
by LRRK2 under these conditions that I have examined are not rate limiting. 
To investigate whether I could enhance phosphorylation of T500 and T671 by adding 





lysis buffer with Microcystin-LR (Figure 4.10). Microcystins are a family of cyclic 
peptides that are potent inhibitors of the protein phosphatase families PP1 and PP2A 
(MacKintosh et al., 1990). We argued whether by adding a Microcystin-LR I could 
augment the phosphorylation of T500 and T671 by minimizing the activity of PP1 
protein phosphatases dephosphorylating MYPT1 during cell lysis and 
immunoprecipitation. According to my results, addition of Microcystin-LR into the 


















Figure 4.10: Assessment of MYPT1 phosphorylation in MEF cells (A) Endogenous 
MYPT1 was immunoprecipitated from MEF LRRK2 WT and MEF LRRK2 [A2016T] drug 
resistant cells treated with DMSO or indicated LRRK2 inhibitor, and resolved on a SDS gel. 
(B)  XIC for T500 and T892 was generated based on the intensities in a control sample as 
well as in LRRK2 inhibitor treated samples (t-test, T500 downregulated in MEF WT cell, 
p>0.05; T892 is downregulated in MEF WT cells (p>0.05). (C) Cell lysates were subjected to 
immunoblotting analysis with total and phospho LRRK2 antibodies to show that LRRK2 
kinase inhibitors worked. 
 
In this experiment, Orbitrap analysis gave no evidence that T671, T761, T524 and 
T529 were phosphorylated in cells. XIC for T500 and T82 were generated based on 
the intensities and compared among different condition. My results revealed that 
phosphorylation of T500 in wild type MEFs treated with LRRK2 inhibitor was non-





there was a slight reduction in T892 phosphorylation in wild type MEFs. Overall, this 
data suggests that LRRK2 inhibition did not have an effect on MYPT1 
phosphorylation in these conditions. It could be that inhibition of myosin phosphatase 
by Microcystin-LR could have an effect on these results. It is possible that PP1 
inhibition by Microcystin-LR could have resulted in dissociation of PP1: MYPT1: M20 
complex leading to its incorrect folding and inability of LRRK2 kinase reach MYPT1 
phosphorylation sites. This hypothesis is supported by the fact that according to a 
SDS gel, MYPT1 was not immunoprecipitated this time as PP1: MYPT1: M20 
complex. 
To sum up, my results indicate that inhibition of LRRK2 activity in cells results in a 
slight decrease of MYPT1 phosphorylation at T500 and T671 sites. It could be that 
LRRK2 is not the only kinase, which phosphorylates these sites in cells, in the 
conditions described in this thesis.  
4.2.5 Validation of MYPT1 phospho-T500 antibody 
As mass spectrometry data is only semi-quantitative and did not provide me with the 
clear evidence that LRRK2 phosphorylates MYPT1 in vivo, we generated phospho 
MYPT1 Thr500 polyclonal antibody (see Materials and Methods) to address this 
question. Four bleeds of MYPT1 T500 antibody were tested. For this purpose, 
HEK293 stably overexpressing GFP-tagged LRRK2 G2019S protein were transiently 
transfected with Flag-tagged MYPT1 WT or Flag-tagged MYPT1 [T500A] constructs, 
24 hours after transfection HEK293 cells were induced with the doxycycline to allow 
LRRK2 protein expression and then 24 hours later were lysed and subjected to 






Figure 4.11: Validation of MYPT1 pT500 antibody HEK293 stably overexpressing GFP-
tagged LRRK2 G2019S were transiently transfected with Flag-tagged MYPT1 WT or Flag-
tagged MYPT1 [T500A] constructs.48 hours after transfection cells were lysed and subjected 
to immunoblot analysis with indicated MYPT1 pT500 (1-4) bleeds. 
 
As a result, MYPT1 pT500 antibodies were shown to be unable to specifically 
recognize MYPT1 pT500 in a total cell lysate. To test whether it is possibly to 
immunoprecipitate MYPT1 protein phosphorylated at T500 in HEK293 cells stably 
over-expressing LRRK2 G2019S. HEK293 stably overexpressing GFP-tagged 
LRRK2 G2019S protein were transiently transfected with Flag-tagged MYPT1 WT or 
Flag-tagged MYPT1 [T500A] constructs, 24 hours after transfection HEK293 cells 
were induced with the doxycycline to allow LRRK2 protein expression and then 24 
hours later were lysed and subjected to immunoprecipitation with indicated MYPT1 







immunoblot analysis with Flag antibody (Figure 4.12). 
 
Figure 4.12: Validation of MYPT1 pT500 antibody HEK293 stably overexpressing GFP-
tagged LRRK2 G2019S were transiently transfected with Flag-tagged MYPT1 WT or Flag-
tagged MYPT1 [T500A] constructs.48 hours after transfection cells were lysed and subjected 
to immunoprecipitation with indicated MYPT1 pT500 (1-4) bleeds. Immunoprecipitates were 
then analysed by immunoblot using Flag antibody. 
 
Unfortunately, tested pT500 MYPT1 antibodies were unable to immunoprecipitated 
MYPT1 phosphorylated at T500 from HEK293 stably over-expressing LRRK2 
G2019S. 
As a result, no good polyclonal pT500 MYPT1 were found.  
4.2.6 Evidence that endogenous LRRK2 does not interact with MYPT1 in MEF 
cells. 
 
As described in the introduction, it has been reported that MYPT1 interacts with 
LRRK2 in mass spectrometry screen. To confirm this finding, endogenous LRRK2 





terminal monoclonal LRRK2 antibody. Immunoprecipitates were then subjected to 
immunoblot analysis by LRRK2 and MYPT1 total antibodies (Figure 4.13). 
 
Figure 4.13: Co-immunoprecipitation of LRRK2 with MYPT1. Endogenous LRRK2 was 
immunoprecipitated with anti-LRRK2 (100-500) (UDD3) antibody from LRRK2 WT as well as 
fromLRRK2 KO MEF cells. Immunoprecipitates were subjected to immunoblotting with anti-
LRRK2 and anti-MYPT1 antibodies 
 
According to my results there is no evidence that endogenous MYPT1 interacts with 
LRRK2 in MEF cells. I have repeated the co-immunoprecipitation several times but 
observed no binding between these proteins under these immunoprecipitation 
conditions. Interestingly, in my comparative mass spectrometry analysis I detected a 
very low amount of endogenous MYPT1 coming down with endogenous LRRK2 WT 








Table 4.1: Comparative mass-spectrometry analysis of LRRK2 immunoprecipiates 
from LRRK2 WT, LRRK2 [S910A+S935A] and LRRK2 KO MEFs (Numbers correspond to 
the number of peptides found in the screen) 
  
 
However, mass spectrometry data is not very strong as only 4 and 2 MYPT1 
peptides were found interacting with LRRK2 WT protein. Taking into consideration 
the size of MYPT is about 130 kDa, this data is a very bordering score significant. 
However, the interaction between the kinase and its substrate can be very transient 
and therefore it could be very difficult to detect kinase-substrate interaction by co-
immunoprecipitation analysis. 
4.2.7 Generation of MYPT1 KO cells. 
4.2.7.1 Attempt to generate MYPT1 KO cells using TALENs. 
To investigate whether MYPT1 plays a role in controlling the S910/S935 regulatory 
phosphorylation feedback loop I next decided to study how the deletion of MYPT1 
protein in cells affects phosphorylation of S910 and S935.  
There are no MYPT1 KO cells available at the moment and it has been reported that 
deletion of MYPT1 in mice results in very early embryonic lethality with no embryos 
being detected even at embryonic day 7.5 (Okamoto et al., 2005) 
I first decided to try and attempt to knockout MYPT1 in HEK293 cells using the 
transcription activator-like effector nucleases (TALENs). Transcription activator-like 
effectors (TALEs) are a class of naturally occurring DNA-binding proteins identified in 
the plant pathogen Xanthomonas spp. bacteria (Sanjana et al., 2012). It has been 
Identified Proteins  Abbreviation kDa WT WT WT  KI KI KI KO KO KO  
Leucine rich repeat 
kinase 
LRRK2 285 54 51 46 33 31 36 0 0 0  
Myosin phosphatase 
target subunit 1 





reported that fusions of transcription activator-like (TAL) effectors of plant pathogenic 
Xanthomonas spp. to the FokI nuclease, TALENs bind and cleave DNA in pairs 
(Sanjana et al., 2012). In fact, TALENs are peptides made of a DNA binding domain 
(represented by multiple loop structure) and an endonuclease domain (represented 
by Folk1). Therefore, customized TALENs have been adapted for a wide variety of 
genome engineering applications, including transcriptional modulation and genome 
editing. DNA binding domain binds to a specific DNA sequence as each loop is 
designed in such a way so that it recognizes a specific nucleotide. Folk1 
endonuclease domain produces a double-stranded DNA break when forms a dimer. 
It was reported that 14-20 base pairs region is an optimum distance between two 
TALENs so that Folk1 can be dimerized (Sanjana et al., 2012).  
With the help of Dr Piotr Szyniarowski I designed a pair of TALENs to target MYPT1 
exon 1 (see Materials and Methods) using a hierarchical ligation procedure 
described by Sanjana et al., 2012. To facilitate the screening process we designed 
TALENs in the way that they specifically target MYPT1 exon 1 at the PUVII 
restriction enzyme site. Our idea was that when Folk1 produces a double strand 
break at the targeted exon 1 PUVII site (see Materials and Methods), non- 
homologous end joining repair (NHEJ) can result in deletion of several nucleotides in 
this region and this can cause a deletion of this site and also knockout of a desired 
gene. Digestion with PVUII of such clones will not be possible and they will appear in 
a gel as a single band. However, if TALENs cleavage did not take place, two bands 
on the gel will appear, suggesting that TALENs didn’t work or NHEJ repaired the 
target region without causing a frame shift. Three bands on the gel will result if clone 
is heterozygous or it is a heterogeneous cell population and needs to be re-single 











Figure 4.14: A schematic representation of TALENs (A) A schematic representation of 
how TALENs work, a diagram adopted and modified from Sanjana et al., 2012. TALENs can 
be used to generate site-specific double-strand breaks to facilitate genome editing through 
non-homologous repair or homology directed repair. Two TALENs target a pair of binding 
sites flanking a 14-20 bp spacer comprising PVUII restriction site. The left and right TALENs 
recognize the top and bottom strands of the target sites, respectively. Each TALE DNA-
binding domain is fused to the catalytic domain of FokI endonuclease; when FokI dimerizes, 
it cuts the DNA in the region between the left and right TALEN-binding sites. (B) A 
theoretical digest: a strategy that allows to screen for MYPT1 KO using PVUII restriction site. 
 
Designed TALENs were used to transfect HEK293 cells. The pool of transfected 
cells was then single cell sorted into 96 well plates via FACS and allowed to grow for 
2-3 weeks. Single clones were isolated and their genomic DNA was purified, 
amplified by PCR, and tested with PVUII restriction enzyme digestion (for more 
details see material and methods). Example of MYPT1 KO screening at this stage is 
represented in Figure 30 A. In this experiment, over 800 clones were tested. Clones, 





selected. The DNA of these clones was extracted and sequenced (see example 
Figure 30.B). However, the sequence analysis of the target region of the exon 1 
showed that all of these clones possess a cleaved as well as non-cleaved version of 
this region. This indicated that all of these clones might be heterozygous or, 
alternatively they could consist of a mixture of clones comprising the wild type 
MYPT1 comprising cells as well as MYPT1 null cells. To exclude the last option 
these clones were re-single cell cloned again by FACS and tested by Western 
blotting analysis (Figure 30 C). After a massive screening analysis of different 
clones, I was unable to obtain homozygous knockout cell lines that might be 
because of MYPT1 deletion results in cell lethality. This conclusion is supported by 
several studies including (Yamashiro et al., 2008), which suggest that depletion of 


















Figure 4.15: Example of MYPT1 knockout screening: (A) HEK293 cells were transfected 
with TALENs and single cell cloned. Single cell clones were then selected and tested by 
PCR and PVUII digestion. From this screen, Clone 20 and Clone 21 appear to be resistant 
to PVUII digestion, suggesting that non-homologous end-joining repair of the targeted 





PVUII cleavage resistant clones: Clones, which were shown to be resistant to PVUII 
cleavage, were selected. The DNA of these clones was extracted, inserted into TOPO vector 
and sequenced. However, the sequence analysis of the target region of the exon 1 showed 
that all of these clones possess a cleaved as well as non-cleaved version of the sequence. 
This indicated that all of these clones might be heterozygous or, alternatively they could 
consist of a mixture of clones comprising the wild type MYPT1 comprising cells as well as 
MYPT1 KO cells. (C) Western blotting analysis of Clone 21. Clone 21 was re-single cell 
cloned and further analyzed by Western blotting. Although 7, 51, 54. 65, 67, 69 and 91 show 
no protein, these wells contained no cells and they are highlighted in red. 
 
4.2.7.2 Attempt to generate MYPT1 KO cells using Crispr/Cas9 technology. 
After the last few years following my attempt of the TALENs approach to knock-out 
MYPT1, the RNA-‐guided CRISPR‐Cas nuclease system has been developed and 
many labs have successfully adopted this technology for gene editing (Rojas-
Fernandez et al., 2015). The advantage of this technology is that it is relatively easy 
to manipulate, highly specific, efficient and fairy fast for genome engineering in 
distinct cell lines. CRISPR-Cas was initially identified in a microbial adaptive immune 
system that uses RNA-guided nucleases to cleave foreign genetic material 
(Marraffini & Sontheimer, 2010).  Later, the best characterized type II Crispr system, 
which consists of the endonuclease Cas9, the crRNA array that encodes the guide 
RNAs and a supplementary trans-activating crRNA (tracrRNA) that helps the 
processing of the crRNA array, became widely implemented for customized gene 
editing. The basic principle behind this technique is that each crRNA contains a 20 
nucleotide guide sequence, which directs Cas9 to a 20 nucleotide DNA target via 
Watson-Crick base pairing (Ran, Hsu et al. 2013). However, further research 
showed that for more successful binding of Cas9, the genomic target sequence must 
also contain the correct Protospacer Adjacent Motif (PAM) sequence immediately 
following the target sequence. The binding of the gRNA/Cas9 complex localizes 
Cas9 to the genomic target sequence so that the wild-type Cas9 can cut both 





functional domains including RuvC and HNH, each cutting a different DNA strand. 
When both of these domains are active, the Cas9 causes DSBs in the genomic 
DNA, which can be repaired by either Non‐Homologous End Joining (NHEJ) or 
Homology Directed Repair (HDR) (similar to TALENs). However, the Cas9 enzyme 
can be modified to possess a single inactive catalytic domain, known as a nickase. 
The Cas9 nickase is still able to bind DNA based on gRNA specificity (Rojas-
Fernandez et al., 2015). The majority of CRISPR plasmids currently used are 
derived from S. pyogenes and the RuvC domain can be inactivated by a D10A 
mutation while the HNH domain can be inactivated by an H840A mutation (Jinek, 
Chylinski et al. 2012). Although a single-strand break can be quickly repaired 
through the HDR pathway, using the intact complementary DNA strand as a 
template (if one wishes to make a knock-in mutation), two proximal, opposite strand 
nicks introduced by a Cas9 nickase are treated as a DSB. A double-nick induced 
DSB can be repaired by either NHEJ or HDR. 
For generation of HEK293 MYPT1 KO cells I used the Crispr/Cas9 approach which 
utilized a Cas9 nickase rather Cas9 wild type and possesses two plasmids: one 
antisense guide cloned into the Cas9 D10A vector pX335 and a sense guide cloned 
into pBABED puro U6.  
Table 4.2: CRISPR/Cas9 construction details (All constructs generated by Thomas 
McCartney, DSTT, University of Dundee) 
Materials Function  Sequence 
Guide RNA/Cas9 D10A complex 3) Each guide RNA contains a 20 
nucleotide guide sequence, 
which directs Cas9 D10A 
nickase to a 20 nucleotide DNA 
target via Watson-Crick base 
pairing. 
4) Cas9 creates a double-nick 
induced DSB that can be 
repaired by either NHEJ or HDR 
Targeting MYPT1 exon3:  
 
Antisense RNA guide:  
GTCCTCCTCCGCAATATCTAA  
cloned into the Cas9 D10A vector pX335 
 
Sense RNA guide: 
GCAAAATGAAGTTAATCGGCA 
cloned into pBABED puro U6 
Guide protected MYPT1 
sequences 
 
Previous studies strongly indicated 
that MYPT1 KO is lethal. Guide 
protected MYPT1 sequences allow 
to rescue this phenotype. 
Sequence 1 :  
pcDNA5D FRT/TO GFP MYP1 guide 
protected 





pcDNA5D FRT/TO GFP MYP1 T500 
guide protected 
Sequence3:  






As my previous work strongly indicated that deletion of MYPT1 could be lethal for 
cells. I firstly generated HEK293 cells over-expressing GFP tagged MYPT1 WT and 
GFP-tagged MYPT1 mutant proteins. We designed these proteins to be resistant to 
antisense and sense guides created to target endogenous MYPT1 with the aim to 
delete endogenous MYPT1. This approach would enable to keep cells alive by over-
expressing the GFP-tagged protein in case MYPT1 deletion causes cell death.  
Following transient transfection of HEK293 cells stably overexpressing GFP-tagged 
MYPT1 with Crispr/Cas9 D10A antisense and sense guides and selection of cells 
with puromycin, I have noticed that only cells containing puromycin and doxycycline 
survived the selection. This suggested that cells lacking MYPT1 are lethal and that 
MYPT1 is critical for cell survival. Therefore, for further experiments I kept 
doxycycline in the media to ensure GFP-tagged MYPT1 expression, which is 
essential for cell survival. The pool of transfected cells selected with puromycin and 
doxycycline was then single cell sorted into 96 well plates via FACS and allowed to 








Figure 4.16: Generation of MYPT1 null cell lines using Crispr/Cas9 technology. 
Following transfection and selection of HEK293 cells, lysates of HEK293 WT cells, HEK293 
cells over-expressing MYPT1 and generated clones were subjected to immunoblot analysis 
with MYPT1 antibody. 
 
I have been able to generate MYPT1 null cells over-expressing  GFP-tagged 
MYPT1 [T500A+T524A+T529A+T671A+T761A+T892A] protein. Unfortunately, 
MYPT1 null cells did not look very healthily as they didn’t attach well to the plate and 
never recovered after being split into bigger plate. This might be due to the fact that 
long GFP tag could interfere with MYPT1 being folded properly with PP1 and M20 
subunit. In addition, these cells were kept under constant doxycycline, puromycin 
and blasticidin treatment to ensure constant GFP-MYPT1 expression and these 
might have added some difficulty for MYPT1 null cells to survive. Unfortunately, I run 









I found that MYPT1 is efficiently phosphorylated by LRRK2 in vitro at T500, T524, 
T529, T671 T761 and T892. There are likely to be more minor LRRK2 
phosphorylation sites in vitro as mutation of all identified sites to alanine, although 
greatly suppressed LRRK2 phosphorylation, did not abolish it. After unsuccessful 
attempts to map additional sites I decided to focus on whether phosphorylation of 
already identified MYPT1 sites is impaired by inhibition of LRRK2 kinase activity in 
cells. I observed that in over-expressed cells, T500 and T671 are seen to be 
phosphorylated and that inhibition of LRRK2 kinase activity results in a slight 
decrease in phosphorylation at these sites. No other sites were seen phosphorylated 
in cells. To exclude that in over-expressed system MYPT1 folding is disrupted and 
this affected my results, I tested phosphorylation of endogenous MYPT1 in MEFs. 
My data again showed that there is no significant change at T500 or T671 
phosphorylation because of LRRK2 inhibition, indicating that LRRK2 might not be a 
rate-limiting kinase that phosphorylates MYPT1 in cells. Moreover, in cells and 
immunoprecipitation conditions I used, I found no evidence for MYPT1 to interact 
with LRRK2. Although my data indicates that MYPT1 is not a physiological LRRK2 
substrate. It would be important to assess MYPT1 phosphorylation at identified 
LRRK2 sites in cell lines other than HEK239 and MEFs and how this is affected by 
LRRK2 inhibitors. 
To address whether myosin phosphatase could act on S910 and S935 LRRK2 sites, 
I attempted to generate MYPT1 KO cells with the aim to treat them with LRRK2 
kinase inhibitor and determine whether this will affect phosphorylation of S910 and 
S935. In spite of a huge effort I could not generate MYPT1 null cells, indicating that 





cells overexpressing GFP-MYPT1 mutant. Unfortunately, these cells did not live long 
due to their unhealthily conditions and I could not test the impact of MYPT1 on 








Chapter 5:      












To date only Rab GTPases, including Rab8A, Rab10 and Rab12 were reported and 
validated by the stringent criteria used within our lab (Figure 1.3) to be direct 
physiological LRRK2 substrates. However, multiple other proteins such as actin-
cytoskeleton-regulated (ERM) proteins (Jaleel et al., 2007; Parisiadou et al., 2009), 
cellular tumour antigen p53 (Ho et al., 2015), mitogen-activated kinase kinase 3, 4, 
6, and 7 (Gloeckner, Schumacher, Boldt, & Ueffing, 2009), microtubule stabilizing 
tau protein (Bailey et al., 2013), SNARE-associated protein Snapin (Yun et al., 
2013), eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) (Imai et al., 2008), 
Ras-related protein (Rab5b) at non effector site T6 (Yun et al., 2015), 40S ribosomal 
subunit protein S15 (RPS15) (Martin et al., 2014), Protein kinase B (PKB) (Ohta, 
Kawakami, Kubo, & Obata, 2011), N-ethylmaleimide-sensitive fusion protein (NSF) 
(Belluzzi et al., 2016) were reported to be also phosphorylated by LRRK2 in cells. All 
these reports provided a novel and potential perspective of LRRK2 function within 
the cell and its potential link to Parkinson’s disease. For instance, it was described 
that LRR2 phosphorylated NSF protein at threonine 645, a hexameric AAA+ 
ATPase. Giving that G2019S LRRK2 mutant evidently increased this 
phosphorylation resulting in an increased ATPase activity and augmented rate of 
SNARE complex disassembling, it was suggested that mutant LRRK2 might disturb 
synaptic vesicle dynamics via aberrant phosphorylation of NSF (Belluzzi et al., 
2016). Another example of reported LRRK2 substrate is PKB, which was shown to 
be phosphorylated at S473. Once activated, PKB was suggested to negatively 
regulate a number of apoptosis-associated molecules such as Bad and caspase 9 as 
well as induce several signal transduction cascades for cell survival such as GSK-3b 





PKB phosphorylation and therefore it is resistance to apoptosis.  Based on this, it 
was suggested that the cell-protective ability of LRRK2 is exerted through 
phosphorylation and activation of PKB (Ohta et al., 2011).  
However, many of these sites have not been properly validated and shown that 
endogenous protein is indeed phosphorylated by LRRK2, and that phosphorylation 
of endogenous protein is abolished by treatment with LRRK2 kinase inhibitors. 
Unless this data is obtained doubts must be cast on the validity of these conclusions.  
In this chapter, I am reporting the work I undertook to attempt to validate RPS15 as a 
LRRK2 physiological substrate. In addition, I report my data from a comparative 
mass-spectrometry analysis to compare interacting partners derived from LRRK2 
immunoprecipitates from LRRK2 WT, LRRK2 [S910A+S935A] and LRRK2 KO 
mouse embryonic fibroblasts. In particular, I investigate whether Paralemmin (PALM) 
protein, identified in my analysis, could be a potential LRRK2 substrate or interactor. 
5.2 Results 
5.2.1 Studies undertaken to attempt to validate RPS15 protein as LRRK2 
substrate 
Dawson’s laboratory reported that ribosomal protein s15 (RPS15) is a crucial 
pathogenic LRRK2 substrate in Drosophila and human neuron PD models (Martin et 
al., 2014). According to their results, phospho-deficient RPS15 possessing a 
threonine 136 to alanine substitution rescues dopamine neuron degeneration in 
G2019S LRRK2  transgenic Drosophila and significantly blocks G2019S LRRK2-
mediated neurite loss and cell death in human dopamine and cortical neurons 
(Martin et al., 2014). In addition, it was reported that pathogenic G2019S LRRK2 
stimulates mRNA translation and induces a massive increase in protein synthesis in 





al., 2014). These results suggested a novel mechanism of PD pathogenesis linked to 
elevated LRRK2 kinase activity and aberrant protein synthesis in vivo. Before 
investigating this hypothesis further I decided first to attempt to confirm the reported 
results.  
To confirm whether RPS15 is phosphorylated by LRRK2 in vitro, recombinant GST- 
tagged LRRK2 [1326-end] (G2019S) was HEK293 purified and incubated in 
presence of recombinant GST-tagged RPS15 bacterially purified protein and Mg 2+-
[γ- 32ATP] for indicated amount of time at 30ºC at 1000 rpm in presence or absence 
of 1 µM LRRK2 GSK2578215A kinase inhibitor  (Figure 5.1). My results confirmed 
that RPS15 is efficiently phosphorylated by LRRK2 in a time-dependent manner and 
that the treatment with LRRK2 kinase inhibitor blocks RPS15 phosphorylation. The 
stoichiometry of phosphorylation was estimated to be 22% of the protein was 
phosphorylated. 
 
Figure 5.1: RPS15 is phosphorylated by LRRK2 in vitro: GST-tagged LRRK2 [1326-end) 
[G2019S] was HEK293-purified. Purified LRRK2 protein was then incubated with 





presence or absence of 1 µM LRRK2 specific kinase inhibitor (GSK2578215A) at 30ºC at 
1000 rpm. Samples were then subjected to electrophoresis on a polyacrylamide gel and 
autoradiography. 
 
To map the phosphorylation site, [32P] RPS15 protein was phosphorylated by 
Hek293-purified LRRK2 [G2019S] for 40 mins at 30ºC at 1000 rpm and digested with 
the endoproteinase Trypsin. Digests were then analyzed by chromatography on a 
C18 column. One major 32-P labelled phospho-peptide was observed in the HPLC 
sample (Figure 5.2.A). Solid-phase Edman sequencing and mass spectrometry 
identified phosphorylation site as T136 (Figure 5.2.B). My results showed that 
RPS15 is phosphorylated by LRRK2 at T136 in accordance with the previously 
reported data. Moreover, mutation of T136 to alanine largely blocked LRRK2 






















Figure 5.2: Mapping of RPS15 phosphorylation site (A) Recombinant GST-RPS15 
protein was incubated with LRRK2 (1326-end) [G2019S] in the presence of Mg2+ -[γ-32P] 
ATP for 40 min at 30ºC at 1000 rpm. Phosphorylated RPS15 was digested with Trypsin and 
peptides were separated by reversed phase high performance liquid chromatography on a 
C18 column. The peak containing the 32P-labeled phosphopeptide is labelled with the 
identified phosphorylated residue. (B) Summary of the mass spectrometry and solid-phase 
Edman sequencing data obtained after analysis of the peak fraction. The deduced amino 
acid sequence of each peptide is shown and the phosphorylated residue is indicated (in 
bold). (C) Purified LRRK2 protein was incubated with recombinant GST-tagged RPS15 WT 
or GST-tagged RPS15 T136A proteins and Mg2+-[γ- 32ATP] for the indicated times in 
presence or absence of 1 µM LRRK2 specific kinase inhibitor (GSK2578215A). Samples 
were then subjected to electrophoresis on a polyacrylamide gel and autoradiography. 
 
 
My data, consistent with the previously reported results, indicates that LRRK2 
efficiently phosphorylates RPS15 in vitro at T136 and mutation of this site to alanine 
evidently blocks this phosphorylation. To test whether LRRK2 phosphorylates 
RPS15 in cells, HEK293 cells stably over-expressing GFP-tagged LRRK2 [G2019S] 
were transfected with Flag-tagged RPS15 and treated with DMSO or 8µM 
GSK2578215A LRRK2 kinase inhibitor to determine whether inhibition of LRRK2 
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Figure 5.3: RPS15 phosphorylation in cells (A) Transiently over-expressed Flag-tagged 
RPS15 was immunoprecipitated from HEK293 T-REx cells stably overexpressing GFP- 
tagged G2019S LRRK2 treated with DMSO or 8µM of indicated LRRK2 inhibitor. 
Immunoprecipitates were then resolved on a SDS gel and stained with coomassie. (B) Cell 
lysates were subjected to immunoblot analysis with total and phospho LRRK2 antibody to 
confirm that inhibitor worked. (C) Gel bands corresponding to RPS15 were extracted from 
the gel and subjected to Orbitrap Velos analysis. XIC for T136 generated based on the 
intensities in a control sample as well as in LRRK2 inhibitor treated samples. 
 
According to this data, there are no obvious changes in RPS15 phosphorylation due 
to LRRK2 inhibition in cells. To summarise, LRRK2 phosphorylates robustly RPS15 





To address whether endogenous LRRK2 phosphorylates RPS15 in cells. I tested 
DSTT generated (see Materials and Methods) polyclonal phospho T136 RPS15 and 
total RPS15 antibodies. For this purpose, first of all, HEK293-purified LRRK2 (1326-
end) [G2019S] was incubated with the recombinant GST-tagged RPS15 WT or GST-
RPS15 T136A proteins in the presence of Mg2+-[γ- 32ATP] and 1µM of LRRK2 
specific kinase inhibitor as a negative control for 30 mins at 30ºC at 1000 rpm. 
Samples were then subjected to electrophoresis on a polyacrylamide gel and 
autoradiograph to confirm that the reaction worked (Figure 5.4.A). Subsequently, 
samples were subjected to immunoblot analysis with different bleeds of RPS15 
antibodies to test them (Figure 5.4.B). According to my results, only Bleed 2 of 
phospho T136 RPS15 antibody specifically recognized phosphorylated T136 residue 











Figure 5.4: Assessment of pT136 and total RPS15 antibody on purified RPS15 protein 
phosphorylated by LRRK2 in vitro. (A) HEK293-purified LRRK2 (1326-end) [G2019S] was 
incubated with the recombinant GST-tagged RPS15 WT or GST-RPS15 T136A proteins in 
the presence of Mg 2+-[γ- 32ATP] and 1 µM LRRK2 specific kinase inhibitor as a negative 
control. Samples were then subjected to electrophoresis on a polyacrylamide gel and 
autoradiograph. (B) Samples were also subjected to immunoblot analysis with different 
bleeds of indicated pT136 and total RPS15 antibodies. 
 
To test further RPS15 antibody in over-expressed cells, transiently transfected 
FLAG-tagged RPS15 WT or T136A proteins were immunoprecipitated from HEK293 
stably over-expressing GFP-tagged LRRK2 [G2019S] treated with DMSO or 1µM 
GSK2578215A LRRK2 kinase inhibitor. The immunoprecipitates as well as cell 
lysates were resolved on a SDS gel and analysed by distinct bleeds of indicated total 
RPS15 antibodies (Figure 5.5). My results showed that first of all, the transient 





amount of Flag-tagged RPS15 in the total cell lysate as well as immunoprecipitates. 
Secondly, I found no total RPS15 antibodies able to specifically recognize RPS15 
protein in the total cell lysate. However, all total RPS15 antibody bleeds are capable 
of specifically recognizing RPS15 protein immunoprecipitated from cells with FLAG 
antibody. In parallel, pT136 RPS15 antibodies were tested (Figure 5.6). As a result, I 
found no pT136 RPS15 bleed capable of specifically recognizing phosphorylated 
RPS15 protein neither in the total cell lysate or immunoprecipitated with FLAG 
antibody from HEK393 cells stably over-expressing LRRK2 G2019S. Subsequently, I 
could not test if endogenous RPS15 is phosphorylated by LRRK2 in cells.  
Matthias Mann’s laboratory also detected RPS15 to be phosphorylated in MEF cells 
at T136 in their mass spectrometry screen, however this phosphorylation was not 









Figure 5.5: Assessment of total RPS15 antibody in over-expressed cells. HEK293 cells 
stably over-expressing GFP-tagged LRRK2 [G2019S] cells were transiently transfected with 
FLAG-tagged RPS15 WT or T136A proteins. 24 hours after transfection HEK293 cells were 
induced with the doxycycline to allow LRRK2 expression and 24 hours later cells were then 
treated with DMSO or 1µM GSK2578215A LRRK2 kinase inhibitor for 1 hour. Cell lysates 
were then resolved on polyacrylamide gel and subjected to immunoblot analysis with 
different bleeds of total RPS15 antibody. In addition, FLAG-tagged RPS15 proteins were 












Figure 5.6: Assessment of pT136 RPS15 antibody in over-expressed cells Hek 293 
cells stably over-expressing GFP-tagged LRRK2 [G2019S] cells were transiently transfected 
with FLAG-tagged RPS15 WT or T136A proteins. 24 hours after transfection HEK293 cells 
were induced with the doxycycline to allow LRRK2 expression and 24 hours later cells were 
then treated with DMSO or 1µM GSK2578215A LRRK2 kinase inhibitor for 1 hour. Cell 
lysates were then resolved on polyacrylamide gel and subjected to immunoblot analysis with 
different bleeds of pT136 RPS15 antibody. In addition, FLAG-tagged RPS15 proteins were 











5.2.2 Proteomic fingerprint analysis of endogenous LRRK2 
immunoprecipitated from MEF WT, MEF [S910A+S935A] and MEF KO cells 
A comparative proteomic fingerprint analysis was performed with the aim to identify 
novel LRRK2 interacting partners that possibly could function as LRRK2 kinase 
potential substrates. For this purpose, a total of three scale biological replicates of 
endogenous LRRK2 were immunoprecipitated from the wild type, LRRK2 
[S910A+S935A] knock-in and knock-out mouse embryonic fibroblast cells using N-
terminal (100-500) monoclonal LRRK2 antibody. LRRK2 [S910A+S935A] knock-in 
MEFs were used in this experiment to investigate weather phosphorylation of serines 
910 and 935 can have an effect on LRRK2 binding properties. Resultant 
immunoprecipiates were then subjected to Tryptic digestion and analysed by mass 
spectrometry (Orbitrap Velos). Obtained data was analysed using the Proteome 
Discoverer Software and visualised in Scaffold based on how many peptides of a 
protein were detected in a particular sample. My results are summarised in the Table 
5.1. Endogenous LRRK2 immunoprecipitated from MEF wild type cells brings down 
a great number of proteins associated with cytoskeleton such as CAPZB, MYO1B, 
MYO1D, ARC1B, and ARPC4; cell adhesion, for instance, THBS1, VINC, CTNNA1 
and MFGM; GTPases, for example, RAB11A, RASN, RRAS2 and RALB; vesicle 
transport such as SNAP23, PALM and VAPA, and ion transport. In contrast, 
endogenous LRRK2 derived from [S910A+S935A] MEFs brings down substantially 
reduced number of interacting partners indicating that this mutation might affect 
LRRK2 binding properties. For instance, SNAP23, VDAC1, PALM, TSPH1, NRAS 
and CTNNA1 seem to come down only with endogenous LRRK2 WT but not LRRK2 
[S910A+S935A] or LRRK2 KO. In contrast, CYB5, STX12, CARF, MRC2 are 





MME, THSB1 and RAB11A proteins appear to be present in both LRRK2 WT and 
LRRK2 [S910A+S935A] samples. Some of these proteins where shown to be linked 
to Parkinson’s disease such as GNAI2, Rab11, VDAC1 and TSN6. It should be 
noted that Rab11 is not phosphorylated by LRRK2 in the experiments that have 
been undertaken thus far in our laboratory by Federico Diaz (unpublished data). 
Interestingly, 14-3-3 protein was detected in all my samples including LRRK2 KO 
cells and it was discarded from my analysis by Scaffold as non-specific interactor. It 
could be that not only LRRK2 but other proteins bind 14-3-3 and bring it with them, 
making it difficult to study this interaction by immunoprecipitation.  
Table 5.1.A:  Identity of proteins found in immunoprecipiates derived from LRRK2 WT 
but not LRRK2 KO MEFs. 




Guanine nucleotide-binding protein G(i) 
subunit alpha-2 
GNAI2 40 20 20 14 0 0 2 45 
2 
Golgi-associated plant pathogenesis-
related protein 1 
GAPR1 17 6 4 5 0 0 0 29 
3 F-actin-capping protein subunit beta CAPZB 31 9 9 7 0 0 3 27 
4 
UPF0444 transmembrane protein 
C12orf23 homolog 
TMEM263 12 3 2 3 0 0 1 22 
5 Thrombospondin-1 THBS1 130 28 26 24 0 0 0 20 
6 Synaptosomal-associated protein 23 SNP23 23 5 4 4 0 0 0 19 
7 Connective tissue growth factor CTGF 38 7 8 6 0 0 0 18 
8 
Leucine-rich repeat serine/threonine-
protein kinase 2 
LRRK2 285 54 51 46 0 0 0 18 
9 
Voltage-dependent anion-selective 
channel protein 1 
VDAC1 32 5 5 5 0 0 0 16 
10 Histone H4 H4 11 4 1 0 0 0 1 15 
11 Ras-related protein Ral-B RALB 23 3 2 5 0 0 0 14 
12 Paralemmin-1 PALM 42 7 7 4 0 0 0 14 
13 Apoptosis regulator BAX BAX 21 3 3 3 1 2 0 14 
14 Ras-related protein Rab-11A RB11A 24 3 4 3 0 0 0 14 
15 Catenin alpha-1 CTNNA1 100 14 14 13 0 0 0 14 
16 Alpha-soluble NSF attachment protein SNAA 33 7 2 4 1 0 0 13 
17 
Vesicle-associated membrane protein-
associated protein A 







Table 5.1.B:   Identity of proteins found in immunoprecipiates derived from LRRK2 WT but 
not LRRK2 [S910A+S935A] or LRRK2 KO MEFs. 
18 Ras-related protein R-Ras2 RRAS2 23 4 2 3 0 0 1 13 
19 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
OST48 49 6 7 6 1 0 0 13 
20 Caveolin-1 CAV1 21 3 3 2 0 0 0 13 
21 GTPase NRas RASN 21 4 2 2 0 0 0 13 
22 Vinculin VINC 117 20 12 12 0 0 0 13 
23 Lactadherin MFGM 51 8 6 5 0 0 2 12 
24 
Cluster of Transmembrane emp24 
domain-containing protein 9 
TMED9 27 3 3 4 0 0 0 12 
25 Neprilysin NEP 86 13 10 8 0 0 0 12 
26 Unconventional myosin-Ib   MYO1B 129 15 13 16 1 0 5 11 
27 Tetraspanin-6 TSN6 27 3 3 3 0 0 0 11 
28 Cysteine and glycine-rich protein 1 CSRP1 21 1 2 4 0 0 0 11 
29 Polymerase I and transcript release factor PTRF 44 5 5 4 0 1 0 11 
30 
Actin-related protein 2/3 complex subunit 
4 
ARPC4 20 3 2 1 0 0 0 10 
31 
Myosin phosphatase Rho-interacting 
protein 
MPRIP 116 17 10 7 0 0 0 10 
32 
Actin-related protein 2/3 complex subunit 
1B 
ARC1B 41 5 4 3 0 0 0 10 
33 Adenylyl cyclase-associated protein 1 CAP1 52 9 3 3 0 1 0 10 
34 NEDD8-conjugating enzyme Ubc12 UBC12 21 3 3 0 0 1 0 10 
35 
Inhibitor of nuclear factor kappa-B kinase-
interacting protein 
IKIP 43 4 5 3 0 0 0 9 
36 Golgi reassembly-stacking protein 2 GORS2 47 5 3 5 0 1 0 9 
37 Unconventional myosin-Id MYO1D 116 12 10 10 0 0 0 9 
38 
Vesicular integral-membrane protein 
VIP36 
LMAN2 40 4 5 2 0 0 0 9 
39 
Endoplasmic reticulum-Golgi intermediate 
compartment protein 1 
ERGI1 33 3 4 2 0 0 0 9 
40 Calponin-1 CNN1 33 4 2 3 0 0 0 9 
41 Catenin beta-1 CTNB1 85 8 9 6 0 0 0 9 
42 Prostacyclin synthase PTGIS 57 7 4 4 0 0 0 9 
  Identified Proteins  Abbreviation kDa WT WT WT 
 










pathogenesis-related protein 1  
2 Thrombospondin-1  TSP1 130 28 26 24 4 4 5 0 0 0 20 
3 
Synaptosomal-associated 
protein 23  
SNP23 23 5 4 4 0 0 1 0 0 0 19 
4 Connective tissue growth factor  CTGF 38 7 8 6 0 0 0 0 0 0 18 
5 
Voltage-dependent anion-
selective channel protein 1  
VDAC1 32 5 5 5 0 0 0 0 0 0 16 
6 Ras-related protein Ral-B RALB 23 3 2 5 0 1 0 0 0 0 14 
7 Paralemmin-1  PALM 42 7 7 4 0 0 0 0 0 0 14 
8 Cluster of Catenin alpha-1  CTNA1 100 14 14 13 1 0 0 0 0 0 14 
9 
Cluster of Ras-related protein R-
Ras2  
RRAS2 23 4 2 3 0 1 0 0 0 1 13 
10 Cluster of GTPase NRas  NRAS 21 4 2 2 0 0 0 0 0 0 13 
11 
Peptidyl-prolyl cis-trans 
isomerase FKBP1A  
FKB1A 12 1 2 1 0 0 1 0 2 1 11 
12 
Actin-related protein 2/3 
complex subunit 1B  
ARC1B 41 5 4 3 0 1 1 0 0 0 10 
13 Unconventional myosin-Id  MYO1D 116 12 10 10 0 0 1 0 0 0 9 
14 Catenin beta-1  CTNB1 85 8 9 6 0 0 0 0 0 0 9 
15 
Immunoglobulin superfamily 
containing leucine-rich repeat 
protein  
ISLR 46 5 3 4 0 0 0 0 0 0 9 
16 
Cluster of Calpain small subunit 
1  
CPNS1 28 3 2 2 0 0 1 0 1 0 8 
17 
FERM, RhoGEF and pleckstrin 
domain-containing protein 1  
FARP1 119 10 10 8 0 0 0 0 0 0 8 
18 
Transforming growth factor beta-
1-induced transcript 1 protein  
TGFI1 50 4 3 4 0 0 0 0 0 0 7 
19 Glypican-4  GPC4 63 4 5 3 1 1 1 0 0 0 6 
20 
4F2 cell-surface antigen heavy 
chain  
4F2 58 4 3 4 0 0 0 0 0 0 6 
21 Catenin delta-1  CTND1 105 8 6 4 0 0 0 0 0 0 6 
22 Cadherin-2  CADH2 100 7 4 6 0 0 0 0 0 0 6 
23 Flotillin-1  FLOT1 48 2 3 3 0 0 0 0 0 0 6 
24 Annexin A6 ANXA6 76 5 3 3 0 0 0 0 0 1 5 
25 
Cluster of Band 4.1-like protein 
2  
E41L2 110 7 5 3 1 0 0 0 0 0 5 
26 Integrin beta-5  ITB5 88 5 3 3 0 0 0 0 0 0 4 
27 
Sorbin and SH3 domain-
containing protein 2 






Table 5.1.C:  Identity of proteins found in immunoprecipiates derived from LRRK2 
[S910A+S935A] but not LRRK2 KO MEFs. 
 
  Identified Proteins  Abbreviation kDa KI KI KI KO KO KO 
Number of 
peptides/100kDa 
1 Atrial natriuretic peptide receptor 3 ANPRC 60 5 8 9 0 0 0 12 
2 
Leucine-rich repeat serine/threonine-
protein kinase 2 
LRRK2 285 33 31 36 0 0 0 12 




SQRD 50 5 5 3 0 0 0 9 
5 
Endoplasmic reticulum-Golgi 
intermediate compartment protein 1 
ERGI1 33 2 3 3 0 0 0 8 
6 Protein ERGIC-53 LMAN1 58 4 4 5 0 0 0 7 
7 Prostacyclin synthase PTGIS 57 5 3 3 0 0 0 6 
8 
Myosin phosphatase Rho-interacting 
protein 
MPRIP 116 6 5 11 0 0 0 6 
9 
Vesicular integral-membrane protein 
VIP36 
LMAN2 40 2 2 3 0 0 0 6 
10 CDKN2A-interacting protein CARF 60 4 2 2 0 0 0 4 
11 Perilipin-4 PLIN4 139 5 6 4 0 0 0 4 
12 Thrombospondin-1 TSP1 130 4 4 5 0 0 0 3 
13 Neprilysin NEP 86 2 2 3 0 0 0 3 
14 Vinculin VINC 117 3 4 2 0 0 0 3 










28 Neural cell adhesion molecule 1  NCAM1 119 7 2 3 1 0 1 0 0 0 3 
29 Cytochrome P450 1B1  CP1B1 61 2 2 2 0 0 0 0 0 0 3 
30 Cadherin-11  CAD11 88 4 2 2 0 0 0 0 0 0 3 
31 
General vesicular transport 
factor p115  
USO1 107 4 2 2 0 0 1 0 0 0 2 





Table 5.1.D:  Identity of proteins found in immunoprecipiates derived from LRRK2 
[S910A+S935A] but not LRRK2 WT or LRRK2 KO MEFs. 
  Identified Proteins  Abbreviation kDa WT WT WT KI KI KI KO KO KO 
Number of 
peptides/100kDa 




SQRD 50 1 2 1 5 5 3 0 0 0 9 
3 Syntaxin-12  STX12 31 0 1 0 3 2 1 0 0 0 6 
4 CDKN2A-interacting protein  CARF 60 0 0 0 4 2 2 0 0 0 4 
5 C-type mannose receptor 2  MRC2 167 0 0 0 3 2 2 0 0 0 1 
 
 
One of the limitations of this approach is that the interaction between LRRK2 and 
any putative substrates needs to be strong enough to resist the handling of the 
immunoprecipitates that is why some of the potential LRRK2 interactors could be 
missing from this list. In addition, the interaction could be indirect and we could be 
detecting proteins that interact with LRRK2 interactors and this will be difficult to 
validate. Moreover, LRRK2 could share some of its interactors with other proteins 
that could come down from LRRK2 KO cells, for instance the case with 14-3-3, and 
in this experiment, it will be hard to identify false negative and positive LRRK2 
interactors. The other thing to consider is that some proteins could bind LRRK2 non-
specifically and also could bring down with them other non-specific proteins. To 
reduce this possibility cell lysates were pre-cleared with IgG antibody before cell 
lysates were incubated with LRRK2 specific antibody. Finally, it is important to note 
that MEF WT, MEF [S910A+S935A] and MEF KO cells were immortalised 
simultaneously by prolong passaging and this could results in accumulation of 
random distinct mutations between these cell lines that could affect the results. 





is critical to undertake further analysis to confirm that proteins identified also bind to 
LRRK2. 
5.2.3 Validation of proteomic hits in over-expressed cells. 
5.2.3.1 Attempt to validate PALM as an interactor of LRRK2. 
Paralemmin (PALM), a prenyl-palmitoyl-anchored phosphoprotein abundant in 
neurons and implicated in plasma membrane dynamics and cell process formation 
(Kutzleb et al., 1998).  Paralemmin is highly expressed in the brain but also less 
abundantly in many other tissues and cell types. Prenylation and palmitoylation of a 
COOH-terminal cluster of three cysteine residues confers hydrophobicity and 
membrane association to paralemmin. Paralemmin is also phosphorylated, and its 
mRNA is differentially spliced in a tissue-specific and developmentally regulated 
manner (Kutzleb et al., 1998). It was reported that paralemmin is associated with the 
cytoplasmic face of the plasma membranes of postsynaptic specializations, axonal 
and dendritic processes and perikarya, and also appears to be associated with an 
intracellular vesicle pool. Moreover, it was shown that overexpression in several cell 
lines shows that paralemmin concentrates at sites of plasma membrane activity such 
as filopodia and microspikes, and induces cell expansion and process formation. The 
lipidation motif is essential for this morphogenic activity. It was proposed that 
function of paralemmin is linked to the control of cell shape, for instance, through an 
involvement in membrane flow or in membrane–cytoskeleton interaction (Kutzleb et 
al., 1998). However, little is known about its mode of action, or about the biological 
functions of the other paralemmin isoforms: paralemmin-2, paralemmin-3 and 
palmdelphin (PALM D). It was suggested that the four paralemmin isoform genes 





gene in the two early vertebrate genome duplications (Hultqvist, Ocampo Daza, 
Larhammar, & Kilimann, 2012) (Figure 5.7). 
 
Figure 5.7: Conserved organization of paralemmin isoform genes (Adopted from 
(Hultqvist et al., 2012) 
 
To validate identified proteomic hits, their interaction with LRRK2 was first of all 
verified in over-expressed system. For this purpose, HEK293 cells over-expressing 
Flag-tagged empty or LRRK2 WT proteins were transfected with the corresponding 
HA-tagged construct from LRRK2 WT vs LRRK2 KO list. HA-tagged empty and 14-
3-3 constructs were used as a negative and positive control correspondingly. 14-3-3 
was chosen as a positive control because it was found previously to interact with 
LRRK2 through phosphorylated S910 and S935 residues in over-expressing cells 
(Nichols et al., 2010). My findings are summarized in Figure 5.9. According to my 
data, HA-tagged 14-3-3 protein interacts with Flag-tagged LRRK2 but not with empty 
vector control. This is consistent with the previously reported data and indicates that 
the experiment worked. Moreover, I found that HA-tagged paralemmin (PALM), also 
strongly interacts with Flag-tagged LRRK2 in this system. In addition, an evident 
interaction with LRRK2 was detected between HA-tagged GTPases NRAS and 





recently discovered LRRK2 substrate (Steger et al., 2016), were described to be 
palmitoylaited at their C-terminus (Kang et al., 2008). This suggests that 






Figure 5.8: Validation of mass spectrometry hits in over-expressed cells. HEK293 cells 
over-expressing LRRK2 were transfected with indicated HA-tagged proteins, 24 hours later 
cells were induced with doxycycline. 48 hours after transfection, cell lysates were subjected 
to immunoprecipitation with FLAG or HA antibodies. Immunoprecipitates were then analyzed 
by immunoblotting with indicated antibodies.   
 
As my data indicated that PALM interacts with LRRK2 in over-expressed system, 
this interaction was further investigated by testing whether it is affected by LRRK2 
kinase activity and S910+S935 phosphorylation. For this purpose, HEK293 cells 
stably over-expressing FLAG-tagged empty or LRRK2 WT proteins were transfected 





positive control and HA-tagged empty used as a negative control. Cells were then 
induced and subsequently treated with DMSO or 1µM of LRRK2 kinase inhibitor 
GSK2578215A.  My results are shown in Figure 5.10. According to this data, 14-3-3 
binding with LRRK2 is significantly reduced upon LRRK2 kinase inhibitor treatment, 
which is consistent with the previously reported data. However, this binding is only 
detected by immunoprecipitating of HA-tagged protein and blotting for LRRK2 
protein using FLAG antibody but not the other way around. PALM interaction with 
LRRK2 was detected either way but this interaction was not shown to be affected by 
inhibition of LRRK2 kinase activity. This suggests that PALM interacts with LRRK2 in 















Figure 5.9: PALM interaction with LRRK2 is not affected by LRRK2 kinase activity. 
HEK293 cells stably over-expressing FLAG-tagged empty or LRRK2 WT were transfected 
with corresponding HA constructs, 24 hours after transfection cells were induced with 
doxycycline, 48 hours after transfection cells were treated with DMSO or 1µM LRRK2 kinase 
inhibitor GSK2578215A for 1 hour and lysed. Cell lysates were then subjected to 
immunoprecipitation with FLAG or HA antibodies. Immunoprecipitates were then analyzed 








In order to identify LRRK2 PALM binding domain, HA-tagged PALM protein was co-
expressed with LRRK2 FLAG-tagged N-terminal (1-1326), C-terminal (1326-end) 








Figure 5.10: Co-immunoprecipitation of HA-PALM with Flag-LRRK2 fragments. 
HEK293 cells were co-transfected with HA-tagged PALM and indicated Flag-tagged LRRK2 
fragments. Cell lysates were then subjected to immunoprecipitation with FLAG or HA 






According to this data PALM is binding to the N-terminal, C-terminal and full length 
LRRK2. This could be explained by the existence of two LRRK2 PALM binding 
domains or simply by non-specific interaction.  
To verify if this interaction is specific, HA-tagged PALM protein was co-expressed 
with Flag-tagged LRRK2 WT as well as five other randomly chosen proteins (Figure 
5.12). My results revealed that PALM protein is coming down with LRRK2 protein 
and with other four randomly chosen proteins such as KCC3a, Rab8a, SGK2, and 
SGK3 but not with MYPT1. This data suggests that PALM interaction with LRRK2 is 






Figure 5.11: PALM co-expression with different proteins in HEK293 cells. HA-tagged 
PALM was co-expressed with FLAG-tagged indicated proteins. 48 hours after transfection 
cells were lysed and cell lysates were subjected to immunoprecipitation with indicated 







To completely rule out the possibility of specific PALM LRRK2 interaction, these 
proteins were visualized together in over-expressed Hek293 cells with the aim to 
detect their co-localization. For this purpose, Hek293 cells stably over-expressing 
GFP-tagged LRRK2 WT or LRRK2 [S910A+S935A] were transiently transfected with 
HA-tagged PALM. Cells were then, fixed, stained and analyzed by Alan Prescott 
using Confocal Microscopy (Figure 5.13). According to the obtained data, GFP-
tagged LRRK2 is diffused throughout the cytoplasm. Although GFP-tagged LRRK2 
[S910A+Ser935A] protein is also diffused throughout the cytoplasm, it accumulates 
in aggregates. This is consistent with the previously reported data (Nichols et al., 
2010) indicating that S910A+S935A mutation causes LRRK2 aggregation in cell. 
PALM protein is localized at the cell membrane and there is no obvious co-
localization observed between these proteins. These results indicate that most 
probably PALM LRRK2 interaction is not specific.  
 
 
Figure 5.12: HA-tagged PALM co-localization with GFP-tagged LRRK2   proteins in 
HEK293 cells. HEK293 cells stably over-expressing indicated GFP-tagged LRRK2 protein 
were transiently transfected with HA-tagged PALM. Cells were fixed to the microscopy slide, 









Finally, to test whether PALM is phosphorylated by LRRK2, distinct GST-tagged 
PALM isoforms were bacterially purified and incubated in presence of HEK293-
purified LRRK2 (1326-end) [G2019S] protein, Mg2+ and 32P ATP for 30 mins at 30ºC 




































Figure 5.13: Assessment of PALM isoforms phosphorylation by LRRK2 in vitro. GST-
tagged LRRK2 [1326-end) [G2019S] was HEK293-purified. Purified LRRK2 protein was then 
incubated with recombinant GST-tagged RPS15 protein, indicated GST-tagged PALM 
isoforms and Mg2+-[γ- 32ATP] for 30 mins at 30ºC at 1000 rpm. Samples were then subjected 







According to my results PALM and PALMD are phosphorylated by LRRK2 in vitro. 
To test whether inhibition of LRRK2 kinase activity blocks PALM phosphorylation. 
PALM was phosphorylated by LRRK2 in presence of DMSO or 1µM GSK257821A 







Figure 5.14: Assessment of PALM phosphorylation by LRRK2 in vitro. GST-tagged 
LRRK2 [1326-end) [G2019S] was HEK293-purified. Purified LRRK2 protein was then 
incubated with recombinant GST-tagged RPS15 protein, GST-tagged PALM and Mg 2+-[γ- 
32ATP] for the indicated times in presence or absence of LRRK2 specific kinase inhibitor 
(1µM GSK2578215A). Samples were then subjected to electrophoresis on a polyacrylamide 






My data revealed that inhibition of LRRK2 kinase activity does not block PALM 
phosphorylation indicating that it is probably non-specific. It might be that another 
protein kinase could have immunoprecipitated with GST-LRRK2, which has been 
isolated from HEK293 cells used in this protein, and phosphorylated PALM. 
 
5.2.3.2  Validation of other proteomic hits by in vitro phosphorylation 
To test whether proteins which came down with LRRK2 such as CTNNA1, M-RIP, 
MME, CAPZB and GNAI2 could be potential LRRK2 substrates I have subjected 
bacterially purified GST-tagged proteins in vitro phosphorylation by HEK293-purified 
1236-end LRRK2 [G2019S in presence of Mg2+ and 32PATP in presence and 
absence of LRRK2 kinase inhibitor. I used RPS15 as a positive control. My results 







Figure 5.15: In vitro phosphorylation screen by LRRK2. GST-bacterially purified 
indicated proteins were subjected to an in vitro kinase assay by HEK293-purified LRRK2 
[G2019S] in the presence or absence of 1 μM LRRK2 kinase inhibitor. Proteins were then 
resolved in SDS gel and developed by autoradiography.  
 
 
From this data is clear that RPS15 is phosphorylated by LRRK2 and inhibition of 
LRRK2 kinase activity blocks this phosphorylation. PALM and MRIP seem to be 
phosphorylated by LRRK2 but this phosphorylation is not abolished by the LRRK2 
inhibitor indicating that it is not specific. Other proteins were not shown to be 
significantly phosphorylated by LRRK2.  
 
5.2.4. LRRK2 might not be a threonine specific kinase 
As mentioned before, previous work in our lab has shown that moesin, a member of 





T558, a previously identified in vivo phosphorylation site that regulates the ability of 
moesin to bind actin (Jaleel et al., 2007). In addition, it was shown, that LRRK2 
phosphorylates the other ERM proteins, ezrin and radixin, that are related to moesin 
at the residue equivalent to T558 as well as peptide encompassing T558. This 
peptide was named LRRKtide: RLGRDKYKTLRQIRQ (Nichols et al., 2009b). 
Furthermore, a scanning library approach was used to improve the optimal 
phosphorylation motif of LRRK2. It was found that the optimal LRRK2 
phosphorylation motif between -5 and+4 positions is WWRFYTLRRA, which was 
substituted into the moesin sequence from which the LRRKtide was derived. The 
resulting sequence was called Nictide: RLGWWRFYTLRRARQGNTKQR. Nictide 
was shown to be phosphorylated to a much greater extend by LRRK2 [G2019S] 
(1326-end) compared to LRRKtide or moesin (Nichols et al., 2009b). Moreover, it 
was reported that mutation of Thr in Nictide peptide to Ser abolished phosphorylation 
of LRRK2 suggesting that LRRK2 has a marked preference for phosphorylating 
threonines instead of serines (Nichols et al., 2009a). To date, most identified LRRK2 
phosphorylation sites are threonines, including RPS15 T136. 
Recently, Ben Turk’ laboratory from the University of Yale discovered that the 
residue located at position + 1 from the DFG motif plays a critical role in controlling 
whether protein kinases phosphorylate Ser or Thr residues (C. Chen et al., 2014). 
His work suggests that protein kinases with an Ile residue at this position makes 
protein kinases phosphorylate Thr residues rather than Ser residues. This is very 
interesting because LRRK2 has a Ile2020 at this position that is also mutated to Thr 
in patients with Parkinson's disease. Therefore, I wanted to explore how LRRK2 
mutations of I2020T and G2019S impact on Thr/Ser phosphorylation substrate 






To test this hypothesis, recombinant GST fused LRRK2 (1326-end) proteins 
comprising the following mutations LRRK2 [G2019S], LRRK2 [I2020T], LRRK2 
[I2020L], LRRK2 [I2020F], LRRK2 [I2020G] and the wild type were HEK293-purified. 
Nictide and LRRKtide peptides, and moesin comprising T or S residue at the 
phosphorylation site were subjected to phosphorylation by these recombinant 








Nictide              RLGWWRFYTLRRARQGNTKQR 
LRRKtide      RLGRDKYKTLRQIR 
 Moesin       RLGRDKYKTLRQIRQGNTKQRIDEFESM 
 






C                   Nictide 500 µM (Thr vs Ser) 
 











Figure 5.16: Determination of the preferred T/S phosphorylation site for LRRK2 (A) 
The wild type and indicated mutations of GST-LRRK2-(1326-end) were HEK293-purifeid and 
analysed by SDS/PAGE followed by Colloidal Blue staining. (B) Amino acid composition of 
implemented peptides was summarized. (C) The same amounts of each form of LRRK2 
were assayed against 500 µM Nictide for 20 mins. Each measurement was taken in 
triplicate, and the results are the means +/- S.E.M. for peptide phosphorylation relative to 
wild-type enzyme for each peptide. Similar results were obtained with two independent 
enzyme preparations. (C) The same amounts of each form of LRRK2 were assayed against 
500 µM LRRKtide for 20 mins. Each measurement was taken in triplicate, and the results 
are the means +/- S.E.M. for peptide phosphorylation relative to wild-type enzyme for each 
peptide. Similar results were obtained with two independent enzyme preparations. (D) The 
same amounts of each form of LRRK2 were assayed against 500 µM LRRKtide for 20 mins. 
Each measurement was taken in triplicate, and the results are the means +/- S.E.M. for 
peptide phosphorylation relative to wild-type enzyme for each peptide. Similar results were 
obtained with two independent enzyme preparations. (E)  GST fused moesin proteins 
comprising indicated mutations were subjected to phosphorylation by the same amount of 
indicated form of LRRK2. Reactions were stopped by the addition of sample buffer, and 
products were subjected to SDS/PAGE. Gels were analysed by staining with Colloidal Blue, 
and phosphorylation was monitored by autoradiography (32P).  
 
My results confirmed that Nictide is efficiently phosphorylated by wild type LRRK2. 
Consistent with previous work G2019S mutation stimulates LRRK2 activity to 4 folds 





reported data, mutation of phosphorylated threonine residue in Nictide to serine 
dramatically decreases LRRK2 phosphorylation. However, LRRK2 [G2019S] does 
seem to tolerate serine residues in Nictide much better than the wild type. 
Surprisingly, LRRKtide peptide sequence comprising a serine, as LRRK2 
phosphorylation site is much better tolerated by wild type LRRK2 and, G2019S and 
I2020T mutants. Mutation of threonine in LRRKtide peptide to serine seems to 
increase LRRK2 phosphorylation. Therefore, my data indicates that LRRK2 might 
not be a threonine specific kinase. The most important thing that this analysis show 
is that LRRK2 G2019S mutant might be able to phosphorylate Ser residues much 
better than the wild type. It was reported that indeed LRRK2 G2019S mutant 
autophosphorylates at S1292 with much greater extent than the wild type (Sheng et 
al., 2012). Moreover, in our lab RAB12 was shown to be phosphorylated by LRRK2 
in cells at S106 (unpublished work). It would be interesting to compare its 
phosphorylation by LRRK2 WT and LRRK2 G2019S in more detail.  
In addition, my results do not provide much evidence to support Ben Turk’s model. 
Mutation of Ile 2020 to Thr (I2020T) or Leu (I2020L) has little impact on Ser/Thr 
specificity whereas I2020G and I2020F mutations resulted to be catalytically inactive. 
Maybe for some kinases this residue is important for Ser/Thr specificity but my data 
suggests that this is not the case for LRRK2.  
5.2.5 MAP4 kinases phosphorylate LRRK2 S910 and S935 in vitro but not in 
vivo 
Previously in our laboratory, Paul Davies demonstrated that LRRK2 is 
phosphorylated by MAP4 kinase in vitro. However, there was no evidence for this to 
be true in cell. To test whether LRRK2 is phosphorylated by MAP4 kinases in cells I 





purpose I used purified GST-tagged MAP4K3 recombinant protein available in our 
lab to phosphorylate commercially purified recombinant GST-tagged LRRK2  full 
length protein as well as truncate LRRK2 (880-1300) WT and (880-1300) 
[S910A+S935A] mutant in the presence of Mg2+ and ATP at 30 mins at 30ºC. 
Reactions were stopped by 4xloading buffer, resolved on a SDS gel and subjected to 





Figure 5.17: MAP4K3 phosphorylates LRRK2 in vitro at S910 and S935. (A) Schematic 
representation of LRRK2 protein fragments employed in this assay. (B) Recombinant GST 
MAP4K3 kinase was incubated with recombinant G2019S LRRK2 (Invitrogen) full length 
protein as well as its fragments LRRK2 (883-1300) WT and mutant (S910A and S935A) n 
the presence of Mg2+ and ATP at 30ºC for 30 mins at 1000 rpm. Reactions were stopped by 
the sample loading buffer and resolved on a SDS gel, which has been subjected to 







Interestingly, Guan, Kun-Liang laboratory reported that they selectively knocked out 
all isoforms of MAP4 kinases (1-9) in HEK293 cells (Meng et al., 2015). Guan’s lab 
kindly shared these HEK293 MAP4 kinase null cells with us so that we could test 
whether deletion of MAP4 kinases from cells impairs LRRK2 S910 and S935 
phosphorylation.  To test this, I have immunoprecipitated endogenous LRRK2 from 
HEK 293 or HEK293 MAP4 null cells treated with DMSO or 1µM of GSK2578215A 




Figure 5.18: LRRK2 S935 phosphorylation is not affected by deletion of MAP4K1-9 
isoforms. HEK293 MAP4K1-9 knock-out cells as well as HEK293 control cells were treated 
with LRRK2 specific inhibitor or DMSO. Cell lysates were then subjected to 
immunoprecipitation with monoclonal LRRK2 antibody and subjected to phospho S935 and 
total LRRK2 antibodies. Also cell lysates were subjected to immunoblot analysis with 
MAP4K4 antibody.  
 
To confirm MAP4 kinase isoform deletion, I used MAP4K4 antibody, which 
specifically recognized MAP4K4 protein in HEK293 WT cells but not in HEK293 





inhibitor as expected resulted in dephosphorylation of S935. Moreover, S935 
phosphorylation in HEK293 WT cells is the same as in HEK293 MAP4 (1-9) null 
cells, suggesting that deletion of MAP4 kinases did not have any effect on LRRK2 
phosphorylation under basal conditions.  
5.3 Summary 
To summarise, RPS15, a previously reported LRRK2 substrate, is efficiently 
phosphorylated by LRRK2 in vitro at T136 and mutation of this site to alanine 
significantly abolishes LRRK2 phosphorylation. Also, addition of LRRK2 specific 
inhibitor blocks RPS15 phosphorylation by LRRK2. However, in overexpressed cells, 
inhibition of LRRK2 kinase activity does not lead to any obvious changes in RPS15 
phosphorylation at T136. This could be explained by incorrect RPS15 folding in cells 
due to its over-expression. Alternatively, it could also be that other kinases 
phosphorylate this site in cells and that LRRK2 is not a rate limiting kinase for this 
protein. However, to date there is not known, which kinase could phosphorylate 
RPS15 at this site. The attempt to assess phosphorylation of T136 in cells was 
unsuccessful as generated phospho-specific antibodies for this site were proven to 
be not sufficiently selective and therefore, could not be used.  
In order to identify novel LRRK2 interactors, I used a comparative mass 
spectrometry analysis derived from LRRK2 immunoprecipitates of LRRK2 WT, MEF 
LRRK32 [S910A+S935A] and LRRK2 KO MEFs. My data revealed a great number 
of proteins coming down with the wild type LRRK2. Interestingly, a significantly 
reduced number of proteins were shown to come down with knock-in LRRK2. 
Reported proteins should be validated as a number of factors could affect the 
results. I have tested at least ten different proteins from the mass spectrometry list I 





NEP, RAB11, CRAF and MRCK but my data did not provide strong evidence that 
any of these proteins bind LRRK2 specifically. PALM was the only protein that 
looked promising initially as it was binding strongly to LRRK2 in vitro but further 
research revealed that this binding was most likely to be non-specific as it seems to 
bind other FLAG-tagged proteins similarly to LRRK2. In spite of the fact that PALM 
and PALMD are phosphorylated by LRRK2 in vitro, inhibition of LRRK2 kinase 
activity did not block its phosphorylation, indicating that this phosphorylation was 
likely caused by another kinase that associated with LRRK2 from HEK293 cells.  
In my opinion, one of the major limitations of this mass spectrometry experiment is 
that littermate MEFs used were spontaneously immortalized in parallel and this could 
have led to accumulation of distinct mutation between these lines. These diverse 
mutations, which took places during immortalization process could have altered 
differently each littermate cell line and as a result influence my data. In order, to 
obtain more homogeneous cells, one could use primary non-immortalized cells or 
immunoprecipitate LRRK2 directly from mouse tissues of LRRK2 wild type, knock-in 
or knock-out cells.  Also, considering the evidence that penetrant mutations in 
LRRK2 such as R1441G massively increase the efficiency of LRRK2 mediated 
phosphorylation of Rabs, it would be important to validate future MS hits using these 
mutants. Mass spectrometry experiments could also be conducted using 
endogenous knock in models of these mutations.  
In addition, my LRRK2 substrate specificity data provides no evidence to support 
Ben Turk’s model. This is because mutation of Ile 2020 to T (I2020T) or L (I2020L) 
has little impact on Ser/Thr specificity. Maybe for some kinases this residue is 
important for Ser/Thr specificity but my data indicates that this is not the case for 





increase LRRK2 phosphorylation. Therefore, my data indicates that LRRK2 might 
not be a threonine specific kinase, as it was reported previously, because it also 
efficiently phosphorylates serines.  
Finally, it has been proposed that MAP4 kinases could phosphorylate LRRK2 at 
S910 and S935 but to date there was no evidence to support this hypothesis in cells. 
It was not until Guan’s lab managed to produce MAP4 (1-9) null cells I could test that 
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